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1 Abstract 
The increasing issues of drug-resistant bacteria has quickly become a global concern 
as infections spread from healthcare settings to the wider community. The rapid 
spread of these infections is partly facilitated by a decrease in the development of 
new drugs. 
Because of their antimicrobial properties, ferrocenyl chalcones, which are 
organometallic chalcone derivatives, have gained attention from researchers. Early 
classes of ferrocenyl chalcones were reportedly cytotoxic, which encouraged the 
need to develop next-generation ferrocenyl chalcone compounds that are less toxic. 
One-to-one dilutions of stock ferrocenyl chalcone solution and MHB, resulting in the 
formation of small, brown particles, was suggested to arise from iron ion chelation 
of casein hydrolysate, a component of MHB. After solubilisation in DMSO, each of 
the iodine-containing ferrocenyl chalcone compounds, changed from deep red to 
dark brown. There was no evidence that iodine was displaced when diethyl ether was 
used.  
Using 2-fold broth microdilution, results demonstrated that five of the ten 
methylated ferrocenyl chalcones, possessed greater antimicrobial activity against 
resistant and non-resistant Gram-positive organisms than Gram-negative organisms. 
These compounds contain increasing alkyl chain lengths from pentyl to decyl on ring 
‘B’ of the compounds.  
The results of MTT assays of Gram-positive bacteria indicated that there were no 
viable cells, where the mean (± SD) percentage of actively respiring cells were 
observed.  
SEM images of bacterial cells, which were treated with an active ferrocenyl chalcone, 
exhibited significant cell membrane damage as ultrastructurally observed. 
Key findings of this research indicate that further investigations into these 
compounds are required so that the inhibition of biofilm formation and the 
cytotoxicity towards mammalian cells are clearly defined. Additionally, the results 
ii | P a g e  
 
advance the possibility that these newly developed ferrocenyl chalcone compounds 
could be important antimicrobial agents in the treatment of infections from clinically 
resistant bacteria in an environment where current treatments are failing. 
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1 Introduction 
The prevention and treatment of infectious diseases remain critical goals in 
maintaining a healthy population. While several approaches, such as health 
surveillance and health management have been implemented, clinicians are faced 
with substantial challenges in achieving these targets. One of these challenges is the 
increasing prevalence of the spread of bacterial pathogens and the consequences of 
this phenomenon, as discussed by Davies (2011). 
1.1 Significance and classification of bacterial pathogens 
1.1.1 Importance to humans 
Published data from the World Health Organisation (WHO) (2015) indicates that, 
while non-communicable diseases (e.g., cardiovascular disease and diabetes) are 
responsible for approximately 41 million deaths annually across the globe, infections 
from microbial pathogens continues to be a significant concern in world public health 
and remain as one of the top 10 causes of worldwide deaths. Within the past century, 
there were over half million deaths annually caused by microbial infections, which 
was higher combined when compared with deaths resulting from other causes such 
as malaria, with billions more enduring various pathogenic disorders (Mishra & 
Agrawal, 2012). As detailed by Hogg (2013), several infectious diseases are caused by 
micro-organisms, mainly bacteria, some of which are identified in Table 1-1. 
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Table 1-1 Common infections caused by bacteria (Hogg, 2013). 
Disease Bacterial Pathogen 
Anthrax Bacillus anthracis 
Gonorrhoea Neisseria gonorrhoeae 
Typhoid fever Samonella typhi 
Tuberculosis Mycobacterium tuberculosis 
Cholera Vibrio cholerae 
Diphtheria Corynebacterium diphtheriae 
Tetanus Clostridium tetani 
Bacterial Pneumonia Streptococcus pneumonia 
Gas gangrene Clostridium perfringens 
Plague Yersina pestis 
Botulism Clostridium botulinum 
Dysentery Shigella dysenteriae 
Whooping cough Bordetella pertussis 
Rocky Mountain spotted fever Rickettsia rickettsii 
 
Many of the diseases highlighted in the above table, such as tuberculosis, are defined 
as healthcare-associated infections (HCAIs). M. tuberculosis, which is the causative 
agent of this disease, is one of many bacterial pathogens that are being increasingly 
isolated from hospital patients who became infected while under care in health 
settings (WHO, 2015). With a prevalence of 6.4% (HPA, 2012), the spread of HCAI and 
their subsequent control has become an important issue in hospitals. The frequency 
of HCAIs are reported to cause adverse consequences, including patient death (WHO, 
2015). The Institute of Medicine (2000) reported that there were 90,000 deaths 
annually in U.S. hospitals because of care-associated complications as discussed by 
Baron, Jorgensen, & Landry (2007). Nosocomial infections, which also includes those 
that result from the presence of drug resistant bacteria, such as methicillin-resistant 
Staphylococcus aureus (MRSA), have begun to emerge in the community and in non-
clinical environments (Hadley, 2014). Subsequently, the WHO (2015) compiled a 
comprehensive report on the existence of other multidrug-resistant (MDR) bacteria 
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including carbapenemase-producing Enterobacteriaceae (CPEs), the most common 
species being Klebsiella pneumonia and Escherichia coli as identified by Tseng et al., 
(2011). The occurrence of both non-resistant and resistant bacterial pathogens, and 
their effect on human health, promotes the urgent need for potent antimicrobial 
compounds as reviewed by Henry et al. (2017). 
The increasing resistance of microorganisms to antibacterial agents is a global threat 
to public health with over-prescription and misuse of antibacterial drugs being 
identified as key factors in the development of bacterial antimicrobial resistance 
(Davies & Davies, 2010). Resistance in bacteria can be influenced by the minimum 
inhibitory concentration (MIC) of a particular antimicrobial compound at lethal or, 
more often, at sub-lethal levels, where treatment with low antimicrobial 
concentrations indirectly result in selection for drug resistance  (Andersson & 
Hughes, 2012). MIC refers to the lowest concentration of antibacterial agent that 
inhibits growth. Other key contributors to drug resistance in bacteria are those which 
involve environmentally-derived mutations in bacterial genes that are responsible 
for antimicrobial susceptibility, both of which may be insular or transferable, 
(Gullberg et al., 2011), and antimicrobial efflux pumps in bacterial cells (Edwards et 
al., 2014). Another contributing factor of drug resistance involves dosage increases 
and/or inefficient breakdown of antimicrobial agents in the blood leading to raised 
levels of active drug to favour selection for resistant strains or physiological changes, 
which may result from altered bacterial growth conditions, that trigger natural 
resistance, as reviewed by Normark et al. (1977) and Song et al. (2009). Mechanisms 
of antimicrobial resistance will be discussed in Section 1.4. The expression of these 
mechanisms may be determined by the category of bacteria, which are primarily 
classified based on morphological identification using the Gram stain technique. 
1.1.2 Classification of bacteria based on Gram Stain 
In 1884, Hans Christian Gram developed a staining method that enables the 
differentiation between most bacterial cells, as discussed by several researchers 
including Sumbali & Mehrotra (2009). This differential staining method facilitates the 
classification of most bacterial cells into Gram-positive and Gram-negative bacteria 
(Heritage, Evans, & Killington, 2000), classifications which cover the most frequent 
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micro-organisms involved in antimicrobial resistance. These organisms differ by the 
structure of their peptidoglycan layer, which surrounds the bacterial cell membrane. 
Peptidoglycan, also called murein, is a structural, polymer scaffold within the 
bacterial cell wall (Salton, 1964; Ghuysen, 1968; Schleifer & Kandler, 1972; Vollmer, 
Blanot, & Pedro, 2008). This polymer is composed of glycans, N-acetylmuramic acid 
and N-acetylglucosamine, cross-linked with short peptides (Rogers, Perkins, & Ward, 
1980; Williams & Edwards, 1994; Heijenoort, 2001; Desmarais et al., 2013). The 
differential feature of Gram’s stain involves the use of crystal violet dye, which is 
trapped within the peptidoglycan layer, depending on the thickness of the layer 
(Willey, Sherwood, & Woolverton, 2008).  
1.1.3 Gram-positive organisms 
A Gram-positive bacterial cell possesses a thick peptidoglycan layer (Figure 1-1), 
approximately 30-100 nm thick and 60% of cellular mass, and is comprised of many 
sub-layers (Navarre & Schneewind, 1999; Silhavy, Kahne, & Walker, 2010).  
This thick layer, which provides protection against turgor pressure from the cell 
membrane, contains teichoic acids that are primarily copies of various phosphate 
polymers (Silhavy, Kahne & Walker, 2010). Wall teichoic acids, which are a sub-group 
of teichoic acids, are covalently bonded to the peptidoglycan layer, while another 
sub-group of teichoic acids, which are called lipoteichoic acids, are bonded to the 
lipid components of the cell membrane. Wall teichoic acids are usually comprised of 
a disaccharide unit with repeating units of either ribitol phosphate or glycerol 
phosphate, as discussed by Silhavy, Kahne & Walker (2010). Both groups of polymers, 
which strengthen the structural integrity of the cell, are interwoven within 
peptidoglycan (Silhavy, Kahne & Walker, 2010). Although lipoteichoic acids are 
similar to wall teichoic acids in that they contain glycerol phosphate polymers, the 
chiral nature of their phosphate polymers differ, and their phosphate polymers are 
comprised of fewer sub-units.  
The thick peptidoglycan layer found with Gram-positive bacteria also contain protein 
units. These structures may be covalently bonded to peptide components of 
peptidoglycan or they may be attached via ionic bonds to peptidoglycan and teichioic 
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acid components as surface proteins. The primary role of these proteins involves the 
identification of constituents of mammalian cellular matrix (Silhavy, Kahne & Walker, 
2010). 
The main difference between the cell envelopes of Gram-positive bacteria involved 
the presence of diverse peptide cross linkages within glycan units, e.g., pentaglycine 
branches are found in S. aureus but not in Bacillus subtilis. 
Due to their thick peptidoglycan layer retaining the crystal violet dye, Gram-positive 
bacteria appear purple to violet when viewed under the compound light microscope 
as reviewed by Madigan et al. (2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Bacteria that are classified in this group may be both non-pathogenic and pathogenic. 
Non-pathogenic Gram-positive bacteria are considered harmless to humans and may 
be part of the normal microbiota. However, pathogenicity may be induced by 
physiological and environmental conditions in the host. Pathogenic Gram-positive 
Cytoplasm 
Thick peptidoglycan layer 
of Gram-positive bacteria 
Periplasmic space 
Cell membrane 
Figure 1-1 Structure of Gram-positive bacteria with thick peptidoglycan layer (30-100 nm thick), periplasmic 
space and lipid bilayer of cell membrane (illustration by E. Henry, 2016).   
Wall teichoic acid 
Lipoteichoic acid Covalently 
attached protein 
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bacteria, such as Staphylococcus aureus, Clostridium botulinum, Clostridium 
perfringens and Bacillus cereus, produce enterotoxins and exotoxins that cause 
foodborne diseases (Jay, Loessner, & Golden, 2005). Common Gram-positive bacteria 
that cause HCAIs include Streptococcus mitis, Enterococcus spp., Corynebacterium 
jeikeium (Zinner, 1999; Gaynes et al., 2005). 
1.1.4 Gram-negative organisms 
The outer membrane, which is not found in Gram-positive bacteria, is a lipid bilayer 
that is comprised of phospholipids in its inner sub-layer and liposaccharides in its 
outer sub-layer (Silhavy, Kahne & Walker, 2010). Liposaccharides are endotoxins that 
contribute to infections in mammalian cells and are comprised of O-antigen and core 
saccharides. The outer membrane also contains lipoproteins, which possesses lipid 
groups that are bound to the inner sub-layer of the outer membrane, and β-barrel 
moieties, which are considered to be transmembrane proteins. While the function of 
these lipoproteins may not be fully understood, the function of the transmembrane 
β-barrel porins primarily involve the transport of small molecules such as amino acids 
(Silhavy, Kahne & Walker, 2010). 
Peptidoglycan is also present in Gram-negative bacterial cells. This structure is 
approximately 1-10 nm thick and also contains sub-layers (Yao, Jericho, & Pink, 
1999). Additionally, peptidoglycan is covalently linked to the outer membrane by a 
lipoprotein, which is commonly known as Braun’s lipoprotein, and is primarily found 
in E. coli. In contrast, ionically bonded lipoprotein can be found in P. aeruginosa, as 
discussed by Yao, Jericho, & Pink (1999). 
Unlike Gram-positive bacteria, Gram-negative bacteria possess thin peptidoglycan 
layers (Figure 1-2), which do not trap crystal violet dye (Willey, Sherwood, & 
Woolverton, 2008). When counterstained with safranin, Gram-negative bacteria 
appear pink to red when viewed under the compound light microscope (Madigan et 
al., 2012). Gram-negative bacteria can also be both non-pathogenic and pathogenic. 
Pathogenicity in these microorganisms can also be activated in the host under 
physiological and environmental conditions. Common Gram-negative bacteria that 
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cause HCAIs include E. coli, K. pneumonia, and Pseudomonas aeruginosa (Gaynes et 
al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2 Structure of Gram-negative bacteria with outer membrane, thin peptidoglycan layer (1-10 nm thick), 
periplasmic space and lipid bilayer of cell membrane (illustration by E. Henry, 2016). 
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1.2 Traditional antibiotics and antimicrobial agents used in the treatment of 
bacterial infections 
1.2.1 Classification and sources of antibiotics and antimicrobial compounds 
An antibiotic, a term that was first used by Waksman in 1941, is a compound that is 
used to treat microbial infections by inhibiting microbial growth, as reviewed by 
Clardy, Fischbach, & Currie (2010). Conventional antibiotics, which are manufactured 
by micro-organisms such as bacteria and fungi or as synthetic agents, possess either 
bactericidal (killing) or bacteriostatic (growth inactivity) mechanisms (Madigan et al., 
2012). The first well-known antibiotic, penicillin (PEN), which was produced by the 
Penicillium fungal species, was discovered by Alexander Fleming in 1928 (Aminov, 
2010). This discovery initiated the “Golden Era of Antibiotics”, which lasted until the 
1970s, and resulted in the development of several classes of solely synthetic 
compounds known as antimicrobial agents, as reviewed by Phoenix, Harris, & 
Dennison (2015). Antibacterial agents can be classified as antibiotic compounds or 
antimicrobial compounds. 
Conventional antibiotics and antimicrobial compounds that have exhibited clinical 
and financial success are classified according to their target bacterial enzymes 
(Hughes & Karlén, 2014). The major classifications of these therapeutic agents are 
detailed in Table 1-2, which is based on information taken from Irving et al. (2005) 
and Coates, Halls, & Hu (2011). Discovery of these antimicrobial agents led to the 
production of analogues of these drugs. 
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Table 1-2 Major antibiotic and antimicrobial classifications, mechanisms of action and examples (Irving, 
Ala’Aldeen, & Boswell, 2005; Coates, Halls, & Hu, 2011). 
Class Mode of action Examples of antibiotics 
β-lactam: Penicillins Inhibit synthesis of bacterial 
cell wall 
Penicillin G, Ampicillin, 
Piperacillin 
β-lactam: 
Cephalosporins 
Inhibit synthesis of bacterial 
cell wall 
Cephradine (1st gen.) 
Cefprozil (2nd gen.) 
Ceftriazone (3rd gen.) 
Cefipime (4th gen.) 
Ceftaroline (5th gen.) 
β-lactam: 
Monobactam 
Inhibit synthesis of bacterial 
cell wall 
Aztreonam 
β-lactam: 
Carbapenems 
Inhibit synthesis of bacterial 
cell wall 
Imipenem, Meropenem, 
Ertapenem 
Glycopeptides Inhibit bacterial cell wall 
formation 
Vancomycin, Teicoplanin, 
Telavancin 
Fluoroquinolones Inhibit bacterial 
deoxyribonucleic acid (DNA) 
replication and transcription 
Norfloxacin, 
Ciprofloxacin, Fleroxacin 
Tetracyclines Inhibit bacterial protein 
synthesis 
Tetracycline, Doxacycline, 
Methacycline 
Aminoglycosides Inhibit bacterial protein 
synthesis 
Gentamycin, Netilmycin, 
Kanamycin 
Macrolides Inhibit bacterial protein 
synthesis 
Erythromycin, 
Clarithromycin, 
Streptomycin 
Other: Polymixins Produce physicochemical 
effect that disrupts bacterial 
cell membrane 
Polymixin B, Polymixin E 
(Colistin) 
Other: 
Sulphonamides 
Inhibit folate synthesis in 
bacteria 
Sulfamethoxazole, 
Sulphanilamide, 
Sulfadiazine 
Other: Isoniazid Inhibits synthesis of bacterial 
cell wall components 
Not applicable 
Other: 
Trimethoprim 
Inhibits bacterial DNA 
synthesis 
Not applicable 
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1.2.2 Common mechanisms of action of antibiotic and antimicrobial agents 
The β-lactam class of antibiotics contains a four-ring chemical structure  (Figure 1-3), 
which inhibits cell wall synthesis by irreversibly binding to penicillin-binding proteins 
(PBP) such as transpeptidase (Madigan et al., 2012).  
 
 
 
 
 
 
 
 
 
 
Penicillins, which belong to the β-lactam class of antibiotics, are involved in the 
inhibition of transpeptidase, which is an enzyme that catalyses the cross-linking of 
peptidoglycan components (Wise et al., 1965; Kong, Schneper, & Mathee, 2011). This 
class of antibiotics includes PEN-G, ampicillin and methicillin (Willey, Sherwood, & 
Woolverton, 2008). Cephalosporins, antimicrobial agents that also belong to the β-
lactam class of antibiotics, exhibit a mechanism of antimicrobial action that is similar 
to penicillins but differ in their chemical structure (Madigan et al., 2012). This drug is 
divided into generations from 1st to 5th based on their degree of antimicrobial 
activity, or antimicrobial spectrum, as detailed by Watkins & Bonomo (2017). 
Cephalosporins are administered to patients who develop an allergy to penicillins 
(Campagna et al., 2012) and include analogues such as cephalothin (1st generation), 
cefoxitin (2nd generation) and ceftriaxone (3rd generation) (Willey, Sherwood, & 
Woolverton, 2008). Fluoroquinolones, also known as quinolones, are broad-
spectrum antimicrobial agents that inhibit bacterial DNA gyrase and topoisomerase 
Figure 1-3 Structure of β-lactam ring (based on a review by Hacker, Messer, & 
Bachmann, 2009). 
H 
C 
N C 
H 
C 
O 
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IV, which are enzymes that are involved in DNA cleavage, a crucial step in bacterial 
DNA replication and transcription (Wolfson & Hooper, 1989; Kohanski, Dwyer, & 
Collins, 2010). Common quinolones include ciprofloxacin (CIP), which is a derivative 
of an older quionolone known as nalidixic acid, and the next generation quinolone 
called moxifloxacin, as reviewed by Madigan et al. (2012). Tetracyclines block the 
binding of aminoacyl-transfer ribonucleic acid and the 30S sub-unit in the bacterial 
ribosome, which results in the inhibition of bacterial protein synthesis (Chopra & 
Roberts, 2001). Compounds that belong to the tetracycline class of antibiotics include 
chlortetracycline (1st generation), doxycycline (2nd generation) and tigecycline (3rd 
generation) (Nguyen et al., 2014). The mechanism of action of the aminoglycoside 
class of antibiotics involves the inhibition of bacterial protein synthesis by binding to 
bacterial ribosomal ribonucleic acid and transfer ribonucleic acid (Kotra, Haddad, & 
Mobashery, 2000). These bactericidal agents include neomycin, spectinomycin and 
streptomycin (Wilson, 2014). Macrolides also possess an affinity for bacterial 
ribosomes, which results in the inhibition of polypeptides from exiting ribosomes and 
the synthesis of bacterial proteins (Tenson & Lovmar, 2003; Kannan et al., 2014). 
Antimicrobial agents that belong to this class include ERY, a broad spectrum 
macrolide, clarithromycin and azithromycin (Madigan et al., 2012). Antimicrobials 
that inhibit bacterial metabolism comprise the classification of other. These 
antimicrobial agents are structurally similar to bacterial growth factors and 
metabolites. Examples include sulphonamides, e.g., sulfmethoxazole, which is an 
analogue of the folic acid precursor called p-aminobenzoic acid, the narrow-
spectrum antimicrobial agent known as isoniazid, which is a nicotinamide analogue, 
and trimethoprim, which inhibits the conversion of dihydrofolic acid to 
tetrahydrofolic acid by binding to dihydrofolate reductase (Willey, Sherwood, & 
Woolverton, 2008; Madigan et al., 2012). 
Antibiotic discovery and antimicrobial development are critical in the treatment of 
patients with bacterial infections. However, susceptibility of pathogenic bacteria to 
antimicrobial agents must be assessed prior to therapy, ensuring that health recovery 
is successful. 
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1.3 Antimicrobial Susceptibility Testing (AST) of bacteria 
AST is the method of categorizing microorganisms as treatable or non-treatable 
based on the MIC breakpoints, which are the antimicrobial concentrations used to 
determine susceptibility, of antimicrobial agents used to inhibit growth (Doern, 
2011). In terms of antimicrobial activity, results of susceptibility tests classifies 
bacteria as clinically susceptibility, clinically intermediate and clinically resistant, as 
detailed by Kahlmeter et al. (2003).  
European Union Committee on Antimicrobial Susceptibility Testing (EUCAST), which 
now incorporates the British Society of Antimicrobial Chemotherapy (BSAC), defines 
a microorganism as susceptible based on the level of antimicrobial susceptibility that 
leads to a successful therapeutic outcome (MacGowan & Wise, 2005). Intermediate 
is defined as the level of antimicrobial susceptibility that leads to an indeterminate 
therapeutic outcome, while resistant is defined as the level that results in 
antimicrobial susceptibility that leads to the higher possibility of therapeutic failure 
(MacGowan & Wise, 2005). Several assays can be used to determine the 
susceptibility of bacteria post-exposure to antimicrobial agents.  
The BSAC and the EUCAST have developed standard AST protocols, including the 
preparation of stock and working antimicrobial solutions, the preparation of bacterial 
inocula and the steps involved in MIC determination. These standardised methods 
were detailed by Andrews (2006), Matuschek, Brown, & Kahlmeter (2013) and 
Wootton et al. (2014). Since both committees provide harmonized standardized 
protocols in AST, the current study, which commenced in 2014, prior to the migration 
of BSAC susceptibility testing methods to those of the EUCAST in 2016, will primarily 
refer to BSAC methods (Chapter 2). 
1.3.1 Agar well diffusion method 
One common assay used to measure the susceptibility of bacteria to antimicrobial 
drugs is the agar well diffusion method. This method involves the even spreading of 
an appropriate volume of bacterial inoculum on the entire surface of a sensitivity 
agar Petri dish, followed by the boring of wells in the sensitivity agar using a sterile 
cork-borer (Balouiri, Sadiki, & Ibnsouda, 2016). Desired volumes of antimicrobial 
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solution at various concentrations are pipetted into the wells and the agar plate is 
incubated at the optimal growth temperature for a period of time, usually overnight 
(Balouiri, Sadiki, & Ibnsouda, 2016). After incubation, the diameter of the zones of 
growth inhibition are measured. This method has been used to determine the 
antimicrobial activity of new drugs, including medicinal plant compounds (Das, 
Tiwari, & Shrivastava, 2010). Agar well diffusion is a simple assay that requires little 
to no specialised equipment and the clear zones of growth inhibition can be easily 
read by clinical technicians. The antimicrobial compound can diffuse directly into the 
sensitivity agar. This method will be used to determine antimicrobial activity of novel 
compounds in Section 2.2.4. 
1.3.2 Disk diffusion method 
Another diffusion method used in antimicrobial sensitivity testing is the disk diffusion 
method, which is also known as the Kirby-Bauer method as detailed by Engelkirk & 
Duben-Engelkirk (2008). The standard protocol of this method is similar to that of the 
agar well diffusion method where the bacterial inoculum is spread on the entire 
surface of the sensitivity agar. However, unlike the agar well diffusion method, disk 
diffusion employs paper disks of diameter of 6 mm that are impregnated with a 
predetermined concentration of antimicrobials (Matuschek, Brown, & Kahlmeter, 
2013). These disks are deposited aseptically on the inoculated sensitivity agar, 
followed by incubation of the plates for the optimal time period and temperature, 
and the diameter of the zones of growth inhibition are measured (Matuschek, Brown, 
& Kahlmeter, 2013). While fastidious and slow-growing bacteria are difficult to assess 
when using this method, the zones of growth inhibition that are produced in disk 
diffusion are considered to be easy to interpret by technicians in the clinical field, and 
the method does not require specialised instrumentation (Jorgensen & Ferraro, 
2009). This method will be used in antimicrobial sensitivity testing in Section 2.2.3. 
1.3.3 Broth dilution methods 
Broth dilution methods are used to assess the MIC and the minimum bactericidal 
concentration (MBC) of antimicrobial compounds against bacteria. MIC refers to the 
lowest concentration of antimicrobial agent that inhibits bacterial growth, while the 
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MBC is defined as the lowest concentration at which an antimicrobial agent reduces 
the bacterial colony count by ≥99.9% as stated by Clinical & Laboratory Standards 
Institute (CLSI) (1999). These in vitro quantitative methods can be performed in tubes 
(macrodilution) or 96-well microtitre plates (microdilution) as discussed by Varma & 
Sharma (2017). In both macrodilution and microdilution, appropriate volumes of 
antimicrobial compound are serially diluted using MHB (Parija, 2012), which is the 
recommended sensitivity broth used in antimicrobial sensitivity testing (EUCAST, 
2003; CLSI, 2012). Equivalent volumes of bacterial inoculum are added to the tube or 
microtitre plate, which is then incubated at the optimal temperature and time for 
growth dependent on the bacterial species. After incubation, MIC can be visibly 
measured as the lowest concentration of an antimicrobial compound at which 
inoculated solution is clear, i.e. no growth. MIC can also be measured using a 
spectrophotometer at 620 nm, where absorbance of the solution is obtained. The 
absorbance of inoculated solution corresponds with the concentration of bacterial 
cells that are present in the solution, a theory that is based on Beer-Lambert’s Law. 
While the MIC is a measure of the bacteriostatic (growth inhibition) concentration of 
an antimicrobial agent, MBC is a measure of the bactericidal (reduction of bacterial 
concentration by ≥99.9%). MBC can be determined by inoculating growth agar plates 
with post-treated solutions from tubes or microtitre plates that show no visible 
bacterial growth, as detailed by Schaechter et al. (2012). Although the MBC method 
may be laborious, the results are important in antimicrobial chemotherapy in terms 
of dosage of antimicrobials given to infected patients and the efficacy of drugs in 
therapy. Broth dilution methods will be further explored in Section 2.2.5. 
1.3.4 Thin-Layer chromatography-Bioautography (TLC-B) 
Bioautography is a method used to screen for the activity and inactivity of 
antimicrobials and is often combined with thin-layer chromatography. TLC-B detects 
the mobility of antimicrobial drugs on a thin-layer chromatography plate in a suitable 
solvent as described by Marston (2011). This method, which can be either contact, 
immersion or direct, the latter being the most preferred technique because of its use 
in biological and chemical screening assays, e.g., screening of antimicrobial residues 
in milk, was reviewed by Choma & Grzelak (2011). In the contact TLC-B technique, 
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the TLC plate, which contains spots of antimicrobial agent, is placed on the inoculated 
agar plate for a short time to facilitate diffusion of an antimicrobial agents to the 
inoculated agar plate. After incubation at optimal temperature for growth, the agar 
plate is observed for zones of growth inhibition. In immersion TLC-B, also known as 
agar-overlay, the TLC plate is submerged in growth medium for a long period, 
inoculated with bacteria and incubated at optimal temperature and time for bacterial 
growth. After incubation, the agar layer is observed for zones of growth inhibition. 
The direct technique (TLC-DB) involves the submersion of the TLC plate, which is pre-
coated with spots of antimicrobial agent, into a solution of bacteria, followed by 
incubation. The zones of growth inhibition are visualised using a dehydrogenase-
based colorimetric reduction reaction, e.g., the use of a tetrazolium salt. TLC-DB has 
been used to successfully screen for the antimicrobial activity of natural products, 
which were extracted from plants, fungi and lichen, against S. aureus ATCC 25923 
and E. coli ATCC 25922 (Valgas et al., 2007). 
1.3.5 Other methods of AST 
With the exception of TLC-DB, the aforementioned tests for antimicrobial 
susceptibility are the standard methods that are recommended by EUCAST, BSAC and 
CLSI. However, these methods are usually completed within 24-48 hours in the 
clinical setting, which may result in delayed antimicrobial treatment of infected 
patients. Therefore, rapid tests are required so that clinical therapy may begin earlier. 
Although some of these assays indirectly determine antimicrobial susceptibility, they 
may be effective ways of providing recommendations to clinicians of antimicrobial 
use in patient therapy. 
One rapid AST method includes the use of polymerase chain reaction (PCR). This 
method involves the use of restriction endonucleases and ligases in the amplification 
of nucleic acids from specific genetic sequences (Mullis, Ferre, & Gibbs, 2012). PCR 
was initially used to identify pathogenic bacteria by amplifying their genomes (Espy 
et al., 2006). However, some PCR methods have been modified to detect bacterial 
genes that facilitate resistance to antimicrobial drugs (Pulido et al., 2013). One 
successful PCR-based method detects the presence of the mec A gene in MRSA that 
encodes for an altered penicillin-binding protein (PBP) with decreased affinity for β-
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lactam drugs (Pournajaf et al., 2014). One advantage of this method is that clinicians 
can quickly eliminate the administration of antimicrobials to which bacteria may be 
resistant. The disadvantage of this method is that the presence of resistance genes 
do not always equate to phenotypic manifestations (Pulido et al., 2013). 
Like PCR-based methods, matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) has also been used to identify bacterial 
pathogens in a rapid manner (Bizzini & Greub, 2010; Emonet et al., 2010; Sauer & 
Kliem, 2010; Sogawa et al., 2011; Croxatto, Prod, & Greub, 2012). The MALDI-TOF MS 
identifies bacteria by comparing their protein fingerprint to a database of known 
protein structures, as reviewed by Calderaro et al. (2014). (Lee et al., 2013) have 
successfully identified bacterial genes, such as single-minded homologue-1 and New 
Dheli metallo-beta-lactamase-1, which encode for proteins that are resistant to 
carbapenems. This inexpensive method is high in accuracy when compared to 
conventional phenotypic techniques such as Gram staining. Prompt identification of 
bacterial pathogens, and possible presence of resistant genes, allow for the clinical 
treatment of patients with bacterial infections (Biswas & Rolain, 2013). 
Another technique that is used in the identification of bacterial nucleic acids is the 
microarray. This process relies on the hybridization of complementary DNA strands, 
which may be substituted with ribonucleic acid (Knudsen, 2011). These 
complementary nucleic acid sequences, or nucleotides, can be deposited on to 
membranes, which allows for the identification of thousands of sequences in one 
assay (Pulido et al., 2013). DNA microarrays have been successfully employed in the 
identification of extended-spectrum β-lactamase genes (Leinberger et al., 2010) and 
carbapenemase genes in Gram-negative bacteria (Naas et al., 2011; Peter et al., 
2012). 
Microfluidics, known as “lab on a chip”, are micro-assays used to identify bacterial 
antimicrobial resistance as reviewed by Pulido et al. (2013). This method utilizes 
minute volumes of sample and reagent that are inserted into polymer-based or glass-
based channels, and can be combined with techniques based on nucleic acid 
identification (Saleh-lakha & Trevors, 2010). Choi et al. (2012) reported that this 
droplet-based method effectively identified bacterial growth in the presence of 
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antimicrobial agents using a microscope. In addition to the use of small volumes (10 
– 100 µl), advantages of microfluidics include no loss of analyte and high-throughput 
and concurrent assays (Saleh-lakha & Trevors, 2010). Some disadvantages of this 
method include the possibility of sample contamination and the ability of the system 
to differentiate target bacteria in polymicrobial samples (Saleh-lakha & Trevors, 
2010).  
The afore-mentioned alternative approaches to AST reduces the time taken to 
identify resistant bacterial strains. However, one limitation of these techniques that 
must be considered is inconsistent concordance of results obtained from each 
method. While this is an important factor in clinical laboratory identification of 
bacteria, these methods demonstrate effective and rapid bacterial classification, and 
resistance genes, when compared to conventional methods. 
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1.4 Common mechanisms of antimicrobial resistance 
Antimicrobial resistance mechanisms are commonly classified into three types: 
alteration of proteins located in bacterial cell membranes, e.g. efflux pumps, and 
acquisition of genes that alter the metabolism of key structural target sites found in 
the bacterial cell wall, and acquisition of antimicrobial-destroying genes (Tenover, 
2006). 
1.4.1 Role of efflux pumps in antimicrobial resistance 
Efflux pumps are membrane-bound proteins that prevent compounds, such as 
antimicrobial agents, from entering the bacterial cell, and may block the transport of 
one antimicrobial or multiple antimicrobials (Piddock, 2006). Pumps that block more 
than one antimicrobial drug are called MDR efflux pumps and are usually classified 
into 5 groups: ATP-binding cassette, major facilitator superfamily, multi-drug and 
toxic compound extrusion, resistance nodulation division and small multi-drug 
resistance, as reviewed by Piddock (2006). These proteins effectively stabilise 
membrane permeability in both Gram-positive bacteria and Gram-negative bacteria 
as detailed by Mahamoud et al. (2007).  
1.4.2 Acquisition of genes involved in metabolism – Plasma-mediated gene 
transfer 
Resistance genes are often located on circular extrachromosomal DNA material 
called plasmids, which may be transferred from one bacterial cell to another via 
conjugation (Thomas, 2003). Liu et al. (2016) reported that there was increased 
prevalence of plasma-mediated transfer of the mcr-1 gene, which is responsible for 
bacterial resistance against colistin, in Enterobacteriacieae. The presence of such 
genes that are transferred via plasmids can be detected by the random amplified 
polymorphic DNA method, which is a PCR-based assay (Nyberg et al., 2016). 
1.4.3 Acquisition of genes involved in metabolism – Emergence of MRSA 
MRSA is a subgroup of S. aureus that possesses the mecA resistant gene, which 
encodes a subgroup of PBP called PBP2a and is located in the cell membrane, 
resulting in reduced susceptibility to β-lactam drugs, as reviewed by researchers 
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including Fuda et al. (2004) and Assis, Nedeljković, & Dessen (2017). Production of 
this protein results in bacterial resistance to first-line antimicrobials, such as the β-
lactams, used to treat patients with S. aureus infections (Lindsay, 2014). This resistant 
microorganism was first reported in 1961 and quickly became one of the most 
prevalent forms of resistant S. aureus, as discussed by Moreira Osório et al. (2012). 
There are two common theories that explains the presence of the mecA gene in 
MRSA. The first theory is that methicillin-sensitive S. aureus acquired the gene via 
horizontal gene transfer from S. epidermidis and other bacterial strains (Wielders et 
al., 2002). The second theory is that the mecA gene entered the S. aureus by 
horizontal gene transfer at an unknown stage of development resulting in a single 
MRSA strain that has mutated several times and rapidly spread across the globe 
(Wielders et al., 2002). The expression of mutant PBP in MRSA strains is facilitated by 
the presence of the sequence of resistant genes that are found in the mobile genetic 
element known as the Staphylococcal Cassette Chromosome mec as reviewed by 
Assis, Nedeljković, & Dessen (2017). 
1.4.4 Acquisition of genes involved in metabolism – Emergence of VRSA 
The emergence of S. aureus microorganism that exhibit resistance to β-lactam drugs 
advanced the use of the glycopeptide vancomycin (Smith et al., 1999). However, this 
evolved into the phenotypic manifestation of heteroresistant vancomycin-
intermediate S. aureus, which produced multiple genotypic stages of vancomycin 
resistance from vancomycin-intermediate S. aureus to vancomycin-resistant 
Staphylococcus aureus (VRSA), as discussed by Bal et al. (2013). Cafiso et al. (2012) 
summarised the complexity of the bacterial cell changes that result in reduced 
vancomycin susceptibility, which includes an aggregation of D-Ala-D-Ala subunits, a 
proliferation in the number of non-amidated muropeptides and a reduction in the 
alanylation of techoic acids. These genotypic alterations produce structural changes, 
such as thicker cell walls, which leads to a loss of surface binding sites for 
antimicrobial action (Bal et al., 2013). 
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1.4.5 Acquisition of antimicrobial-destroying genes – Emergence of CPEs 
Carbapenem drugs can be effective therapeutic agents against Enterobacteriaceae 
since these compounds are usually resistant to hydrolysis by either class A, B or D β-
lactamases (Oelschlaeger et al., 2010). These transpeptidase analogues hydrolyse the 
β-lactam ring in penicillins and cephalosporins, which inactivates the antimicrobial 
compounds, as detailed by Oelschlaeger et al. (2010). However, increased use of 
carbapenems against Enterobacteriaceae, which produce serine β-lactamases 
resulted in the development of resistant Enterobacteriaceae strains. These strains 
produce four main subclasses of hydrolytic carbapenemases, which are oxacillinase, 
K. pneumoniae carbapenemase, Verona integron-encoded metallo-betalactamase 
and imipenemase (Oelschlaeger et al., 2010). The oxacillinase group of 
carbapenemases are members of the class D enzymes and have been identified in 
Gram-negative bacteria such as Acinetobacter baumannii (Smith et al., 2013) and 
Enterobacter cloacae (Majewski et al., 2014). K. pneumoniae carbapenemase-
producing K. pneumonia, which produce class A K. pneumoniae carbapenemase, was 
first reported in 2001 in the United States and its rapid spread has become a major 
concern, as reviewed by Vaux et al. (2011). These resistant strains have been isolated 
in the United Kingdom in healthcare environments (Virgincar et al., 2011). Class B 
enzymes, which include Verona integron-borne metallo-β-lactamase and inosine 
monophosphate dehydrogenase, have been isolated from Pseudomonas aeruginosa 
(Ageevets et al., 2014) Citrobacter freundii, E. cloacae, Escherichia coli, and 
Enterobacter aerogenes (Li et al., 2014). 
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1.5 Alternative Methods of Combatting Resistant Bacterial Strains 
Increased prevalence of infections caused by MDR bacteria has advanced the 
development of alternative treatment methods. These methods include synergistic 
therapies, antisense therapy and the use of bacteriophages (Giamarellou, 2006). 
1.5.1 Combatting Resistant Bacterial Strains – Synergistic Therapies 
One form of treatment against MDR bacteria is to combine two or more antimicrobial 
drugs, as reviewed by Worthington & Melander (2013). This method has been used 
in the treatment of cancers (Lane, 2006) and Human Immunodeficiency Virus as 
discussed by Worthington & Melander (2013). Stepanović et al. (2003) reported that 
propolis, a resinous compound comprised of bee saliva and tree sap and used by bees 
in the construction of their hives, exhibited antimicrobial activity against MDR 
bacteria when mixed with oxacillin. A combinatorial approach was also used to 
investigate the antimicrobial activity of pannarin, a lichen-based organic compound, 
with five known antimicrobial agents against MRSA (Celenza et al., 2012). Although 
the findings of this study indicated that activity ranged from antagonistic to 
moderate synergism, pannarin appeared to be a promising scaffold for combination-
type antimicrobial treatment. In another synergistic study, essential oils that were 
extracted from Myrtus communis leaf, commonly known as true murtle, were 
combined with eight antimicrobial agents against several MDR strains of A. 
baumannii (Aleksic et al., 2014). Aleksic et al. (2014) reported that the combinatorial 
method significantly reduced growth of the resistant organisms. Combinations of 
aminoglycosides and 3-benzylchroman derivatives of sappan lignum, a medicinal 
compound that was extracted from the Chinese plant known as Caesalpinia sappan 
were also assessed by Zuo et al. (2014). Findings of the study indicated that at least 
one aminoglycosides/3-benzylchroman combination exhibited a reduction in MIC 
values by more than 50% against clinical isolates of MRSA. Despite promising results 
from the previously mentioned synergistic studies, some combination approaches 
that utilise only conventional antimicrobial drugs show little success. Máthé et al. 
(2007) have reported that amikacin and imipenem exhibit no significant difference in 
antimicrobial activity when used individually or in synergism against extended-
spectrum β-lactamase-producing K. pnuemoniae. 
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1.5.2 Combatting Resistant Bacterial Strains – Antisense Therapy 
Antisense therapy involves the use of synthetic ribonucleic acid sequences that bind 
to messenger RNA, which results in gene inactivation of genes coding for essential 
growth proteins and inhibits their production, as detailed by Rasmussen et al. (2007). 
Despite the initial difficulties of utilising this technology in clinical practice, 
researchers have become increasingly interested in this therapeutic method and 
have developed novel antisense nucleic acid material such as peptide nucleic acids, 
as reviewed by Good (2002). In terms of antimicrobial treatment, antisense 
technology can be used to restore antimicrobial susceptibility in resistant bacteria. 
One method employed in this process is the production of phosphorothioate 
oligodeoxynucleotides by substituting one of the oxygen atoms that are present in 
the phosphodiester bonds of DNA with sulphur (Rasmussen et al., 2007). Meng et al. 
(2006) reported that these oligonucleotides were used to successfully re-establish 
the sensitivity of MRSA to oxacillin by inhibiting the expression of antimicrobial-
resistant mecA gene. In a similar study, Bai et al. (2012) utilised synthetic peptide 
nucleic acids to inhibit the expression of the resistant rpoD gene in MDR Gram-
negative bacteria, such as E. coli and K. pneumonia, which resulted in reduced 
bacterial growth. 
1.5.3 Combatting Resistant Bacterial Strains – Bacteriophages 
Bacteriophages are naturally-occurring viruses that specifically target bacterial cells 
(Kutateladze & Adamia, 2010). These bacteria-targeting microorganisms contain 
double-stranded DNA and may be lytic or temperate (lysogenic) (Madigan et al., 
2012). Lytic bacteriophages infect bacterial cells with their dsDNA, which results in 
viral DNA replication and lysis. Conversely, the injected dsDNA of lysogenic 
bacteriophages integrates with the host bacterial genome, which produces a 
dormant state and prevents bacterial cell lysis (Madigan et al., 2012). While 
antimicrobials are usually broad-spectrum, bacteriophages explicitly target narrow 
ranges of bacterial species. Thus, precise knowledge of the bacterial causative agent 
of an infection is of significant importance prior to use of bacteriophages 
(Kutateladze & Adamia, 2010). The use of bacteriophages in clinical therapy possess 
several advantages including rapid and cost-effective production compared to 
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antimicrobial development, inhibition of the horizontal transfer of resistant genes 
and increased potency when synergistically used with antimicrobial drugs (Lu & 
Koeris, 2011). In terms of antimicrobial therapy, virulent or lytic bacteriophages are 
more commonly used. Additionally, these microorganisms can be modified to 
enhance their lytic activity. Clinically isolated MRSA strains exhibited susceptibility to 
enhanced phage K organisms, which was achieved by multiple successive 
subculturing of the bacteriophage in S. aureus DPC5246  (O’Flaherty et al., 2005). 
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1.6 Novel Compounds as Potential Antimicrobial Agents 
Due to the growing unavailability of effective antimicrobial agents, there is an urgent 
need for the discovery and development of novel compounds that exhibit 
antimicrobial activity. Research into new sources of potential antimicrobial agents 
has exponentially increased to rectify this problem. These new sources have 
contributed to the synthesis of novel antimicrobial compounds with bacteriostatic 
and bactericidal activity and can be categorised into primary classifications based on 
their sources. 
1.6.1 Classifications and sources of novel antibiotic and antimicrobial compounds 
During the “Golden era” of antibiotic drug discovery, the origin of many of the 
therapeutic agents was natural-based. Many of the novel antibiotic compounds have 
been extracts from natural sources, while other agents have been synthetically 
produced.  
1.6.2 Antimicrobial agents from plants 
One major natural source of antimicrobial compounds are plants, both land plants 
(Gechev et al., 2014; Yong et al., 2015; Vandal et al., 2015) and marine plants (Kavita 
et al., 2014). In a study by Duric et al. (2013), methanolic extracts, both in powdered 
form and as decoctions, were isolated from Betula pendula, which is a species of 
birch. Methanolic extracts from birch possess antimicrobial active compounds, such 
as triterpenes, oleanolic acid and betulinic acid, whose mode of action is not yet 
defined (Cîntă-Pînzaru et al., 2012). AST of these compounds demonstrated mixed 
efficacy against non-resistant bacteria where the compounds inhibited growth of 
Gram-positive cells, while dimethyl sulfoxide (DMSO) solvent, and not the extracts, 
contributed to growth inhibition of Gram-negative cells  (Duric et al., 2013).  
Karioti et al. (2011) investigated the antimicrobial activity of phenolic compounds 
that were extracted from the leaves of Quercus ilex. The findings of the Karioti study 
indicated that compounds 1-11 possessed greater antimicrobial activity than 
compounds 12-17 against Gram-negative and Gram-positive bacteria (Karioti et al., 
2011).  
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Another plant-based compound of therapeutic importance is α-mangostin. This 
xanthone compound is extracted from Garcinia mangostana (mangosteen), which is 
a tropical fruit tree that is a noted source of traditional medicinal compounds used 
to treat various bacterial infections (Pedraza-Chaverri et al., 2008). α-Mangostin 
exhibited antimicrobial activity against non-resistant Gram-positive bacteria and 
against three MRSA strains (Koh et al., 2013). Koh et al. (2013) proposed that the 
mode of action of α-mangostin is the depolarisation of the bacterial cell membrane 
resulting in cell lysis.  
In a study of 38 methanol extracts from seaweed, antimicrobial activity was 
demonstrated against two Gram-positive bacteria and two Gram-negative bacteria 
(Kavita et al., 2014). Due to the growth inhibiting activity of these compounds from 
a renewable marine source, seaweed can provide potent antimicrobial agents (Kavita 
et al., 2014). 
1.6.3 Antimicrobial agents from the human body 
Natural-based antimicrobial agents can also be isolated from the human body. β-
defensins are composed of 36-42 amino acids and have been assessed as possessing 
antimicrobial activity (Yamaguchi et al., 2002). These cationic antimicrobial peptides 
belong to one of two families of defensins (α or β), which contain six cysteine residues 
(Yamaguchi et al., 2002). Yadava et al. (2006) evaluated the antimicrobial activity of 
three human β-defensins against four Bacillus spp. Findings of the study indicated 
that the compounds inhibited growth of the four isolates (Yadava et al., 2006). It was 
proposed that cell lysis, caused by penetration of the bacterial cell membrane, and 
inhibition of DNA and/or protein synthesis were possible modes of action of these 
peptides (Yadava et al., 2006). 
Another naturally occurring defense mechanism against bacteria are antibodies. 
These structures, which are found in serum, were first used in the 19th Century 
against diphtheria and tetanus, and were further administered in serum therapy 
against pneumonia and meningitis until the introduction of antimicrobials 
(Casadevall & Scharff, 1994). Antibodies are polypeptide structures produced by B 
cells and possess active sites that bind with foreign entities known as antigens 
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(Alberts et al., 2002). Antibody-producing B cells can produce cloned cells called 
hybridomas, which secrete structures, known as monoclonal antibodies that 
recognise specific antigens (Alberts et al., 2002). Monoclonal antibodies were the 
more common type of antibody used in early therapeutic strategies. Due to the 
increased occurrence of infections caused by MDR bacteria, there has been a 
resurgence in the use of monoclonal antibodies against bacterial infections 
(Oleksiewicz et al., 2012). Domanski et al. (2005) induced the production of 
monoclonal antibodies against non-resistant S. aureus and MRSA. These proteins 
successfully opsonized the bacterial cells, which was proposed to be their primary 
mode of action. 
1.6.4 Antibiotic Agents from Bacteria 
Bacteria produce defensive mechanisms known as bacteriocins, which are defined as 
protein molecules that possess bactericidal activity (James et al., 1991; Riley & Wertz, 
2002). These proteins are found in almost all bacteria species and there are many 
types that have been identified (James et al., 1991; Riley & Wertz, 2002; Cavera et 
al., 2015). Bacteriocins differ from antimicrobial agents in that they possess narrow 
spectrum of activities and target closely related species (Riley & Wertz, 2002). In a 
review by Cavera et al. (2015), bacteriocins that are produced by Gram-positive 
bacteria are grouped in to Class I and Class II, while bacteriocins that are produced 
by Gram-negative bacteria are classified as small peptides, such as microcins, and 
large peptides, such as colicins. These defensive peptides inhibit the growth of 
related bacteria species by using modes of action that are similar to those used by 
antimicrobial agents (Cavera et al., 2015). A common type of bacteriocin that has 
been studied extensively is Nisin A. Studies indicate that many bacteriocins lack N-
terminal leaders, making these “leaderless” bacteriocins favoured for their ease of 
chemical modification and their small size, as reviewed by Ovchinnikov et al. (2014). 
In a recent study by Ovchinnikov et al. (2017), a leaderless bacteriocin known as 
enterocin K1 was evaluated for its antibiotic activity. The findings of the assay 
indicated that enterocin K1 exhibited antibiotic activity against non-resistant 
Enterococcus spp. and Streptococcus pneumonia (Ovchinnikov et al., 2017). 
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1.6.5 Antibiotic Agents from Soil Bacteria 
Teixobactin is an antibiotic agent that was isolated and identified from uncultured 
bacteria in soil using iChip technology (Ling et al., 2015). Due to its reported ability to 
avoid bacterial resistance, this newly discovered antibiotic agent has gained extreme 
interest by researchers and clinicians (Ling et al., 2015). The report by Ling et al. 
(2015) proposed that the mode of antibiotic action of teixobactin was inhibition of 
bacterial cell wall synthesis, which involved binding of the antibiotic compound to 
specific compounds in the cell wall (Ling et al., 2015). Because of its reported 
antibiotic activity against non-resistant Gram-positive bacteria and against MRSA, 
teixobactin could be a potential candidate for antibiotic therapy. 
1.6.6 Synthetic Antimicrobial Agents 
Another approach to developing novel antimicrobial agents involves the production 
of laboratory-produced antimicrobial drugs. A solution of silver ion was assayed for 
its potential antimicrobial action against S. aureus and E. coli (Jung et al., 2008). Due 
to its inhibition of thiol groups found in enzymes, silver ion exhibited reductions in 
the growth of both bacterial samples (Jung et al., 2008). In a 2013 review, gold was 
described as an antimicrobial scaffold of interest because of its chemical stability 
(Khan et al., 2013). Gold nanoparticle surfaces have been employed as antimicrobial 
surfaces against E. coli (Ehmann et al., 2015). Ehmann et al. (2015) attempted to 
enhance the antimicrobial properties of chitosan, which is an anticoagulant 
polysaccharide, by coating gold nanoparticles with the polymer (Ehmann et al., 
2015). This technique proved successful as bacterial growth was reported to have 
been significantly reduced (Ehmann et al., 2015). 
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1.7 Chalcone compounds 
Another compound that has gained attention from researchers are chalcones. 
Chalcones are plant-based flavonoids (Cushnie & Lamb, 2011; Henry et al., 2017) that 
can be found widely in most plant material, including leaves and stems (Cushnie & 
Lamb, 2005; Henry et al., 2017). These chemicals are responsible for the colour of 
pollinating flowers and for protection against harmful ultra violet rays from the sun 
(Harborne & Williams, 2000; Henry et al., 2017). Chalcones have been reported to 
possess many biological activities such as anticancer, antiparasitic, antifungal and 
antibacterial (Dhar, 1981; Dimmock et al., 1999; Ni et al., 2004; Go et al., 2005; de 
Carvalho Tavares et al., 2011; Rozmer & Perjési, 2016; Henry et al., 2017). 
1.7.1 Biosynthesis and Synthetic Production of Chalcones 
The biosynthesis of chalcones is catalysed by the enzyme chalcone synthase 
(Kreuzaler & Hahlbrock, 1972). This enzymatic reaction begins with the consecutive 
condensation of one p-coumaroyl-coenzyme-A and three malonyl-coenzyme-A 
moieties and terminates with the Claisen condensation of a tetraketide intermediate 
into a hydroxylatedaromatic ring system (Kreuzaler & Hahlbrock, 1972; Ferrer et al., 
1999). 
In the laboratory, synthesis of chalcones and their derivatives is achieved by the 
Claisen-Schmidt condensation reaction, which is also known as aldol condensation 
(Pavia, 2005). This process involves a reaction between a benzaldehyde and an 
acetophenone in the presence of a base solution (Vyvyan et al., 2002). 
1.7.2 Derivatives of Synthetic Chalcones 
Because synthetic chalcone compounds can be easily altered, several active 
derivatives of the organic scaffold have been developed. For example, Liu et al. 
(2008) have synthesised a library of functionalised chalcone derivatives with 
antibacterial activity against S. aureus (Liu et al., 2008). These compounds differ by 
the substitution of Ring A, with organic moieties that possessed molecules such as 
methoxy groups and phenolic hydroxide (OH) groups, and the addition of R groups 
on Ring B (Liu et al., 2008). 
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1.7.3 Potential Mode of Action of Chalcones 
The mechanism of action of chalcones has not yet been defined. However, the 
consensus regarding the nature of chalcone activity on cells is that the hydrophobic 
compounds disrupt the disrupt the integrity of the cell membrane resulting in 
morphological damage and cell death (Nielsen et al., 2005; Sivakumar et al., 2009). 
Sivakumar et al. (2009) demonstrated that synthetic chalcone derivatives exhibited 
bactericidal activity against S. aureus (Sivakumar et al., 2009). One method of 
enhancing the antibacterial properties of chalcone compounds is the substitution of 
either Ring A or Ring B with a ferrocene moiety. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 | P a g e  
 
1.8 Antimicrobial Activity of Ferrocenyl Chalcones 
Chalcone derivatives, especially those comprised of ferrocenyl groups, are being 
developed as antimicrobial agents (Attar et al., 2011; Pejović et al., 2012; Kowalski et 
al., 2013; Prasath et al., 2013; Ahmed et al., 2015; Henry et al., 2017). These 
combination compounds possess useful benefits including small size, increased 
lipophilicity for diffusing across lipid membranes, and ease of chemical modification 
(Attar et al., 2011). 
Ferrocenyl chalcone compounds are primarily classified into Type I or Type II, where 
the carbonyl group could be located near the ferrocenyl ring in Type I compounds 
and where the carbonyl group can be found near the phenyl ring in Type II (Attar et 
al., 2011). One theory of the mode of action of these chalcone derivatives is the 
interference of respiratory enzymes found in the electron transport chain, which is 
located on the bacterial cell membrane (Attar et al., 2011). Inhibition of bacterial 
respiration may result in severe morphological damage to the cell membrane 
followed by cell death. 
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1.9 Synopsis of research 
1.9.1 Description of research  
In the current study, Type II ferrocenyl chalcone compounds (Appendix 1, Table 7.1) 
were created and produced by Robert B Smith (RS), a medicinal/organic chemist and 
senior lecturer at University of Central Lancashire (UCLAN) with a PhD in design and 
development of novel metalloporphyrin compounds, using a combined approach 
involving a Claisen-Schmidt base-catalysed condensation reaction and a nitrogen and 
pyrimidine methylation. This technique incorporated the substitution of Carbon-5 on 
Ring A with a nitrogen atom followed by the addition of increasing chains of alkyl 
iodide, and the substitution of Ring B with a ferrocenyl group (Figure 1-4). Due to 
their desirable electrochemical characteristics, which may involve inhibition of 
reproduction as a result of DNA binding, ferrocenyl chalcones have been shown to 
have anti-nematodal, anti-cancer and anti-plasmodial activities (Attar et al., 2011). 
Thus, derivatives of these compounds may also show antibacterial activity. 
32 | P a g e  
 
 
1.9.2  
1.9.2 Aims of the research 
The aim of this project is to investigate the antimicrobial capacity of new ferrocenyl 
chalcone derivatives with increasing lipophilicity using antimicrobial sensitivity tests 
to measure MIC.  
1.9.3 Objectives of the research 
The objectives of this research are: 
 To assess the physical properties of the ferrocenyl chalcone compounds using 
solubility tests and the effect of environmental conditions on these 
compounds (Chapter 3). 
Figure 1-4 Basic structure of a novel ferrocenyl ferrocenyl chalcone compound used in the current study. This 
compound was derived from the nitrogen substitution and alkyl iodide addition on Ring A, and ferrocenyl group 
substitution on Ring B of a chalcone scaffold (illustration by Henry, 2014). 
Fe 
O 
A B 
I- 
R 
A B 
O 
Chalcone 
Substituted Ferrocenyl Chalcone 
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N+ 
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 To investigate the antimicrobial activity of these compounds against non-
resistant laboratory-adapted bacteria using disc diffusion and the minimal 
inhibitory concentrations using 2-fold broth microdilution (Chapter 2). 
 To determine the antimicrobial activity of these compounds against non-
resistant and resistant clinical isolates, which were donated by Mr. Michael 
Collins, Service Manager in the Department of Microbiology at Chesterfield 
Royal Hospital (CRH), using 2-fold broth microdilution (Chapter 2). 
 To investigate the molecular profile of these novel compounds using proton 
nuclear magnetic resonance (1H NMR) and mass spectrometry (MS) as a 
means of quality control (Appendix 2). 
 To determine the possible mechanisms of action used by these compounds 
against such organisms using and the MTT assay to determine cell viability in 
terms of cellular respiration (Chapter 4). 
 To evaluate the potential external physical changes of bacterial cells after 
exposure to the ferrocenyl chalcone compounds using scanning electron 
microscopy (SEM) (Chapter 5). 
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2 Materials and Methods 
2.1  Chemicals and reagents 
2.1.1 Standard conditions for sterilisation 
All consumables, reagents, deionised water, agar, etc. were autoclaved at 121oC at 
15 per square inch for 15 minutes. 
 
2.1.2 Preparation and sterilisation of sterile agar, reagents, tubes and other 
consumables 
IsoSensitest agar (ISA) plates for the diffusion assays were prepared according to the 
manufacturer’s instructions by dissolving 15.7 g ISA powder (Oxoid, Thermo Fisher, 
UK) in 500 ml deionised water, while nutrient agar (NA) (Lab M Limited, Bury, UK) 
plates used for broth dilution assays were prepared by dissolving 28 g of agar powder 
in 1 L of sterile deionised water. These were then autoclaved as described in Section 
2.1.1 and cooled to 50oC before pouring into sterile agar plates. Stock phosphate 
buffered saline (PBS) (Sigma, Dorset, UK), deionised water, Meuller-Hinton Broth 
(MHB), IsoSensitest broth (ISB), tubes and blank paper disks were also sterilised as 
detailed in Section 2.1.2. Stock solutions were dispensed into 10 ml aliquot post-
sterilisation. 
 
2.1.3 Preparation of stock ferrocenyl chalcone solutions for sensitivity 
determinations, MTT assays and SEM 
Ferrocenyl chalcones of increasing alkyl chain lengths (methyl to decyl) were 
provided by RS (UCLAN, UK). For broth macrodilution assays, fresh stock of each 
ferrocenyl chalcone solution were prepared at concentrations of 5 mg/ml in DMSO 
(Alfa Aesar, Heysham, UK). Fresh stock solutions of each compound were prepared 
at concentrations of 1 mg/ml in DMSO for diffusion assays and for broth 
microdilution. The final concentrations of each ferrocenyl chalcone are shown in 
Table 2-1 and Table 2-2. 
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Table 2-1 Final concentrations of ferrocenyl chalcones (mg/ml) and DMSO (% v/v) for broth macrodilution assays. 
Tube # Concentrations of Chalcone and DMSO 
Chalcone (mg/ml) DMSO (% v/v) 
1 2.500 50.000 
2 1.250 25.000 
3 0.630 12.500 
4 0.310 6.250 
5 0.150 3.125 
 
Table 2-2 Final concentrations of ferrocenyl chalcones (mg/ml) and DMSO (% v/v) for broth microdilution assays. 
Well# 
Final Concentrations of Chalcone and DMSO 
Chalcone (mg/ml) DMSO % v/v 
1 0.500 50.000 
2 0.250 25.000 
3 0.125 12.500 
4 0.063 6.250 
5 0.031 3.125 
6 0.016 1.563 
7 0.008 0.782 
8 0.004 0.391 
9 0.002 0.195 
10 0.001 0.098 
 
2.1.4 Preparation of antimicrobial solutions for sensitivity determinations and MTT 
assays 
Stock antimicrobial solutions (250 mg/ml) of  PEN-G (Sigma, Dorset, UK) and 
oxytetracycline (OXY) were prepared in sterile deionised water according to the 
standard method described by Andrews (2001). Each solution was divided into 1 ml 
aliquots in sterile microcentrifuge tubes and then stored at -20oC. 
 
2.1.5 Preparation of stock MTT solution 
Appropriate volumes of stock MTT solution were prepared at a ratio of 5 mg/ml of 
MTT reagent powder in PBS. The stock solution was stored at -20oC until required. 
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2.2 Organisms used in each assay and their origins 
All organisms that were donated by Mr. Michael Collins of Chesterfield Royal Hospital 
(CRH) were stored in cryogenic storage vials with beads in nutrient broth (Thermo 
Fisher, Loughborough, UK) at -80oC. Other organisms were subcultured once per 
month on NA plates, incubated at 37oC for 18-24 hours and stored at 4oC. 
Table 2-3 Organisms used in the current study for the determination of MIC, time-kill assay, MTT assay and SEM. 
Organism Origin 
Klebsiella pneumoniae (IH) Mr. Ian Hopkins (IH) 
Enterococcus aerogenes NCIMB 
10102 
National Collection of Industrial, Food and 
Marine Bacteria 
Escherichia coli NCIMB 9483 National Collection of Industrial, Food and 
Marine Bacteria 
Pseudomonas aeruginosa NCTC 
10332 
National Collection of Type Cultures 
Staphylococcus aureus NCIMB 
8244 
National Collection of Industrial, Food and 
Marine Bacteria 
Kocuria kristinae NCIMB 8884 National Collection of Industrial, Food and 
Marine Bacteria 
Enterococcus faecalis NCTC 12697 National Collection of Type Cultures 
Staphylococcus aureus Fully 
Sensitive (CRH) 
Clinical isolate, CRH 
PEN-resistant Staphylococcus 
aureus (CRH) 
Clinical isolate, CRH 
PEN/ERY*/CLI**-resistant 
Staphylococcus aureus (CRH) 
Clinical isolate, CRH 
MRSA (CRH) Clinical isolate, CRH 
Salmonella “Manchester” NCTC 
7372 
National Collection of Type Cultures 
Escherichia coli Fully Sensitive 
(CRH) 
Clinical isolate, CRH 
*Erythromycin 
**Clindamycin 
2.2.1 Preparation of inocula for sensitivity assays, MTT assays and SEM 
Each inoculum was freshly prepared each time by suspending at least 3-4 colonies of 
the appropriate organism in 10 ml of ISB for broth macrodilution and 10 ml of sterile 
MHB for broth microdilution, time-kill assays, MTT assays and SEM. The colonies 
were dispersed until the turbidity of the suspension was equal to, or greater than, 
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that of 0.5 McFarland Standard and compared against a white background with a 
contrasting black line, which produced bacterial concentrations of 107 cfu/ml to 108 
cfu/ml. These suspensions were further diluted in sterile ISB or MHB to 
approximately 105 cfu/ml. Each inoculum was used within 30 minutes of preparation 
as detailed by Andrews (2001). 
 
2.3 Disk Diffusion 
Eight plates were divided into 6 sections and labelled for each compound (2 plates 
per organism). A minimum of 3-4 colonies of pure cultures of Klebsiella pneumonia 
(IH), Enterococcus aerogenes NCIMB 10102, Escherichia coli NCIMB 9483 and 
Pseudomonas aeruginosa NCTC 10332 were each suspended in 10 ml aliquots of 
sterile PBS (Sigma, Dorset, UK), derived from stock PBS, and each inoculum was 
spread onto the appropriately labelled plates. Two types of disk diffusion techniques 
were used: wet disk diffusion (Sharma et al., 2012) and dry disk diffusion (modified 
method by Sharma et al., 2012). The wet disk diffusion method involves the pipetting 
of a known volume and concentration of antibiotic solution on a sterile paper disk 
that has been aseptically placed on an inoculated agar spread plate. The dry disk 
diffusion method involves the aseptic placement of a dried paper disk, which has 
been impregnated with a known concentration of antibiotic solution, on an 
inoculated agar spread plate. 
 
2.4 Preparation of standard curves for broth microdilution and MTT assays 
Standard curves of Staphylococcus aureus NCIMB 8244, Streptococcus pyogenes 
NCIMB 8884, Enterococcus faecalis NCTC 12697, Salmonella “Manchester” NCTC 
7372, Pseudomonas aeruginosa NCTC 10332, Klebsiella pneumoniae (IH) and 
Escherichia coli NCIMB 9483 were prepared by making 10-fold serial dilutions of each 
overnight bacterial sample (0.1 ml broth culture and 0.9 ml sterile deionized water) 
from 10-1 cfu/ml to 10-5 cfu/ml. From each dilution, further 10-fold serial dilutions 
were made in sterile PBS from 10-1 cfu/ml to 10-8 cfu/ml, which will be used to 
determine the bacterial concentration. This preparation was also done for overnight 
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cultures of clinical isolates of fully sensitive S. aureus (CRH), PEN-resistant S. aureus 
(CRH), PEN/ERY/CLI-resistant S. aureus (CRH) and a MRSA (CRH). Ten NA plates were 
divided into quadrants and labelled according to the serial dilutions in PBS (2 agar 
plates per dilution made from sterile deionized water). Three 20 µl drops of each 
dilution made from PBS were pipetted onto each quadrant of the NA plates and 
allowed to dry. The NA plates were incubated at 370C in air for 18-24 hours. The 
number of cfu/ml were determined by identifying the dilution that had 3-30 colonies, 
followed by multiplying the average number of colonies by the appropriate dilution 
factor and then multiplying by 50. This method was first described by Miles et al. 
(1938). Absorbance values of the dilutions in deionized water were measured at 620 
nm on a WPA Biowave II spectrophotometer (Biochrom Limited, Cambourne, UK).  
 
2.5 Initial determination of cfu/ml for sensitivity determinations and MTT 
assays 
Each prepared inoculum was serially diluted 10-fold in sterile PBS from 10-1 cfu/ml to 
10-8 cfu/ml. NA plates were divided into quadrants and labelled 1 to 8 (2 agar plates 
per inoculum). The plates were then inoculated and incubated followed by the 
determination of the number of cfu/ml as described in Section 2.4. 
 
2.6 Preparation of 96-well microtitre plates for broth microdilution and MTT 
assays 
Seventy-five microlitres of MHB was pipetted into all wells except those of columns 
1, 11 & 12. A further 75 µl of prepared ferrocenyl chalcone solution was added to 
wells of columns 1 & 2 followed by 2-fold serial dilutions from column 2 – 10.  
Microdilution plates containing only diluted DMSO were treated in the same manner 
with MHB diluent. Seventy-five microlitres µl of PEN was added to wells of column 
11 and 75 µl of 5 % v/v DMSO was pipetted into wells of column 12. Seventy-five 
microlitres of MHB was added to wells of rows A & B. This was followed by pipetting 
of 75 µl of prepared inocula (S. aureus NCIMB 8244, S. pyogenes NCIMB 8884, E. 
faecalis NCTC 12697, Salmonella “Manchester” NCTC 7372, K. pneumoniae (IH) and 
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E. coli NCIMB 9483, fully sensitive S. aureus [CRH], PEN-resistant S. aureus [CRH], 
PEN/ERY/CLI-resistant S. aureus [CRH] and a MRSA [CRH]) into duplicated rows for 
each organism. The plates were sealed with a microplate lid and incubated at 37oC 
for 18-24 hours in air. After incubation, the absorbance values were measured at 620 
nm on a Rosys Anthos 2010 microplate reader. The blank wells were subtracted from 
the sample wells to give the absorbance of cells. 
 
2.7 Time-kill assay procedure 
Nine sterile polypropylene tubes were labelled for 1xMIC, 2xMIC and control (3 per 
condition). Five hundred microlitres of sterile MHB was pipetted into each control 
tube. Five hundred microlitres of diluted chalcone was pipetted into the MIC tubes 
according to the required concentration. Five hundred microlitres of each prepared 
inoculum was added to all 9 sample tubes, which represented hour 0. Three sets of 
sterile Eppendorf tubes were labelled for each polypropylene sample tube to which 
were added 900 µl of PBS. One hundred microlitres of sample tube (hour 0) solution 
(chalcone/inoculum or inoculum only) was added to each corresponding sterile 
Eppendorf tube containing PBS followed by serial dilution (for colony forming unit 
determination using Miles & Misra method). The polypropylene sample tubes were 
then incubated at 37oC in air and 100 µl were removed at consecutive 2-hour 
intervals (2, 4, 6, 8 and 24 hr) followed by the determination of the number of cfu/ml 
as described in Section 2.4. 
 
2.8 Preparation of bacterial samples for SEM 
Treated and untreated non-resistant bacterial inocula were examined in the SEM. 
The treated organisms were exposed to decyl ferrocenyl chalcone solution at MIC 
value and incubated for 18-24 hours at 37oC, whilst untreated cells were incubated 
under the same conditions in MHB in the absence of chalcone. The total volume of 
each suspension was 500 µl. After incubation at 37oC, 10 µl of crystal violet stain was 
added to both treated and untreated suspensions, which were then centrifuged for 
5 minutes at 13,000 rpm (11,337 g) in a Microcentrifuge Sigma 1-14 (Sigma Germany, 
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Osterode am Harz, Germany). After removal of the supernatant, the treated and 
untreated cells were incubated with 100 µl of 2% glutaraldehyde for 1 hour. This was 
followed by centrifugation of each solution for 1 minute at 13,000 rpm (11,337 g) and 
then washing of the pellets with PBS as proposed by Hartmann et al. (2010). After 
the suspensions were centrifuged for 1 minute at 13,000 rpm (11,337 g), and 
supernatants were removed, the cells were then dehydrated with a graded series of 
ethanol (20% v/v, 40% v/v, 60% v/v, 80% v/v, 95% v/v, 100% v/v, 100% v/v, 100% v/v) as 
detailed by Kaláb et al. (2008). After centrifugation for one 1 minute at 13,000 rpm 
(11,337 g), the cells were re-suspended in sterile deionised water. Ten microlitres of 
re-suspended cells were pipetted on to 0.2 µm Cyclopore Track Etch polycarbonate 
membrane filter disks (Whatman International Limited, Maidstone, UK) and sputter-
coated with gold for 1.5 minutes. Secondary electron images were taken using the 
JEOL JSM 6610V SEM (Herts, UK). The method development for the visualisation of 
bacteria in SEM is further detailed in Section 6.2 of Chapter 6. 
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3 Determination of MIC  
3.1 Introduction 
3.1.1 AST 
The evidence that chalcones with ferrocenyl moieties effectively exhibit 
antimicrobial action against Gram-negative and Gram-positive bacteria has increased 
in the last five years as evidenced by publications from a range of researchers in the 
field (Kowalski et al., 2013; Mishra et al., 2015; Gopi, Sastry, & Dhanaraju, 2016; Khan 
et al., 2017). In such studies, antimicrobial action was determined by the observed 
MIC values of the tested compounds, which reflected the inhibition of bacterial 
growth and susceptibility of the microorganisms. 
The susceptibility of bacteria to antimicrobial drugs can be determined by measuring 
the zone of inhibition using agar-disk diffusion (Wheat, 2001; Howe & Andrews, 
2012) and by using two-fold serial broth dilution (Andrews, 2001; Andrews, 2006; 
Valgas et al., 2007; Wiegand, Hilpert, & Hancock, 2008; CLSI, 2012).  
3.1.2 Disk diffusion test 
The disk diffusion test involves the measuring of zones of inhibition, which is 
influenced by the MIC. Conventionally, this approach refers to the inoculation of a 
pure culture of a bacterial suspension on a plate of Mueller Hinton agar medium or 
similar sensitivity agar and paper disks impregnated with antimicrobials that are 
placed on the surface of the medium (Moosdeen, Williams, & Seeker, 1988; Howe & 
Andrews, 2012; Matuschek, Brown, & Kahlmeter, 2013). After incubation at the 
optimal temperature for the organism for 18-24 hours, clear zones of growth 
inhibition, which indicates antimicrobial susceptibility, is measured in millimetres. 
The larger the zone of growth inhibition, the more  susceptible, indicated by reduced 
bacterial growth, a microorganism is to the antimicrobial compound, as elaborated 
by several investigators, including  Jorgensen & Ferraro (2009). Impregnation and 
drying of sterile disks can also be done with specific concentrations of novel 
antimicrobial drugs, as reported by Thompson (1950) and Vineetha et al. (2015). 
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3.1.3 Agar diffusion test 
The agar diffusion relies on a similar method whereby sensitivity agar plates are 
inoculated with test bacteria followed by the use of a sterile cork-borer that punches 
wells into the agar. This method has been used effectively over a number of years as 
detailed in various publications (Magaldi et al., 2004; Valgas et al., 2007; Balouiri, 
Sadiki, & Ibnsouda, 2016). A specified volume of antimicrobial solution is pipetted 
into the wells and this is allowed to diffuse into the agar. The agar plate is then 
incubated at the optimal temperature for bacterial growth for 18-24 hours after 
which the zone of growth inhibition is measured to give an indication of the efficacy 
of the antimicrobial agent. 
3.1.4 Broth dilution assays 
Another method used to show sensitivity of bacteria to antimicrobial agents is the 
broth macrodilution assay. This is one of the first susceptibility methods (Wiegand, 
Hilpert, & Hancock, 2008), and involves serially diluting one measured volume of an 
antimicrobial agent with an equal volume of sensitivity broth in a tube, as detailed 
by Jorgensen & Ferraro (2009). After inoculation of the diluted solution with test 
bacteria at 105 mg/ml, the suspension is incubated for 18-24 hours and growth is 
checked visually or by spectrophotometry at approximately 600 nm. The inoculum 
concentration of 105 mg/ml is the standardized quantity since lower quantities may 
give false positive results, while higher quantities may give false negative results 
(Wiegand, Hilpert, & Hancock, 2008). Broth microdilution is a modified version of the 
macrodilution method where the assay is performed in a sterile 96-well microplate 
instead of tubes, followed by measurement using a 96-well microplate reader, again 
detailed by Jorgensen & Ferraro (2009). In both methods, the MIC of the 
antimicrobial compound is therefore determined. Advantages of this method are 
that many samples can be assayed at one time and a small quantity of sample, broth 
and antimicrobial drug can be used. The bactericidal activity of an antimicrobial agent 
can also be determined. This is termed as the MBC and is defined by the CLSI as the 
lowest concentration at which a drug kills ≥ 99.9% of bacteria after incubation with 
the antimicrobial agent over a specified period (CLSI, 1999). This method has been 
employed by various researchers in the assessment of the antimicrobial activity of a 
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drug (Pankey & Sabath, 2004; Andrews, 2006; Hernandes et al., 2013). In both assays, 
PEN will be used as a control antimicrobial drug against PEN-sensitive Gram-positive 
bacteria, while OXY will be used as a control antimicrobial agent against PEN-
resistant Gram-positive bacteria and against Gram-negative bacteria, which possess 
resistance mechanisms against PEN as detailed by researchers such as Sutherland 
(1964). 
3.1.5 Time-kill assay 
The time-kill assay measures the rate at which the bacterial killing activity of an 
antimicrobial agent occurs and is dependent on concentration (CLSI, 1999). The 
number of colony forming units of the test sample, which is converted to log10, is 
estimated over specific time intervals, e.g., 1-2 hours (Messick, Rodvold, & Pendland, 
1999) and is plotted against time. The CLSI defined killing activity as the reduction of 
bacterial colonies by ≥99%, while other studies report killing activity as the reduction 
of bacterial colonies by ≥3 log10 (Belley et al., 2008; Bremmer et al., 2017; Cai et al., 
2017). 
3.1.6 Approaches to determining the antibacterial activity of newly developed 
ferrocenyl chalcone compounds 
One approach used in this current determination is to measure the MIC values of the 
newly developed ferrocenyl chalcone compounds against non-resistant laboratory-
adapted bacteria, as well as non-resistant and resistant clinical isolates. Another 
approach is to determine the rate of bactericidal activity of effective compounds over 
time. 
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3.2 Materials and Methods 
3.2.1 Preparation of sterile agar, reagents, tubes and other consumables 
SA plates and NA plates were prepared as described in Section 2.1.1 and Section 
2.1.2. 
3.2.2 Wet Disk Diffusion (Sharma et al., 2012) 
1 mg of each chalcone chemical was dissolved in 1 ml of 100% (DMSO) (Alfa Aesar, 
Heysham, UK) and thoroughly mixed, as detailed in Section 2.1.3. The solutions were 
then diluted 10X and 100X with sterile, deionized water, which was previously 
autoclaved at 1210C for 15 minutes. Sterile blank paper disks (approximately 6 mm 
in diameter) were aseptically placed in each of the labelled sections of the inoculated 
ISA plates, which were prepared as described in Section 2.1.1. 30 µl of each diluted 
chalcone was pipetted onto a sterile blank disk. CIP disks (Oxoid, Thermo Fisher, UK), 
a broad-spectrum antimicrobial agent (Ball, 2000), were used as positive controls 
while 30 µl 10X DMSO on sterile blank disks was used as the negative control. The 
plates were incubated at 370C in air for 18-24 hours. 
3.2.3 Dry Disk Diffusion (Modified Method by Sharma et al., 2012) 
Sterile blank disks were soaked overnight in stock chalcone solution, which were 
prepared as described in Section 2.1.3 (1 mg chalcone powder in 1 ml DMSO) and 
10X dilutions of the solutions. The disks were then air-dried in a Petri-dish in a sterile 
fume hood. Using a sterile pair of forceps, the dried disks were placed on the 
appropriate section of labelled inoculated ISA plates, which were prepared as 
described in Section 2.1.1. CIP disks were used as the positive controls while disks 
impregnated with 10X DMSO were used as the negative controls. The plates were 
then incubated at 37oC in air for 18-24 hours. 
3.2.4 Agar well diffusion 
Chalcone stock solutions were prepared by dissolving 1 mg of the chalcone powder 
in 1 ml of DMSO and mixed by vortexing, as detailed in Section 2.1.3. From these 
stock solutions, 10X working solutions were prepared in sterile deionised water. The 
inocula were prepared by suspending at least 3-4 colonies of pure cultures of 
Klebsiella pneumonia (IH), Enterococcus aerogenes NCIMB 10102, Escherichia coli 
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NCIMB 9483 and Pseudomonas aeruginosa NCTC 10332 in 10 ml aliquots of sterile 
PBS. Each inoculum was spread onto appropriately labelled ISA plates where 2 plates 
were allocated for the stock solution and 2 plates were allocated for the 10X solutions 
(4 plates per organism). A sterile cork-borer was used to create 6 holes (diameter = 
6 mm) in each agar plate. 30 µl of appropriate chalcone solution (stock and 10X 
solutions) were pipetted into their respective holes. A 10X DMSO solution was used 
as the negative control while OXY (Alfa Aesar, Heysham, UK), which was prepared by 
dissolving 0.128 mg per ml of sterile deionised water, was used as the positive 
control. The solutions were allowed to diffuse into the agar and then the plates were 
inverted before incubation at 37oC in air for 18-24 hours. 
 
3.2.5 MIC using Two-fold serial broth macrodilution and microdilution 
3.2.5.1 Preparation of stock ferrocenyl chalcone solution 
For broth macrodilution assays, fresh stock of each ferrocenyl chalcone solution were 
prepared as described in Section 2.1.3 at concentrations of 5 mg/ml in DMSO. Fresh 
stock solutions of each compound were prepared as described in Section 2.1.3 at 
concentrations of 1 mg/ml in DMSO for each broth microdilution. The final 
concentrations of each ferrocenyl chalcone are shown in Table 2-1 and Table 2-2. 
3.2.5.2 Preparation of stock antimicrobial compound 
Stock antimicrobial solutions of PEN-G and OXY were prepared as detailed in Section 
2.1.4. Each solution was divided into 1 ml aliquots in sterile microcentrifuge tubes 
and then stored at -20oC. 
3.2.5.3 Preparation of inocula 
Each inoculum was freshly prepared each time as detailed in Section 2.2.1. 
3.2.5.4 MIC determination using Broth Macrodilution 
Four sets of sterile borosilicate glass tubes (one set per organism) were labelled “Org 
1-5” (Organisms used = E. coli NCIMB 9483, K. pneumonia (IH), E. faecalis NCTC 
12697, S. aureus NCIMB 8244, another 4 sets of glass tubes (1 set per organism) were 
labelled “Org +DMSO 1-5” and 4 tubes (1 per organism) was labelled “Org + 
PEN/OXY”. 500 µl of ISB was pipetted into all tubes. 500 µl of stock chalcone (5 mg in 
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1 ml of 100% v/v) was pipetted into the tubes labelled “Org 1”, which was then 
followed by 2-fold serial dilutions up to tubes labelled “Org 5”. A similar series of 
steps were performed for the tubes labelled “Org + DMSO 1” using 500 µl of DMSO 
while 500 µl of PEN (for Gram-positive organisms) and OXY (for Gram-negative 
organisms) was added to the tubes labeled “Org + PEN/OXY”. An equal volume of 
each prepared inoculum (500 µl) was added to the appropriately labelled tubes and 
mixed by vigorous shaking. The tubes were then incubated at 37oC in air for 18-24 
hours. The absorbance values for each solution were read at 600 nm on the 
spectrophotometer.  
3.2.5.5 Preparation of bacterial standard curves for broth microdilution 
Standard curves of Staphylococcus aureus NCIMB 8244, Streptococcus pyogenes 
NCIMB 8884, Enterococcus faecalis NCTC 12697, Salmonella “Manchester” NCTC 
7372, Pseudomonas aeruginosa NCTC 10332, Klebsiella pneumoniae (IH) and 
Escherichia coli NCIMB 9483 were prepared as described in Section 2.4.  The number 
of cfu/ml, which were converted to log10 cfu/ml, were determined for each organism 
and plotted against absorbance using the graph package ‘MS Excel’ to produce 
standard curves (Appendix 3, Figure 7-34 to 7-43). 
3.2.5.6 Initial determination of cfu/ml 
Each prepared inoculum was serially diluted 10 X in sterile PBS from 10-1 mg/ml to 
10-8 mg/ml as detailed in Section 2.4.  
3.2.5.7 MIC determination using Broth Microdilution 
The microdilution plates for ferrocenyl chalcones and DMSO only were prepared as 
detailed in Section 2.6 and as seen in Appendix 2 (Table 7-2 and Table 7-3, 
respectively). Measurements of log10 cfu/ml were calculated from equations 
generated from the respective standard curves (Appendix 3, Figure 7-34 to Figure 7-
43).  Mean (± SD) MIC values of the ferrocenyl chalcone compounds were 
extrapolated from the calculated log10 cfu/ml values of each bacterial sample that 
were within 1 SD of the initial log10 cfu/ml. Each assay was performed in triplicate 
producing a total of 6 measurements. 
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3.2.5.8 Determination of MBC 
After incubation of each inocula and ferrocenyl chalcone as described in Section 
3.2.5.7, a loopful of each solution with no visible growth was applied to quadrants of 
labelled NA plates. The plates were incubated at 37oC in air for 18-24 hours and 
visually assessed for bacterial growth. 
 
3.2.6 Time-kill assay of Gram-positive organisms 
3.2.6.1 Preparation of stock decyl ferrocenyl chalcone solution 
The compound with the best overall MIC activity, as estimated in Section 3.2.5.7, was 
used in this assay. Fresh stock decyl ferrocenyl chalcone solution was prepared as 
described in Section 2.1.3. The solution was then serially diluted in a 1:1 ratio in 
sterile MH broth up to the required MIC. 
3.2.6.2 Preparation of inocula 
Each inoculum was prepared as described in Section 2.2.1 in sterile MHB. The 
organisms used in this assay were S. aureus NCIMB 8244, Fully Sensitive S. aureus 
(CRH), E. faecalis NCTC 12697 and K. kristinae NCIMB 8884 (previously misidentified 
as S. pyogenes). 
3.2.6.3 Time-kill assay procedure 
Nine sterile polypropylene tubes were labelled for 1xMIC, 2xMIC and control (3 per 
condition). The assay was then prepared and completed as described in Section 2.7. 
Mean (± SD) cfu/ml was plotted against time (hours) in Excel. 
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Results 
3.2.7 Disk Diffusion 
3.2.7.1 Wet Disk Diffusion 
The results showed zones of growth inhibition from 6 mm to 7 mm for disks 
containing 10-fold diluted solutions, 6 mm to 9 mm for disks containing 100-fold 
diluted solutions, and 6 mm-13 mm for disks containing stock solutions (1 mg/ml). 
Zones of inhibition from 27 mm to 41 mm were seen for disks containing CIP against 
all bacterial samples. 
Table 3-1 Zones of inhibition (mm) of 10 ferrocenyl chalcones 10-fold diluted solutions, DMSO and CIP against 
non-resistant laboratory bacteria. 
Chalcone/Compound 
Zone of inhibition (mm) 
K. 
pneumonia 
(IH) 
E. 
aerogenes 
NCIMB 
10102 
E. coli 
NCIMB 
9483 
P. 
aeruginosa 
NCTC 10332  
Methyl 6 7 7 7 
Ethyl 6 6 7 6 
Propyl 6 7 6 7 
Butyl 7 7 6 7 
Pentyl 7 6 6 7 
Hexyl 7 6 7 6 
Heptyl 6 6 7 7 
Octyl 6 7 7 7 
Nonyl 7 7 6 6 
Decyl 6 7 6 6 
DMSO (10% v/v) 6 7 6 7 
CIP (1 µg) 28 38 33 31 
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Table 3-2 Zones of inhibition (mm) of 10 ferrocenyl chalcones 100-fold diluted solutions, DMSO and CIP against 
non-resistant laboratory bacteria. 
Chalcone/Compound 
Zone of inhibition (mm) 
K. 
pneumonia 
(IH) 
E. 
aerogenes 
NCIMB 
10102 
E. coli 
NCIMB 
9483 
P. 
aeruginosa 
NCTC 10332  
Methyl 7 7 6 7 
Ethyl 6 7 6 6 
Propyl 7 7 7 6 
Butyl 6 6 8 6 
Pentyl 6 6 7 7 
Hexyl 6 6 7 7 
Heptyl 7 6 7 7 
Octyl 7 7 6 7 
Nonyl 7 6 6 6 
Decyl 6 6 6 7 
DMSO (10% v/v) 6 9 6 8 
CIP (1 µg) 27 41 36 32 
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Table 3-3 Zones of inhibition (mm) of 10 ferrocenyl chalcones stock solutions, DMSO and CIP against non-
resistant laboratory bacteria. 
Chalcone/Compound 
Zone of inhibition (mm) 
K. 
pneumonia 
(IH) 
E. 
aerogenes 
NCIMB 
10102 
E. coli 
NCIMB 
9483 
P. 
aeruginosa 
NCTC 10332  
Methyl 6 11 6 12 
Ethyl 6 11 6 11 
Propyl 7 12 8 13 
Butyl 8 11 8 10 
Pentyl 7 10 7 10 
Hexyl 9 10 9 12 
Heptyl 10 11 10 12 
Octyl 10 11 9 12 
Nonyl 10 13 8 13 
Decyl 10 11 10 11 
DMSO (10% v/v) 6 8 6 9 
CIP (1 µg) 29 40 36 31 
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3.2.7.2 Dry Disk Diffusion 
The results showed zones of growth inhibition from 6 mm to 8 mm for disks 
containing 10-fold diluted solutions and for disks containing stock solutions (1 
mg/ml). Zones of inhibition from 29 mm to 41 mm were seen for disks containing CIP 
against all bacterial samples. 
Table 3-4 Zones of inhibition (mm) of 10 ferrocenyl chalcones 10-fold diluted solutions, DMSO and CIP against 
non-resistant laboratory bacteria. 
Chalcone/Compound 
Zone of inhibition (mm) 
K. 
pneumonia 
(IH) 
E. 
aerogenes 
NCIMB 
10102 
E. coli 
NCIMB 
9483 
P. 
aeruginosa 
NCTC 10332  
Methyl 6 6 7 6 
Ethyl 7 6 7 7 
Propyl 7 6 6 7 
Butyl 6 7 8 7 
Pentyl 8 7 7 6 
Hexyl 7 6 8 7 
Heptyl 6 6 6 7 
Octyl 7 7 7 7 
Nonyl 7 7 8 6 
Decyl 7 6 6 7 
DMSO (10% v/v) 6 8 7 6 
CIP (1 µg) 30 39 36 31 
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Table 3-5 Zones of inhibition (mm) of 10 ferrocenyl chalcones neat solutions, DMSO and CIP against non-
resistant laboratory bacteria. 
Chalcone/Compound 
Zone of inhibition (mm) 
K. 
pneumonia 
(IH) 
E. 
aerogenes 
NCIMB 
10102 
E. coli 
NCIMB 
9483 
P. 
aeruginosa 
NCTC 10332  
Methyl 8 6 8 6 
Ethyl 6 7 6 6 
Propyl 7 7 8 7 
Butyl 7 8 8 7 
Pentyl 7 7 7 8 
Hexyl 8 7 7 6 
Heptyl 7 7 6 8 
Octyl 6 6 8 7 
Nonyl 7 6 6 7 
Decyl 7 7 6 8 
DMSO (10% v/v) 8 8 7 6 
CIP (1 µg) 31 40 35 29 
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3.2.8 Agar well diffusion 
After incubation for 18-24 hours at 37oC, the results showed zones of growth 
inhibition from 6 mm to 8 mm for wells containing 10-fold diluted solutions and for 
wells containing stock solutions (1 mg/ml). Zones of inhibition from 30 mm to 41 mm 
were seen for wells containing OXY against all bacterial samples. 
Table 3-6 Zones of inhibition (mm) of 10 ferrocenyl chalcones 10-fold diluted solutions, DMSO and OXY against 
non-resistant laboratory bacteria. 
Chalcone/Compound 
Zone of inhibition (mm) 
K. 
pneumonia 
(IH) 
E. 
aerogenes 
NCIMB 
10102 
E. coli 
NCIMB 
9483 
P. 
aeruginosa 
NCTC 10332  
Methyl 7 6 8 7 
Ethyl 6 7 6 6 
Propyl 8 7 7 6 
Butyl 8 7 7 6 
Pentyl 8 6 7 7 
Hexyl 8 8 6 7 
Heptyl 7 7 6 8 
Octyl 7 7 8 8 
Nonyl 6 6 7 8 
Decyl 6 6 7 7 
DMSO (10% v/v) 7 8 8 6 
OXY 34 40 36 30 
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Table 3-7 Zones of inhibition (mm) of 10 ferrocenyl chalcones neat solutions, DMSO and OXY against non-
resistant laboratory bacteria. 
Chalcone/Compound 
Zone of inhibition (mm) 
K. 
pneumonia 
(IH) 
E. 
aerogenes 
NCIMB 
10102 
E. coli 
NCIMB 
9483 
P. 
aeruginosa 
NCTC 10332  
Methyl 6 6 6 7 
Ethyl 7 6 6 6 
Propyl 6 6 8 7 
Butyl 6 8 8 7 
Pentyl 8 8 7 6 
Hexyl 7 7 7 6 
Heptyl 7 8 7 7 
Octyl 6 8 8 7 
Nonyl 8 6 8 7 
Decyl 7 7 8 7 
DMSO (10% v/v) 6 8 6 6 
OXY 30 41 33 32 
 
It became apparent that the initial diffusion assays were performed using DMSO 
contaminated with water thus affecting validity of the results presented in Sections 
3.2.7 and 3.2.8. Even so, the results gave sufficient indication of the potential MIC 
and are included here to justify subsequent research. Progress with the following 
investigations did not allow time to repeat the original diffusion assays. 
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3.2.9 MIC using Two-fold serial broth microdilution and broth microdilution 
3.2.9.1 Broth macrodilution 
Table 3-8 Mean (± SD) MIC values of 10 ferrocenyl chalcone compounds (5 mg/ml) against non-resistant 
laboratory-adapted bacteria. 
Chalcone 
MIC values (mg/ml) 
S. aureus 
NCIMB 8244 
E. faecalis 
NCTC 12697 
K. pneumonia 
(IH) 
E. coli NCIMB 
9483 
Methyl 2.500 2.500 1.250 1.250 
Ethyl 2.500 2.500 2.500 2.500 
Propyl 2.500 2.500 2.500 2.500 
Butyl 2.500 1.250 2.500 2.500 
Pentyl 1.250 0.630 2.500 2.500 
Hexyl 0.310 0.310 2.500 2.500 
Heptyl 0.310 0.630 2.500 2.500 
Octyl 0.310 0.310 2.500 2.500 
Nonyl 2.500 1.250 2.500 2.500 
Decyl 0.150 0.150 2.500 1.250 
 
The MIC values determined from broth macrodilution ranged from 0.150 mg/ml to 
2.500 mg/ml where the percentage of DMSO present ranged from 3.130% v/v to 
50.000% v/v. Additionally, the concentration (5 mg/ml) used in the broth 
macrodilution assays was derived from Medu (2013). However, the absorbance 
values obtained from the current study indicated the difficulty in distinguishing 
between the dark brown colour observed after incubation and actual bacterial 
growth. Even so, the results provided enough indication of the potential MIC, which 
are approximately 5X those obtained from the broth microdilution assays, and are 
included here to justify subsequent research. Progress with the following 
investigations did not allow time to repeat the macrodilution assays. 
3.2.9.2 Broth microdilution 
Methyl to pentyl ferrocenyl chalcones and non-methylated ferrocenyl chalcone 
showed lower antimicrobial activity than hexyl to decyl ferrocenyl chalcones (Table 
3-9). The former group of compounds showed MIC values of 0.125 mg/ml (± 0.000) 
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for all organisms tested. MIC values at 0.125 mg/ml contained 12.500% v/v DMSO, 
which was also the threshold at which microbial growth was seen. The MBC assays 
revealed that bacterial growth in DMSO was only inhibited at greater than, or equal 
to, 12.500% v/v DMSO. The chalcones with longer alkyl chain lengths (hexyl-decyl) 
also had lower MICs against Gram-positive bacteria than against Gram-negative 
bacteria (Table 3-9). MIC values of ferrocenyl chalcones with longer alkyl chains 
ranged from 0.008 mg/ml (± 0.000) and 0.063 mg/ml (± 0.000) for S. aureus NCIMB 
8244, E. faecalis NCTC 12697, K. kristinae NCIMB 8884 and a non-resistant clinical 
isolate of S. aureus (Table 3-9), while MIC values of the same group of ferrocenyl 
chalcones against all Gram-negative bacteria were equal to 0.125 mg/ml (± 0.000). 
MIC values for the same longer alkyl chain ferrocenyl chalcones against resistant 
clinical isolates range of S. aureus from 0.031 mg/ml (± 0.000) to 0.063 mg/ml (± 
0.000) (Table 3-9).  The MBC values of the hexyl to decyl ferrocenyl chalcones against 
the laboratory -adapted bacteria were also equal to the MICs. 
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Table 3-9 Mean (± SD) MIC values of 11 ferrocenyl chalcone compounds (1 mg/ml) against non-resistant and resistant laboratory-adapted bacteria and clinically isolated bacteria. NM = non-
methylated ferrocenyl chalcone. *MBC values. 
Organism  Mean (±0.000, n=6) MIC (mg/ml) 
NM Methyl Ethyl Propyl Butyl Pentyl Hexyl Heptyl Octyl Nonyl Decyl 
S. aureus NCIMB 8244 0.125 0.125 0.125 0.125 0.125 0.125 0.063* 0.063* 0.063* 0.063* 0.031* 
K. kristinae NCIMB 8884 0.125 0.125 0.125 0.125 0.125 0.125 0.031* 0.008* 0.016* 0.016* 0.016* 
E. faecalis NCTC 12697 0.125 0.125 0.125 0.125 0.125 0.125 0.063* 0.063* 0.063* 0.063* 0.063* 
S. aureus Fully Sens. (CRH) 0.125 - - - - - 0.125* 0.063* 0.063* 0.063* 0.063* 
PEN-resistant S. aureus (CRH) 0.125 - - - - - 0.063* 0.031* 0.063* 0.063* 0.063* 
PEN/ERY/CLI-resistant (CRH) 0.125 - - - - - 0.063* 0.031* 0.063* 0.063* 0.063* 
MRSA (CRH) 0.125 - - - - - 0.063* 0.063* 0.063* 0.063* 0.063* 
E. coli NCIMB 9483 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
K. pneumoniae (IH) 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
Salmonella "Manchester" NCTC 
7372 
0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 0.125 
E. coli Fully Sens. (CRH) 0.125 - - - - - 0.125 0.125 0.125 0.125 0.125 
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3.2.10 Time kill assay 
At 1xMIC (0.031 mg/ml), mean (± SD) cfu reduced to 0 (± 0.000) log10 cfu/ml from 4 
hours, while reduction of mean (± SD) cfu to 0 (± 0.000) log10 cfu/ml occurred from 
2 hours after the organism was exposed to 2xMIC (0.063 mg/ml) (Figure 3-1). In the 
same assay, the percentages of DMSO present in solution exhibited no bactericidal 
activity at 3.100% and 6.300%. Untreated cells showed normal growth trends up to 
24 hours. The results of the time kill assay for decyl ferrocenyl chalcone against S. 
aureus NCIMB 8244 confirmed that bactericidal activity occurred.
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Figure 3-1 Time-kill curve (n=3) of decyl ferrocenyl chalcone compound and DMSO against S. aureus NCIMB 8244 at 1xMIC and 2xMIC. The curve for 3.1% DMSO (circle) contained similar values 
to those measured for 6.3% DMSO (diamond).
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Results of the time kill assay for decyl ferrocenyl chalcone also confirmed that the 
compound possessed bactericidal activity against a MRSA. At 1xMIC (0.063 mg/ml) 
and 2xMIC (0.125 mg/ml), mean (± SD) cfu reduced to 0 (± 0.000) log10 cfu/ml from 
2 hours, (Figure 3-2). In the same assay, the percentages of DMSO present in solution 
exhibited no bactericidal activity at 6.300% v/v and 12.500% v/v. Untreated cells 
showed normal growth trends up to 24 hours. 
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Figure 3-2 Time-kill curve (n=3) of decyl ferrocenyl chalcone compound and DMSO against a MRSA at 1xMIC and 2xMIC. The curve for 6.300% DMSO (circle) contained similar values to those 
measured for 12.500% DMSO (diamond), while the curve for 1xMIC (triangle) contained similar values to those measured for 2xMIC (large square).
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Findings of the time kill assay for decyl ferrocenyl chalcone against E. faecalis NCTC 
12697 revealed the effect of bactericidal activity. At 1xMIC (0.063 mg/ml), mean (± 
SD) cfu reduced to 0 (± 0.000) log10 cfu/ml from 2 hours, while reduction of mean (± 
SD) cfu to 0 (± 0.000) log10 cfu/ml occurred from 0 hours after the organism was 
exposed to 2xMIC (0.125 mg/ml) (Figure 3-3). In the same assay, the percentages of 
DMSO present in solution exhibited no bactericidal activity at 6.300% v/v and 12.500% 
v/v. Untreated cells showed normal growth trends up to 24 hours. 
 
 
 
 
 
 
 
 
63 | P a g e  
 
 
Figure 3-3 Time-kill curve (n=3) of decyl ferrocenyl chalcone compound and DMSO against E. faecalis NCTC 12697 at 1xMIC and 2xMIC. The curve for 6.300% DMSO (circle) contained similar 
values to those measured for 12.500% DMSO (diamond).
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Evidence of bactericidal activity was also seen for decyl ferrocenyl chalcone against 
K. kristinae NCIMB 8884. At 1xMIC (0.016 mg/ml) and 2xMIC (0.031 mg/ml), mean (± 
SD) cfu reduced to 0 (± 0.000) log10 cfu/ml from 0 hours (Figure 3-4). In the same 
assay, the percentages of DMSO present in solution exhibited bacteriostatic, but not 
bactericidal activity, at 1.600% v/v and 3.100% v/v. Untreated cells showed normal 
growth trends up to 24 hours. 
 
 
 
 
 
 
 
 
 
 
 
65 | P a g e  
 
 
Figure 3-4 Time-kill curve (n=3) of decyl ferrocenyl chalcone compound and DMSO against K. kristinae NCIMB 8884 at 1xMIC and 2xMIC. The curve for 1.600% DMSO (circle) contained similar 
values to those measured for 3.100% DMSO (diamond), while the curve for 1xMIC (triangle) contained similar values to those measured for 2xMIC (large square).
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3.3 Discussion 
3.3.1 Determination of antimicrobial activity using disc diffusion and agar well 
diffusion methods 
The techniques used in these assays were pilot experiments to determine the 
appropriateness of using diffusion methods in the current study. While most of the 
results indicated that the methods were unsuitable, key details about the inhibition 
of diffusion of the ferrocenyl chalcone compounds into the agar were obtained. 
Therefore, as stated at the end of Section 3.2.8, the inclusion of the results of the 
diffusion methods was necessary in order to determine more suitable procedures as 
the research work progressed.  
The results of both the agar well diffusion and disc diffusion showed little to no clear 
zones of inhibition, with zone diameters from 6 mm to 13 mm, when the organisms 
were treated with stock chalcone solution of all ferrocenyl chalcone compounds. The 
presence of no clear zones of growth inhibition, when compared to visible clear zones 
of bacterial growth with large diameters (29 mm to 40 mm) after exposure to CIP 
were lower than the reported susceptibility values of 14 mm to 40 mm (Wootton et 
al., 2014). The values were also lower than the reported susceptibility values of ≥22 
mm (Enterobacteriaceae) and ≥15 mm (Enterococcus spp.) (EUCAST, 2016). This 
result was unexpected and may be explained by further examination of the solvent 
DMSO. It is frequently used to solubilise lipophilic compounds used in antimicrobial 
sensitivity assays but can be a bacteriostatic agent, i.e., an agent that stops bacterial 
growth but does not kill bacteria as reported by (Basch, Gadebusch, & Brunswick, 
1968). Although the chalcones were completely solubilised in DMSO, they began to 
precipitate after a few minutes. Further investigations have suggested that the DMSO 
used in these assays appeared to be saturated with water, as DMSO is hygroscopic. 
This contamination results in characteristics such as lower solubilisation ability and 
the solvent emits a pungent aroma. As the chalcones were no longer in solution, it is 
possible that the precipitated particles, which may have been larger than the pore 
size of the agar lattice (≥3 mµ) (Hewitt, 2005), could not diffuse into the agar, hence 
resulting in little to no zones of growth inhibition.  
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3.3.2 Determination of MIC using broth macrodilution 
The results of the broth macrodilution showed unusual results with no discernible 
trend. Results of the broth macrodilution tests revealed that bacterial growth was 
inhibited at ≥12.500% v/v DMSO, which was the concentration of DMSO in solutions 
containing   0.630 mg of ferrocenyl chalcone compound. The inhibitory concentration 
of DMSO that was obtained in the current tests were also reported by Basch et al. 
(1968) and Duric et al. (2013). In the same current tests, results showed that alkyl 
chain influenced antibacterial activity of the ferrocenyl chalcone compounds. Thus, 
the results would have been expected to show an increase in sensitivity as chalcones 
alkyl chain lengths increased, particularly with the hexyl to decyl ferrocenyl chalcone 
compounds. However, S. aureus NCIMB 8244 sensitivity was seen against hexyl 
(0.310 mg/ml), heptyl (0.310 mg/ml), octyl (0.310 mg/ml) and decyl (0.150 mg/ml) 
but was reduced against nonyl (2.500 mg/ml). The concentration of DMSO contained 
in solutions with hexyl to octyl and decyl was 3.100% v/v to 6.250% v/v, which was 
lower than the inhibitory concentration of 12.500% v/v and indicated that growth 
inhibition was caused by the presence of ferrocenyl chalcone. In contrast, nonyl 
ferrocenyl chalcone did not have an effect on the same organism since the MIC value 
was 2.500 mg/ml and the DMSO concentration (50.000%) was ≥12.500% v/v. Thus, 
DMSO, and not nonyl ferrocenyl chalcone, inhibited bacterial growth.  
A similar trend was observed for nonyl ferrocenyl chalcone against E. faecalis NCTC 
12697, where the MIC value was 1.250 mg/ml and the inhibitory concentration of 
DMSO (25.000% v/v) was ≥12.500% v/v. Conversely, pentyl (0.630 mg/ml), hexyl 
(0.310 mg/ml), heptyl (0.630 mg/ml), octyl (0.310 mg/ml) and decyl (0.150 mg/ml) 
showed antibacterial activity against E. faecalis NCTC 12697 since the concentrations 
of DMSO (3.125% v/v - 12.500% v/v) were ≤12.500% v/v.  
The MIC values for all ferrocenyl chalcone compounds against K. pneumonia (IH) and 
E. coli NCIMB 9483 were 1.250 mg/ml and 2.500 mg/ml with DMSO concentrations 
(25.000% v/v – 50.000% v/v) that were greater than the inhibitory concentration of 
12.500% v/v. Therefore, DMSO, and not the ferrocenyl chalcone compounds, 
exhibited antibacterial activity against the Gram-negative organisms. 
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The absorbance values that were derived from the experiment were sometimes high 
at increased chalcone concentrations (Table 3-8), which would indicate bacterial 
growth. However, no growth was seen when the solutions were inoculated on NA 
plates. A theory of why no growth was observed is that a quantity of ferrocenyl 
chalcone remained solubilised in hydrated DMSO. Although hydrated DMSO is 
reported to lose its power of solubility with organic compounds (Ellson et al., 2005), 
an unknown quantity of solubilised ferrocenyl chalcone may have exhibited 
bactericidal activity in the assay. This was further proof for the suggestion that the 
DMSO was hydrated and that the ferrocenyl chalcones were reversibly solubilised. 
The insoluble chalcones were possibly rendered ineffective in this suspended state 
since they were unable to cross the lipid bilayer of the bacterial cell membrane. 
Negative absorbance values (Table 3-8) could also be indicative of incomplete 
solubilisation in DMSO. This indicated that DMSO and/or broth, and not chalcone, 
was absorbing more light than the reference solutions. 
3.3.3 Determination of MIC using broth microdilution 
In the broth microdilution assay, fresh DMSO was used as the solvent for the 
ferrocenyl chalcones. The results in Table 3-9 showed that MIC values (0.125 mg/ml 
in 12.500% v/v DMSO) of the non-methylated and methylated ferrocenyl chalcone 
compounds with shorter alkyl chains (methyl to pentyl) were within the reported 
values for PEN (0.000015-0.128 mg/ml) (Andrews, 2001; Andrews, 2006) and the 
reported value of ≤0.125 mg/ml for the same antimicrobial compound (EUCAST, 
2016) against Staphylococci. In the same assay, the MIC values of all 10 compounds 
were 0.125 mg/ml in 12.500% v/v DMSO against Enterobacteriaceae (Table 3-9), 
which were within the values reported by Andrews (2001 & 2006) for tetracycline 
(0.00025-0.128 mg/ml) against Enterobacteriaceae. Breakpoint values for 
tetracycline against Enterobacteriaceae were not reported by EUCAST (2016). 
Reported values by Andrews (2001 & 2006) were used since OXY is an analogue of 
tetracycline. While the MIC values of the above-mentioned ferrocenyl chalcone 
compounds were similar to those of the appropriate control antimicrobial agents, 
growth inhibition, as exhibited by these novel compounds, may also have resulted 
from exposure of the organisms to DMSO. DMSO has been shown to have an 
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inhibitory effect at percentages equal to and/or greater than 12.500% v/v (Basch, 
Gadebusch, & Brunswick, 1968; Duric et al., 2013). The chalcone MIC values for S. 
aureus NCIMB 8244 began to decrease as alkyl chain length increased.  This was 
especially seen with hexyl to nonyl (0.063 mg/ml) and decyl (0.031 mg/ml) (Table 3-
9). Except for hexyl against clinically isolated S. aureus (fully sensitive) (CRH), 
sensitivity was also seen for hexyl to decyl against PEN-resistant S. aureus (CRH), PEN-
resistant, ERY-resistant, CLI-resistant S. aureus clinical isolates (CRH) (0.031 mg/ml to 
0.063 mg/ml) (Table 3-9). Therefore, the presence of long alkyl chains increases 
antibacterial activity. 
The MIC/MBC values reported in Table 3-9 varied between each organism and 
between each chalcone. When used against S. pyogenes NCIMB 8884, which was 
later confirmed to be K. kristinae, all chalcones with longer alkyl chains showed 
MIC/MBC values of 0.016 mg/ml except for hexyl (0.031 mg/ml) and heptyl (0.008 
mg/ml). When used against E. faecalis NCTC 12697, hexyl to decyl ferrocenyl 
chalcones showed MIC/MBC values of 0.063 mg/ml. These values were also within 
the expected range of known antimicrobials (0.0005-0.128 mg/ml), such as PEN, for 
Enterococci (Andrews, 2001; Andrews, 2006). Although antimicrobial activity was 
seen with hexyl to decyl against K. pneumoniae (IH), E. coli (CRH), E. coli NCIMB 9483 
and Salmonella “Manchester” NCTC 7372 (0.125 mg/ml), it may have resulted from 
sensitivity to 12.500% v/v DMSO. 
The overall trend appeared to be that the chalcones had a greater inhibitory effect 
on Gram-positive bacteria than on Gram-negative bacteria. The difference in MIC 
values with respect to the Gram-negative and Gram-positive organisms may be as a 
result of increasing alkyl chain length. One explanation why the Gram reaction may 
be a factor is that the compounds may pass across the hydrophilic peptidoglycan 
layer of Gram-positive bacteria because of the amphipathic DMSO (Matthews et al., 
1975; Hassan, 2014). The long chains may become trapped in the cell membrane 
allowing the attached ferrocenyl groups, which are relatively smaller than the alkyl 
chains, to enter the cytoplasm. Since Gram-negative bacteria have outer envelopes 
with membrane transporter proteins such as porins, followed by thin peptidoglycan 
layers and cell membranes in their cellular envelopes, entry into these cells may be 
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more difficult. These porins allow hydrophilic compounds to enter, while 
hydrophobic compounds may diffuse across the lipid bilayer of the outer envelope, 
as detailed by various researchers (Nikaido, 2003; Pagès, James, & Winterhalter, 
2008; Bolla et al., 2011). However, because of the fluidity of the outer lipid bilayer of 
Gram-negative bacteria (Seltmann & Holts, 2002), the long alkyl chains of the 
ferrocenyl chalcones may become trapped in the outer envelope and would be 
unable to cross the peptidoglycan layer and cell membrane into the cells (Henry et 
al., 2017). Another reason why the difference between Gram-positive and Gram-
negative bacteria may be important is that organisms, such as E. coli, have become 
used to surviving in enriched media, which promotes vigorous growth (Cooper, 
Rozen, & Lenski, 2003; Fux et al., 2005) and may result in phenotypic changes to the 
cell wall. 
3.3.4 Time-kill assay 
In the time-kill assay, decyl ferrocenyl chalcone compound was selected since the 
compound exhibited the best overall bactericidal activity against the Gram-positive 
organisms in the current study (Table 3-9). The mean cfu of S. aureus NCIMB 8244 
was reduced from 4.600 (± 0.130) log10 cfu/ml to 0.000 (± 0.000) log10 cfu/ml after 4 
hours of incubation with the compound at 1xMIC (0.031 mg/ml), while the mean cfu 
decreased from 3.270 (± 0.080) log10 cfu/ml to 0.000 (± 0.000) log10 cfu/ml after 2 
hours of incubation at 2xMIC (0.063 mg/ml) (Figure 3-1). Equivalent concentrations 
of only DMSO solvent (3.100% v/v and 6.300% v/v) against the organism did not inhibit 
bacterial growth, since DMSO exhibits bacteriostatic activity at ≥12.500% v/v (Basch, 
Gadebusch, & Brunswick, 1968; Duric et al., 2013). This meant that in the presence 
of chalcone, increased bactericidal activity was proportional to decreased MIC of 
ferrocenyl chalcone compound. This proportional trend was markedly different to 
the activity seen in the study by Scheerans et al. (2015) with linezolid against S. 
aureus ATCC 29213 where the compound exhibited antibacterial activity from 4-6 
hours at 0.004 – 0.008 mg/ml of linezolid. At this time period and concentration, 
activity was determined to be bacteriostatic since mean (± SD) cfu were reduced from 
approximately 6.00 log10 cfu/ml to 4.50 – 5.50 log10 cfu/ml, which is ≤99.9% of cells. 
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However, from 24 hours at 0.016 mg/ml (8xMIC), there was evidence of bactericidal 
activity since mean (± SD) cfu was estimated to be ≤3 log10 cfu/ml. 
At 1xMIC (0.063 mg/ml) and 2xMIC (0.125 mg/ml) of decyl ferrocenyl chalcone, mean 
(± SD) cfu of a MRSA was reduced from 5.190 (± 0.030) log10 mg/ml and 5.180 (± 
0.000) log10 mg/ml, respectively, to 0.000 (± 0.000) log10 mg/ml from 2 hours (Figure 
3-2). No bactericidal activity was seen at equivalent concentrations of DMSO solvent 
(6.300% v/v and 12.500% v/v), since the chemical inhibits bacterial growth at 
≥12.500% v/v as reported by Basch et al (1968) and Duric et al (2013). Thus, the 
ferrocenyl chalcone possessed bactericidal activity, since ≤99.9% of cells were killed. 
The time taken to kill the MRSA cells in the current assay was less than the time taken 
for ceftobiprole to kill MRSA ATCC 33591 and MRSA clinical isolates reported in a 
previous study by  Barbour et al. (2014), and was less than the time taken for 
telavancin and vancomycin to kill a clinical isolate of a MRSA reported in a later study 
(Rolston et al., 2017). In the former study, the mean (± SD) cfu of MRSA ATCC 33591 
was reduced to ≤3 log10 cfu/ml from approximately 6.00 log10 cfu/ml after 24 hours 
at ≥0.002 mg/ml (1xMIC), while the same time was taken to reduce the mean (± SD) 
cfu of MRSA clinical isolate from approximately 7.00 log10 cfu/ml to ≤3.00 log10 cfu/ml 
at ≥2xMIC. However, in the study by Rolston et al. (2017), the cfu of all 4 MRSA clinical 
isolates were reduced to ≥3.00 log10 cfu/ml from approximately 6.00 log10 cfu/ml 
after 24 hours at 0.004 mg/ml (4xMIC) of vancomycin, while the cfu/ml of only 1 
MRSA clinical isolate was reduced from approximately 6.00 log10 cfu/ml to ≥3 log10 
cfu/ml after 24 hours at 0.008 mg/ml (8xMIC) of telavancin. 
In the current study, mean (± SD) cfu of E. faecalis NCTC 12697 was reduced to 0.000 
(± SD) log10 cfu/ml from 4.27 (± 0.030) log10 cfu/ml from 2 hours at 0.063 mg/ml 
(1xMIC), while bactericidal activity was seen immediately from 0 hour at 0.125 mg/ml 
(2xMIC) of decyl ferrocenyl chalcone (Figure 3-3). At equivalent concentrations of 
DMSO solvents (6.300% v/v and 12.500% v/v), bacteriostatic activity and not 
bactericidal activity, was seen, since there was ≤99.9% reduction of bacterial cells. 
No known previous studies reported DMSO antimicrobial activity against E. faecalis. 
In a previous study (del Valle et al., 2016), cfu of E. faecalis ATCC 29212 was reduced 
to 2.23 log10 cfu/ml from approximately 6.00 log10 cfu/ml from 10 hours at 0.075 
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mg/ml to 0.150 mg/ml (1xMIC) of kaempferol, while cfu of E. faecalis 1076 clinical 
isolate was reduced to 2.24 log10 cfu/ml from approximately 6.00 log10 cfu/ml from 
10 hours at 0.106 mg/ml to 0.175 mg/ml (1xMIC) of the same drug. Del Valle et al. 
(2016) also reported that cfu of E. faecalis ATCC 29212 was reduced to 1.38 log10 
cfu/ml from approximately 6.00 log10 cfu/ml from 10 hours at 0.113 mg/ml to 0.200 
mg/ml of resveratrol, while cfu of E. faecalis 1076 clinical isolate was reduced to 1.45 
log10 cfu/ml from approximately 6.00 log10 cfu/ml from 10 hours at 0.113 mg/ml to 
0.163 mg/ml (1xMIC) of the same drug. 
While there were no known reported findings from time-kill assays involving K. 
kristinae, the current study proposes that favourable bactericidal activity was 
achieved, since the mean (± SD) cfu of K. kristinae NCIMB was estimated to be 0.000 
(± 0.000) log10 cfu/ml at 0.016 mg/ml (1xMIC) and 0.031 mg/ml (2xMIC) from 0 hour 
(Figure 3-4). Furthermore, equivalent concentrations of DMSO solvent (1.600% v/v 
and 3.100% v/v) showed evidence of bacteriostatic activity. No known previous 
studies reported DMSO antimicrobial activity against K. kristinae. 
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3.4 Conclusion 
Ferrocenyl chalcone compounds have been reported to possess broad-spectrum 
antibacterial activity (Kowalski et al., 2013; Mishra et al., 2015; Gopi, Sastry, & 
Dhanaraju, 2016; Khan et al., 2017). This activity, which is characterised by the MIC, 
can be assessed using agar-disk diffusion (Wheat, 2001; Howe & Andrews, 2012) and 
broth dilution (Andrews, 2001; Valgas et al., 2007; Wiegand, Hilpert, & Hancock, 
2008; CLSI, 2012).  
Overall findings of the present study indicate that the ferrocenyl chalcone 
compounds with longer alkyl chains (heptyl to decyl) inhibited bacterial cell growth 
when compared to a non-methylated ferrocenyl chalcone compound and those with 
shorter alkyl chains (methyl to pentyl). This means that the addition of alkyl chains 
and the length of these chains influence antibacterial activity (MIC values) of the 
ferrocenyl chalcone compounds.  
The MIC values, obtained from the broth microdilution assays of the compounds with 
longer alkyl chains, were lower against Gram-positive bacteria than against Gram-
negative bacteria. This means that the compounds with longer alkyl chains were 
more effective against Gram-positive bacteria than against Gram-negative bacteria. 
Additionally, their efficacy was evident against both non-resistant laboratory-
adapted bacteria, and against non-resistant and resistant clinical isolates. 
Particularly, activity against resistant clinical isolates used in the current study 
indicates that the ferrocenyl chalcone compounds should be considered as potential 
antibacterial agents.  
In terms of the time-kill assays, the active compounds also possessed bactericidal 
activity at 1xMIC and 2xMIC after 0 to 4 hours and this activity was maintained up to 
24 hours. This activity was due to the presence of ferrocenyl chalcone compound 
since bacterial growth was either inhibited or unaffected by DMSO depending on the 
test organism. The time taken for bactericidal activity to occur was less than that for 
known compounds in other studies (Scheerans et al., 2015; del Valle et al., 2016; 
Rolston et al., 2017).  
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Although these compounds exhibited antibacterial activity, colour change from deep 
red to dark brown and the presence of brown precipitate were seen. The data 
presented in Chapter 4, including a review of an MSci study performed by Charles 
Bennett, highlights the approaches used to determine causes of these issues and 
whether antibacterial activity is affected. 
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4 Elucidation of the possible causes and consequence of colour 
change and particulate formation in diluted ferrocenyl 
chalcone solutions  
4.1 Bioavailability of antibacterial agents 
Clinical diagnoses, prognoses and treatment of diseases with the use of appropriate 
drugs are determined by assays involving human body fluids such as serum, plasma 
and cerebro-spinal fluid (Hu, Loo, & Wong, 2006; Driscoll et al., 2012). As reviewed 
by Varanda et al. (2006), successful activity of antimicrobial agents relies on the 
solubility of an agent in body fluids, which is a key characteristic of the bioavailability 
of the active ingredient in antimicrobial drugs. The primary routes of antimicrobial 
drug absorption, which ensure maximum system circulation of the active ingredient 
within the body, are intravenous and oral (Levison & Levison, 2009). Oral 
administration of drugs is preferred because of the availability of less expensive, but 
more effective, antibacterial compounds, which can be taken home out of the 
healthcare setting by the patient (Cyriac & James, 2014). Systemic distribution of 
antimicrobials within the body via either route usually necessitates that most drugs 
be water-soluble as detailed by Gao et al. (2011). However, since orally administrated 
antimicrobials are absorbed through the intestinal mucosa, these agents must 
possess hydrophobic properties (Goddard, 1998; Levison & Levison, 2009). 
Within the last fifteen to twenty years, newly developed antibacterial drugs have 
gained the interest of researchers because they are water-insoluble and passively 
diffuse across the lipid bi-layer of cell membranes (Calvey & Williams, 2007). Unlike 
hydrophilic therapeutic molecules, such as β-lactam drugs, which easily diffuse into 
cells through membrane-bound porins, hydrophobic drugs diffuse into bacterial cells 
across the outer membranes of Gram-negative bacteria, which performs the role of 
additional protection (Delcour, 2009).   For example, lipophilic antibacterial drugs are 
needed for treatment of bacterial prostatitis, which is enveloped in a hydrophobic 
membrane (Lipsky, Byren, & Hoey, 2010), and infections of the central nervous 
system, which is protected by the blood-brain barrier (Nau, Sorgel, & Eiffert, 2010). 
Due to increased prevalence of infections caused by MDR bacteria, some of which 
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are Gram-negative, there is the need for effective hydrophobic antimicrobial drugs. 
Therefore, the ferrocenyl chalcone compounds used in the current study were 
engineered to be lipophilic chemicals. These chemicals are synthetic derivatives of 
flavonoids, on which lipophilic data, defined by the octanol-water partition 
coefficient, is variable, as researched by Rothwell et al. (2005). 
4.1.1 Solubility of ferrocenyl chalcone compounds 
The ferrocenyl chalcone chemicals developed as antibacterial agents, and the focus 
of this study to determine their effectiveness and mode of action, are highly 
hydrophobic compounds. The hydrophobicity of the compounds is enhanced due to 
the addition of increasing lengths of alkyl chains, the addition of ferrocene groups, 
and the substitution of C5 on the benzene rings with nitrogen atom (Chapter 1, Figure 
1-3). The alkyl groups of saturated, unbranched alkanes are water-insoluble and their 
hydrophobicity increases as chain length increases, as described by Bell (1973) and 
Stoker (2015). The second group, ferrocene, an aromatic metallocene, is also 
insoluble in water (Remington, 2006). The third component of the ferrocenyl 
chalcone compounds used in the current study, a nitrogen substituted benzene ring, 
is a highly water-insoluble aromatic cyclic structure, as discussed by several papers 
(May, Wasik, & Freeman, 1978; Buttrick & King, 2017; Taleb et al., 2017). The overall 
structure and chemical group composition of each ferrocenyl chalcone compound, 
minus the iodide component, was confirmed by Robert B Smith (UCLAN) using 1H 
NMR (Appendix 2, Figure 9-1 to Figure 9-11), MS (Appendix 2, Figure 9-12 to Figure 
9-22) and IR (Appendix 2, Figure 9-23 to Figure 9-33). The hydrophobicity of the 
ferrocenyl chalcone compounds necessitates the use of an appropriate solvent to 
enable the preparation of stock solutions to be further diluted in an aqueous broth 
for AST. In the current study, a number of solvents were used. In spite of completely 
dissolving the ferrocenyl chalcone compounds, with the exception of one, the stock 
solutions exhibited precipitation when diluted with bacterial growth solutions. DMSO 
was the most favourable compound of choice since it is amphipathic and is less 
inhibitive in terms of bacterial cell growth (Basch, Gadebusch, & Brunswick, 1968; 
Hassan, 2014) when compared to other assessed compounds such as absolute 
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ethanol, polyethylene glycol and (±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-
carboxylic acid (trolox). 
4.1.2 Dilution of ferrocenyl chalcone compounds 
All of the compounds investigated were found to be completely soluble in 100% 
DMSO. It was observed that the solutions change colour from deep red to dark brown 
within 2 hours. At 2X and 4X dilutions in MHB, fine brown particles were also seen 
when the solutions were diluted with MHB, which contains dehydrated infusion from 
beef, casein hydrolysate and starch, as detailed by Oxoid (2017). However, the brown 
particles were observed after incubation. In a study by Kanellopoulos & Wood (1976), 
as well as a review by Nitin (2009), particle size in suspensions are reportedly 0.4 µm 
to 12 µm, and are visible to the naked eye. MHB is the preferred medium since the 
broth efficiently supports the growth of most aerobic non-fastidious bacteria and 
extensive research information has been gathered from assays involving the medium 
(CLSI, 2012). This broth is the reference medium for AST (EUCAST, 2003).  
4.1.3 Colour change of ferrocenyl chalcone compounds 
Once dissolved in DMSO, the stock ferrocenyl chalcone solutions were observed to 
change from deep red to dark brown in polypropylene tubes at a faster rate than in 
borosilicate glass tubes. Assuming that the colour change in the current study was 
due to displaced iodine, diethyl ether was added to the solutions containing colour 
change. Hildebrand et al. (1950) were the first to report the use of diethyl ether to 
demonstrate the possible presence of displaced iodine, where a top layer comprised 
of a brown ring of iodine suspension and a clear, colourless bottom layer were 
observed. This was also observed and reported by Smith et al. (2013). This solvent 
was used since solid iodine readily dissolves in polar solvents such as diethyl ether, 
as discussed by Kaiho (2015). Concurrent with this assay, Charles Bennett conducted 
a research project as part of his Master of Science studies at Staffordshire University 
in 2016 to assess the effect of specific environmental conditions on the compounds 
used in this study, and the consequent antimicrobial activity of the altered 
compounds. 
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4.1.4 Approaches to elucidate causes and consequence of colour change and 
particulate formation in diluted ferrocenyl chalcone solutions 
In the current methods, ferrocenyl chalcone solutions were randomly selected for 
assessment. One approach of this assay is to evaluate the solubility of ferrocenyl 
chalcone chemicals pre- and post-dilution with MHB. Another approach is to 
determine the possible cause of the colour change of these solubilised compounds 
over time. Finally, the study will review the findings of the Bennett project, which 
involved assessing the effect of environmental conditions of solubilised ferrocenyl 
chalcone compounds in terms of their rate of colour change and antibacterial activity 
after the visible colour change.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
79 | P a g e  
 
4.2 Material and Methods 
4.2.1 Preparation of a selected ferrocenyl chalcone for observed precipitate 
Fresh stock nonyl ferrocenyl chalcone solutions were prepared by dissolving 1 mg of 
powder in 1 ml of DMSO in a sterile polypropylene tube (tube 1) and in a sterile 
borosilicate glass tube (tube 2). Stock MHB and deionised water were autoclaved at 
121oC for 15 minutes and dispensed into 10 ml aliquots. Test sterile polypropylene 
tubes (2 x 75 µl sterile deionised water and 2 x 75 µl MHB) were prepared and 75 µl 
of dissolved stock ferrocenyl was added to each tube (tubes 3 – 6). A control tube 
(tube 7) containing 150 µl MHB was also prepared. One tube with MHB diluent (tube 
3) and one tube with water diluent (tube 5) were sonicated for approximately two 
minutes. All tubes were sealed and observed for colour change and precipitate pre- 
and post-incubation at 370C for 72 hours. This method was performed in duplicate. 
4.2.2 Preparation of sample for displaced iodine assay 
Approximately 1 mg of solid decyl ferrocenyl chalcone was dissolved in 1 ml of DMSO 
in a 1.5 ml Eppendorf microcentrifuge tube made of polypropylene and incubated 
overnight at room temperature in a cupboard. After observing a colour change from 
deep red to dark brown in each solution, 0.1 ml of dissolved decyl chalcone was 
added to an equal volume of diethyl ether in a borosilicate glass tube. The solution 
was then visually observed for the presence of an upper brown layer. 
 
 
 
 
 
 
 
 
80 | P a g e  
 
4.3 Results 
4.3.1 Assay for observed precipitate 
Solutions in all tubes (tubes 1-6), except control (tube 7), changed colour from deep 
red to dark brown in the presence of DMSO. 2 of the 6 solutions with MHB diluent 
exhibited fine brown particles (Figures 4-3 & 4-4) regardless of sonication. Tube 7 
exhibited no particle formation. 
 
Figure 4-1 A 2-fold diluted nonyl ferrocenyl chalcone solution with water as diluent post-incubation displaying no 
fine brown particles (tube 6) (drop size of 20 µl on white tile). 
 
Figure 4-2  A 2-fold diluted Nonyl ferrocenyl chalcone solution with water diluent after sonication and incubation 
displaying no fine brown particles (tube 5) (drop size of 20 µl on white tile). 
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Figure 4-3  A 2-fold diluted Nonyl ferrocenyl chalcone solution with MHB diluent post-incubation (tube 3) showing 
aggregates of fine brown particles (black arrows) (drop size of 20 µl on white tile). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4 A 2-fold diluted Nonyl ferrocenyl chalcone solution with MHB diluent after sonication and incubation 
(tube 6) showing aggregates of fine brown particles (black arrows) (drop size of 20 µl on white tile). 
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Figure 4-5 Stock nonyl ferrocenyl chalcone solution prepared in polypropylene tube (tube 1) with no observed fine 
brown particles and presented here in a glass well. 
 
 
Figure 4-6 Stock nonyl ferrocenyl chalcone solution prepared in borosilicate glass tube (tube 2). 
Tubes 1 and 2 (figures 4-5 and Figures 4-6) were shown to demonstrate the lack of 
formation of fine brown precipitate when MHB is not added.  
4.3.2 Assay for displaced iodine 
Brown residue was seen at the bottom of the borosilicate tubes instead of a brown 
ring at the top of the suspension. 
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4.4 Discussion 
4.4.1 Assay for observed precipitate 
After diluting the stock ferrocenyl chalcone solution with MHB, and incubating at 
37oC for 72 hours, brown particles, were observed. One theory for the appearance 
of these brown particles, visible to the naked eye, may be the chelation of Fe2+ ions, 
present in the ferrocene group, by hydrolysate in MHB  (Luo et al. , 2014). The group 
have observed that hydrolysis of proteins, such as sodium caseinate, produces casein 
hydrolysate, a component of MHB, and enhances the metal ion chelating activity of 
the protein hydrolysate. Gu et al.  (2010) reported that Maillard Reaction Products 
(MRP), which contain casein hydrolysate, exhibited Fe2+ chelation. This reaction was 
also reported by Luo, Pan and Zhong (2014), where the group assessed the Fe2+ 
chelation activity of casein hydrolysates. The IUPAC (1997) defines chelation as “the 
formation or presence of bonds (or other attractive interactions) between two or 
more separate binding sites within the same ligand and a single central atom”. It has 
been reported that Fe2+ chelation activity of hydrolysates can result in hydrophobic 
protein-metal complexes (Chinedu & Min, 2017), which potentially caused the 
appearance of macroscopic particles. Therefore, a possible theory on the presence 
of observed fine brown particles in the current method may be the formation of 
casein hydrolysate-iron complexes caused by the chelation of iron ions in MHB-
diluted ferrocenyl chalcone solution. When observed in the MIC assay (Chapter 3), 
these complexes were reversible since increased dilution with MHB led to reduced 
appearance of particles. 
4.4.2 Assay for displaced Iodine 
As indicated in Section 4.1.3, diethyl ether, an organic solvent that completely 
solubilises iodine to form a stable solution, would dissolve the precipitate if it is 
iodine (Hildebrand, Benesi, & Mower, 1950; Smith, Smith, & Nikonov, 2013). The 
reaction between the ferrocenyl chalcone and diethyl ether produced a brown 
precipitate at the bottom of the tube. Since a brown precipitate was seen, the change 
in colour of the ferrocenyl chalcone was not caused by displaced iodine but may be 
the presence of an equal mix of ferrocene (deep red) and ferrocenium (deep blue), 
which creates the brown colour. Although ferrocene is predicted to be soluble in 
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most organic solvents (Yousefinjad, Honarasa, & Solhjoo, 2015), Herrmann (1997) 
has indicated that ferrocene is sparingly soluble in diethyl ether.  
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4.5 Review of subsequent research into solution changes and potential 
antimicrobial effects 
The MSci research project at Staffordshire University completed by Bennett (2016), 
supervised by Dr Pauline Gowland and Mrs Elecia Henry, and further explored the 
factors and antimicrobial effects of the visible colour change observed in stock 
ferrocenyl chalcone solutions. This project was influenced by observations from 
parallel antimicrobial sensitivity tests (as further described in Chapter 3) where the 
dissolved ferrocenyl chalcones changed from reddish-brown to dark brown after 
incubation at room temperature (approximately 21oC) and 37oC in 96-well 
polystyrene plates and disposable 13 ml Sarstedt polypropylene tubes. This occurred 
during preparation of stock solution and working solutions for the determination of 
MIC of the compounds against a selected panel of bacteria. It was also observed that 
when the compounds were dissolved and diluted in borosilicate glass tubes, followed 
by incubation at 37oC, visible colour change appeared to happen at a slower rate. The 
visible change in colour of the compounds, which were possible indications of 
instability after dissolution and whether this potential issue resulted in structural 
changes and, further to that, affected antimicrobial activity, warranted further 
investigation.  
Due to the absence of literature on the colour change of ferrocenyl chalcone 
compounds in solution, Bennett (2016) attempted to identify the possible conditions 
that influenced the visible colour change of the ferrocenyl chalcone compounds with 
longer chains (hexyl to decyl) (See Appendix 1, Table 9-1). These compounds were 
determined to be the more effective compounds as described in Chapter 3, in 
polypropylene and borosilicate glass tubes. Bennett’s (2016) project involved 
incubation of the compounds, dissolved in appropriate volumes of DMSO, under the 
following conditions: room temperature (21oC ± 1oC) and light, room temperature 
(21oC ± 1oC) and darkness, and 37oC in an incubator. Another aim of Bennett’s (2016) 
study was to assess whether discoloured solutions post-incubation in the stated 
conditions affected the antibacterial activity of the compounds against Gram-
positive and Gram-negative bacteria were affected post-incubation under the 
aforementioned conditions. Based on initial observations regarding the occurrence 
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of colour change in DMSO, Bennett proposed that change in absorbance, indicative 
of visible colour change, would occur at a faster rate in polypropylene tubes than in 
borosilicate glass tubes across all the environmental conditions. These observations 
also led Bennett to propose that the antibacterial activity of the solubilised 
compounds would be the same, regardless of the type of tube used.   
4.5.1 Influence of conditions on colour change 
In the first phase of Bennett’s study, 1 mg/ml stock solutions of hexyl to decyl 
ferrocenyl chalcone compounds in DMSO were prepared in 5 polypropylene tubes 
and 5 borosilicate glass tubes for a total of 10 tubes. Absorbance values were 
measured at 620 nm using a WPA Biowave II spectrophotometer (Biochrom Limited, 
Cambourne, UK) at 30-minute intervals up to 5 hours. As reviewed by Lengeler et al. 
(1999), most cells, including bacteria, do absorb light between wavelengths of 500 
nm and 660 nm, facilitating measurement of turbidity, which is linearly proportional 
to concentration. 
After 5 hours at room temperature, Bennett observed that the ferrocenyl chalcone 
solutions appeared to change colour from deep red to a dark brown in both 
polypropylene and borosilicate glass tubes, and in all three environmental conditions 
(Figure 4-7). The assay was performed in triplicate. 
    
 
Bennett also plotted the mean (± SD) absorbance of each ferrocenyl chalcone after 
exposure to specified environmental conditions against sampling intervals in hours. 
Figure 4-7  Colour change of the five ferrocenyl chalcones used at 0 minutes (left) and after five hours (right). 
The same colour change was observed in glass tubes (reproduced with permission from Bennett, 2016).  
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The derived curves were used to estimate the rate of change in absorbance per 
minute (RA [ΔA/min]) from 0 to 180 minutes (Table 4-1), which he proposed to be 
the time period of exponential change in colour. Bennett estimated these values by 
dividing the height of the graph to the measured absorbance value by the width from 
0 to 180 minutes (Appendix 5, Figures 9-44 to 9-53) (Bennett, 2016, pers. comm.).  
Using a two-sample Student’s t-test, Bennett determined the significant difference 
between the RA of ferrocenyl chalcone compounds in polypropylene tubes and 
borosilicate glass tubes. He also used a single-factor ANOVA test to determine the 
significant difference between the RA under exposure to the three environmental 
conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 | P a g e  
 
Table 4-1 RA (ΔA/min) of each ferrocenyl chalcone based on type of vessel and environmental condition. 
Chalcone Vessel Condition RA (ΔU/min) 
Hexyl Polypropylene tubes 37oC 0.0102 ± 0.0005 
21oC (±1) + light 0.0097 ± 0.0007 
21oC (±1) + dark 0.0051 ± 0.0080 
Borosilicate glass tubes 37oC 0.0078 ± 0.0018 
21oC (±1) + light 0.0056 ± 0.0022 
21oC (±1) + dark 0.0024 ± 0.0007 
Heptyl Polypropylene tubes 37oC 0.0096 ± 0.0007 
21oC (±1) + light 0.0095 ± 0.0008 
21oC (±1) + dark 0.0045 ± 0.0010 
Borosilicate glass tubes 37oC 0.0076 ± 0.0032 
21oC (±1) + light 0.0068 ± 0.0021 
21oC (±1) + dark 0.0023 ± 0.0005 
Octyl Polypropylene tubes 37oC 0.0092 ± 0.0009 
21oC (±1) + light 0.0089 ± 0.0016 
21oC (±1) + dark 0.0044 ± 0.0008 
Borosilicate glass tubes 37oC 0.0060 ± 0.0024 
21oC (±1) + light 0.0068 ± 0.0024 
21oC (±1) + dark 0.0021 ± 0.0003 
Nonyl Polypropylene tubes 37oC 0.0096 ± 0.0007 
21oC (±1) + light 0.0095 ± 0.0006 
21oC (±1) + dark 0.0042 ± 0.0007 
Borosilicate glass tubes 37oC 0.0058 ± 0.0020 
21oC (±1) + light 0.0053 ±0.0017 
21oC (±1) + dark 0.0024 ± 0.0006 
Decyl Polypropylene tubes 37oC 0.0088 ± 0.0007 
21oC (±1) + light 0.0091 ± 0.0012 
21oC (±1) + dark 0.0041 ± 0.0009 
Borosilicate glass tubes 37oC 0.0059 ± 0.0022 
21oC (±1) + light 0.0056 ± 0.0017 
21oC (±1) + dark 0.0023 ± 0.0008 
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Bennett’s findings indicated that at room temperature and in light, the mean (± SD) 
rates of change in absorbance were 0.0097 ± 0.0007 ΔA/min (hexyl), 0.0095 ± 0.0007 
ΔA/min (nonyl) and 0.0091 ± 0.0012 ΔA/min (decyl) in polypropylene tubes. He also 
discovered that the mean (± SD) rates of change in borosilicate glass tubes were 
0.0056 ± 0.0022 ΔA/min (hexyl), 0.0053 ± 0.0017 ΔA/min (nonyl) and 0.0056 ± 0.0017 
ΔA/min (decyl). These estimated values were significantly different between 
polypropylene tubes and borosilicate tubes where p=0.0015 (hexyl), p=0.0001 
(nonyl) and 0.0021 (decyl). In the same study, Bennett found that there were no 
significant differences in the mean (± SD) rates of change in polypropylene and 
borosilicate glass tubes produced by heptyl (p=0.1894) and nonyl (p=0.1049).  
Another set of findings from Bennett’s study indicated that, after exposure to 37oC, 
the rates of change in absorbance of all five ferrocenyl chalcone compounds were 
significantly different between polypropylene tubes and borosilicate glass tubes 
where p=0.0112 (hexyl), p=0.0100 (heptyl), p=0.0123 (octyl), p=0.0017 (nonyl) and 
p=0.0129 (decyl). The rates of change in the polypropylene tubes were 0.0102 ± 
0.0005 ΔA/min for hexyl, 0.0096 ± 0.007 ΔA/min for heptyl, 0.0092 ± 0.009 ΔA/min 
for octyl, 0.0096 ± 0.0007 ΔA/min for nonyl and 0.0088 ± 0.0007 ΔA/min for decyl. In 
borosilicate glass tubes, the rates of change were lower for hexyl (0.0078 ± 0.0018 
ΔA/min), heptyl (0.0076 ± 0.0032 ΔA/min), octyl (0.0060 ± 0.0024 ΔA/min), nonyl 
(0.0058 ± 0.0020 ΔA/min) and decyl (0.0059 ± 0 0.0022 ΔA/min). This indicated that 
higher temperatures affected colour stability of the ferrocenyl chalcone compounds.  
Bennett discovered that exposure of all 5 ferrocenyl chalcone compounds to room 
temperature and darkness resulted in significant differences between the rates of 
change in absorbance in polypropylene tubes and borosilicate glass tubes where 
p=0.0042 (hexyl), p=0.0006 (heptyl), p=0.0006 (octyl), p=0.0008 (nonyl), and 
p=0.0067 (decyl). The rates of absorbance change in the polypropylene tubes were 
0.0051 ± 0.0080 ΔA/min for hexyl, 0.0045 ± 0.0010 ΔA/min for heptyl, 0.0044 ± 
0.0008 ΔA/min for octyl, 0.0042 ± 0.0007 ΔA/min for nonyl and 0.0041 ± 0.0009 
ΔA/min for decyl. In the borosilicate glass tubes, the rates of absorbance change were 
0.0024 ± 0.0007 ΔA/min for hexyl, 0.0023 ± 0.0005 ΔA/min for heptyl, 0.0021 ± 0.003 
ΔA/min for octyl, 0.0024 ± 0.0006 ΔA/min for nonyl and 0.0023 ± 0.0008 ΔA/min for 
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decyl. Although absorbance change occurred under dark conditions, the rates of 
change were lower than those that were observed under light conditions. Another 
finding of the Bennett study was that the effect of the selected environmental 
conditions was significantly different. He determined that, for the five ferrocenyl 
chalcone solutions in polypropylene tubes, there were significant differences in the 
rates of change in absorbance between the environmental conditions, where 
p=0.00002 (hexyl), p=0.00005 (heptyl), p=0.000006 (octyl), p=0.0000007 (nonyl) and 
p=0.000003 (decyl). There were significant differences in the rates of change in 
absorbance also for the same solutions in borosilicate glass tubes, between the 
environmental conditions, where p=0.0005 (hexyl), p=0.0032 (heptyl), p=0.0039 
(octyl), p=0.0076 (nonyl) and p=0.0069 (decyl). 
Based on the results presented, Bennett deduced that visible colour change of the 
ferrocenyl chalcone solutions was influenced by the composition of the sample 
vessels, where samples were prepared in polypropylene and borosilicate glass tubes, 
and that light and heat accelerated this change. The change in the observed colour 
of the ferrocenyl chalcone solutions may have resulted from the oxidation of Fe2+, 
found in the ferrocene group, to Fe3+, found in the ferrocenium group (Charette & 
Sholkovitz, 2002). This may indicate a reaction between the solution and potential 
pro-oxidant components in polypropylene tubes (Corti et al., 2010). However, iron 
oxidation in aqueous ferrocene, which is reddish brown in colour, produces aqueous 
ferrocenium, which is blue in colour. Thus, this oxidation may be reversible and may 
result in the presence of both ferrocene and ferrocenium (Rao, Kumar, & Ravikanth, 
2010), producing a dark brown colour. This is the first known report that specifically 
addresses the change in colour of ferrocenyl chalcone compounds in relation to the 
sample vessel and environmental conditions to which the compounds are exposed. 
Therefore, there is a need for further investigation of this theory, including the 
identification of the presence of ferrocenium. 
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4.5.2 Antibacterial activity of the ferrocenyl chalcone compounds after exposure to 
environmental conditions 
The second phase of Bennett’s study was the evaluation of the antimicrobial activity 
of randomly selected compounds (hexyl and heptyl) after visible colour change. The 
MIC values (mg/ml) of these compounds, indicative of antibacterial activity, were 
determined using the broth macrodilution method (EUCAST, 2003). The method 
involved using 2-fold serial broth macrodilution in both polypropylene and 
borosilicate glass tubes, where samples were done in duplicate. Bennett prepared 
appropriate volumes of each stock ferrocenyl chalcone solution at concentrations of 
2 mg per 1 ml of DMSO, and used MHB, derived from 10 ml aliquots of stock MHB 
that was autoclaved at 121oC for 15 minutes, as the diluent to produce working 
concentrations of 1 mg/ml.  The positive control was either PEN-G or OXY, an 
analogue of tetracycline. Each stock antimicrobial solution was prepared to 0.256 mg 
per 1 ml  of sterile deionised water (Andrews, 2001). The negative control was 5% v/v 
DMSO, which was diluted with MHB.  
Bennett used two Gram-positive bacteria, S. aureus NCIMB 8244 and E. faecalis NCTC 
12697, and two Gram-negative bacteria, Salmonella “Manchester” NCTC 7832 and E. 
coli NCIMB 9483 in this assay. He prepared each inoculum using the growth method 
(Andrews, 2001), which involved the suspension of more than 3-4 colonies of each 
bacterial sample in sterile MHB followed by incubation for 15-20 minutes in air at 
37oC until the turbidity was either equal to or greater than that of a 0.5 McFarland 
standard. This resulted in suspensions that contained approximately 107 and 108 
cfu/ml.  Bennet then diluted the suspensions to achieve the final inoculum of 105 
cfu/ml. After adding equal volumes of diluted ferrocenyl chalcone solution and 
inocula, Bennett’s final chalcone concentration ranged from 0.500 mg/ml to 0.001 
mg/ml, and a final antimicrobial concentration of 0.128 mg/ml. After incubating in 
air for 18-24 hours at 37oC, Bennett measured absorbance values at 620 nm, followed 
by numeration of viable bacterial colonies using the Miles and Misra method, as 
described in several studies (Miles, Misra, & Irwin, 1938; Slack & Wheldon, 1978; 
Codd, Richardson, & Andrews, 1998; Hedges, 2002; Mishra, Taneja, & Sharma, 2012; 
Nunes, Graça, & Santo, 2017).  
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Findings of Bennett’s assay indicated that heptyl ferrocenyl chalcone compound 
possessed more efficacy in overall antibacterial activity than hexyl ferrocenyl 
chalcone compound. In the study, Bennett found that heptyl produced the largest 
overall MIC value of 0.500 mg/ml against E. coli NCIMB 9483 (Table 4-2). The MIC 
values estimated against Gram-negative bacteria in Bennett’s study (0.250 mg/ml to 
0.500 mg/ml) were not considered to reflect antibacterial activity, since the 
percentage of DMSO that was present in the solution were greater than 12.5% v/v 
DMSO. DMSO has been reported to exhibit antibacterial activity at concentrations 
≥12.5%  v/v (Basch, Gadebusch, & Brunswick, 1968; Duric et al., 2013). Bennet also 
discovered that hexyl produced the same MIC values in both polypropylene tubes 
and borosilicate glass tube with 0.063 mg/ml against S. aureus NCIMB 8244 and 0.125 
against E. faecalis NCTC 12697 (Table 4-2). The heptyl ferrocenyl chalcone compound 
produced different MIC values in polypropylene tubes when compared to assays in 
borosilicate glass tubes. The MIC values were estimated to be 0.016 mg/ml against 
S. aureus NCIMB 8244 and 0.031 mg/ml against E. faecalis NCTC 12697 in 
polypropylene tubes, and 0.031 mg/ml against S. aureus NCIMB 8244 and 0.063 
mg/ml against E. faecalis NCTC 12697 in borosilicate glass tubes (Table 4-2). At these 
MIC values, Bennett proposed that antibacterial activity was caused by the presence 
of ferrocenyl chalcone, since DMSO displays antibacterial activity a ≥12.5% (Basch, 
Gadebusch, & Brunswick, 1968; Duric et al., 2013). The antibacterial activity of DMSO 
was explored further in Chapter 3. When Bennet exposed the same four organisms 
to DMSO, which was serially diluted 2-fold with MHB, in both polypropylene and 
borosilicate glass tubes, this resulted in MIC values from 12.5% v/v DMSO to 25% v/v 
DMSO (Table 4-2). Overall, Bennett’s results indicated that antibacterial activity of 
the ferrocenyl chalcones remained after exposure to environmental conditions. 
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Table 4-2 MIC values of hexyl and heptyl ferrocenyl chalcone compounds and DMSO control against non-
resistant laboratory-adapted bacteria (reproduced with permission from Bennett, 2016). 
Organism MIC values in 
polypropylene tubes 
(mg/ml) 
MIC values in 
borosilicate glass 
tubes (mg/ml) 
MIC values of 
DMSO (% v/v) 
Hexyl Heptyl Hexyl Heptyl DMSO 
S. “Manchester” 
NCTC 7372 
0.250 0.250 0.250 0.250 12.50 
E. coli NCIMB 
9483 
0.250 0.500 0.250 0.500 25.00 
S. aureus NCIMB 
8244 
0.063 0.016 0.063 0.031 12.50 
E. faecalis NCTC 
12697 
0.125 0.031 0.125 0.063 12.50 
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4.6 Conclusion 
The bioavailability of an antimicrobial drug in the human body relies on the solubility 
of the compound in hydrophilic body fluids (Varanda et al., 2006; Gao et al., 2011). 
The most effective antimicrobial agents are orally administered antimicrobial 
compounds, which are absorbed in the intestine (Cyriac & James, 2014). Orally 
administered antimicrobial drugs must be hydrophobic so that they may enter the 
mucosa by diffusion (Levison & Levison, 2009). Additionally, hydrophobic 
antimicrobial drugs are preferred since they diffuse across highly protected tissues 
such as the blood brain barrier and the prostate (Lipsky, Byren, & Hoey, 2010; Nau, 
Sorgel, & Eiffert, 2010). Due to their hydrophobic nature, such drugs must be 
dissolved in amphipathic compounds, which allow the drug to diffuse across the 
hydrophobic barriers but still be capable of targeting hydrophilic targets. 
The antimicrobial compounds used in this study contained hydrophobic moieties. 
DMSO, an amphipathic chemical, was determined to be the best solvent for the 
ferrocenyl chalcone compounds. After solvation in DMSO, the ferrocenyl chalcone 
solutions were diluted with MHB, the standard medium used in AST (EUCAST, 2003; 
CLSI, 2012). However, initial solvation and dilution resulted in a colour change from 
deep red to dark brown, and the production of brown particles that were visible to 
the naked eye. 
Fe2+ chelation by casein hydrolysate, a chelating component of MHB (Oxoid, 2017), 
was suggested to be the potential cause of particulate formation in the ferrocenyl 
chalcones in the current study. The cause of the colour change from deep red to dark 
brown was hypothesised to be the presence of displaced iodine. However, a negative 
diethyl ether test (Hildebrand, Benesi, & Mower, 1950; Smith, Smith, & Nikonov, 
2013), meant that iodine was not displaced after solubilisation. The presence of pro-
oxidant compounds in polyethylene vessels (Corti et al., 2010) was proposed to be 
the possible cause of the oxidation of Fe2+ in ferrocene to Fe3+ in ferrocenium (Rao, 
Kumar, & Ravikanth, 2010). This reversible colour change may have resulted in an 
equivalent mix of ferrocene (deep red) and ferrocenium (deep blue), which formed 
the dark brown colour. 
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A review of the Bennett (2016) study on the effect of environmental conditions of 
ferrocenyl chalcone compounds and their consequent antimicrobial activity revealed 
key findings. These findings were that solubilised ferrocenyl chalcone compounds 
should be stored at room temperature in the dark. Another finding was that the 
antimicrobial activity of the compounds remained, despite exposure to specific 
environmental conditions, so therefore, this is not an issue affecting the ability of the 
chalcones to exhibit antibacterial activity. In Chapter 3, the antimicrobial activity of 
freshly prepared ferrocenyl chalcone compounds against non-resistant laboratory-
adapted bacteria, as well as resistant and non-resistant clinical isolates, were 
assessed using a number of reference assays. The work presented in both Chapter 3 
and Chapter 4 were performed simultaneously since the colour change and presence 
of brown particulates were observed during the determination of MIC. The next 
chapter will be focussed on the potential mode of action of these ferrocenyl chalcone 
compounds in using the MTT assay. 
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5 Determination of cell viability using MTT assay in the 
identification of a potential mode of action of ferrocenyl 
chalcone compounds 
5.1 Introduction 
Cell viability refers to the capacity of living cells to perform the same range of 
functions that are exhibited pre-exposure and post-exposure to a chemical, drug or 
condition (Pegg, 1989).  Pegg (1989) proposed that these functions include the 
amount of enzyme or product that is released from metabolic reactions, and the 
amount of oxygen consumption that can be measured. In his attempt to define 
viability, Pegg (1989) stressed that the term “viability”, which has a more limited 
meaning, differs from “life”. Further to this, Pegg has stated that loss of the functions 
that constitute viability result in expiration. Using Pegg’s definition of viability, the 
manifestations of these functions, such as the concentration of product, can be 
precisely measured. Techniques used to measure these functions belong to several 
classifications including physical integrity and metabolic activity. The current report 
will attempt to rationalise the use of the MTT cell viability assay as a means of 
identifying the potential mode of action of ferrocenyl chalcone compounds. This 
justification of the use of this approach became necessary since the functional 
compounds exhibited antibacterial activity against bacteria that possessed resistance 
mechanisms such as the production of β-lactamase against PEN, use of enzymes that 
alter ERY and streptomycin structure or the use of efflux pumps, and alteration of 
PBPs that facilitate methicillin binding.  
5.1.1 Cell viability assays 
Traditional cell viability assays involved the use of staining techniques such as those 
that include the use of proteins labelled with 51Cr or radioactive nucleotides such as 
3H Thymidine and 125I Iododeoxyuridine (Mosmann, 1983). The use of tetrazolium 
salts in a rapid cell viability assay was developed by Mosmann (1983) where washing 
steps, used in the conventional staining methods, were no longer required. Evidence 
for the use of these salts in cell viability assays was reported by Slater et al. (1963). 
These compounds, which inhibit different enzymes within the respiratory chain, are 
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2-p-nitrophenyl-3-p-iodophenyl-5-phenyltetrazolium chloride , triphenyltetrazolium 
chloride, neotetrazolium chloride,  2,2'-di-pnitrophenyl-5,5'-diphenyl-3,3'-(3,3'-
dimethoxy-4,4'-diphenylene) ditetrazolium chloride and MTT (Slater et al., 1963). 
The most common tetrazolium salt used in cell viability assays is MTT, which is used 
to measure metabolic functions. 
5.1.2 MTT assay 
MTT is a yellow tetrazolium salt that is reduced by respiratory dehydrogenases in 
cells to a purple formazan product (Slater et al., 1963). This colorimetric assay is 
performed in microtitre plates and can be quantified by measuring absorbance at 
560 nm to 570 nm in a microplate spectrophotometer (Denizot & Lang, 1986). This 
rapid and cost-effective test produces a proportional relationship between the 
amount of formazan product and the amount of actively respiring cells, which, in 
turn, is indicative of cell growth. One limitation of the Mosmann MTT assay (1983), 
as discovered by Denizot & Lang (1986), was that formazan was an insoluble 
compound. Due to its insolubility in cells, formazan accumulates as a crystals within 
the cytoplasm and on the exterior of the cell, which results in rupture of the 
membrane during exocytosis of the formazan crystals as reported by Lü et al. (2012). 
Adapted MTT methods used organic solvents such as sodium dodecylsulphate-
dimethylformamide (Garn et al., 1994) and DMSO (Carmichael et al., 1987) to 
solubilise formazan. The Mosmann MTT assay and its derived methods were first 
used to demonstrate viability with respect to mitochondrial respiration in 
mammalian cells but has been adapted for use in other cell types such as bacteria, 
which share respiratory genes with eukaryotes.  
5.1.3 The endosymbiotic link between bacteria and eukaryotic cells 
Gray et al. (1999) proposed that mitochondria in eukaryotic cells contain genetic 
material that were derived from a proteobacterium ancestor following invasion of 
the cell by the symbiont (Martin et al., 2001). The contentious theory of 
endosymbiosis, which refers to the formation of new cells after the incorporation of 
organelles from two unrelated cells, arguably originated from Mereschkowsky 
(1905), as detailed by Martin & Kowallik (1999). After many years of debates from 
Wallin (1927) to Margulis (1970), a common thread of all proposed hypotheses is that 
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host and endosymbiont share similar genes (Dyall, Brown, & Johnson, 2004). Loss of 
some protein-coding genes that were retained through endosymbiosis resulted in 
the active cellular organelles chloroplasts in plants (Gabaldón & Huynen, 2003) and 
mitochondria Gray et al. (1999) in eukaryote. Historically, use of the MTT assay relied 
on the presence of conserved respiratory genes in eukaryotes, which are responsible 
for essential respiratory enzymes that have been extensively studied. 
5.1.4 Respiratory enzymes in eukaryotes 
Margulis (1970) successfully argued that endosymbionts developed into 
mitochondria and chloroplasts, which are functional cellular entities, by gaining 
metabolites and protection, and producing the energy-rich compound adenosine 
triphosphate (ATP) derived from the respiratory process(Margulis , 1970; Andersson 
& Kurland, 1999). A mitochondrion is a complicated structure comprised of an outer 
membrane and an inner membrane with convolutions known as cristae, as described 
by Fritiof & Sjorstrand (1953). Although various researchers identified the physical 
characteristics of the crista membrane, Vogel et al. (2006) detailed the system of 
protein complexes, including succinate dehydrogenase (SDH), located within the 
structure, and the primary function of this system being respiration and ATP 
synthesis (Figure 5-1). SDH, which was first observed by Thunberg (1909), is a crucial 
component of the Krebs Cycle (Krebs et al., 1938) where the enzyme catalyses the 
oxidation of succinate to fumarate, and has been reviewed by several researchers 
including Hederstedt & Rutberg (1981).  
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Figure 5-1 A summary of metabolism in eukaryotes indicating the major complexes within the electron transport 
system. Complex I = NADH dehydrogenase; Complex II = SDH; Complex III = cytochrome b-c1; Complex IV = 
cytochrome c oxidase; Complex V = ATP synthase; SUCC = succinate; FUM = fumarate; U = ubiquinone; Cyt c = 
cytochrome c (adapted from Alberts et al., 2002a; Sazanov, 2015). 
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5.1.5 Respiration in aerobic bacteria 
Like mitochondria, the energy-producing system present in aerobic bacteria (Figure 
5-2) is also located on its inner membrane and includes SDH as detailed by 
(Hederstedt & Rutberg, 1981). In a review by Haddock & Jones (1977), membrane-
bound proteins involved in bacterial respiration are orientated to derive full 
advantage of chemiosmotic reactions resulting in electron transfer and ATP 
production. Although the constitution of the bacterial respiratory complexes differs 
according to environmental conditions, such as accessibility of oxygen and enzymes, 
the configuration is identical to that of mitochondria as discussed by Melo & Teixeira 
(2015). Oxidase positive bacteria, such as Pseudomonas spp., utilise cytochrome c 
oxidase and employ oxygen as the terminal electron acceptor. In contrast, oxidase 
negative bacteria, such as E. coli, utilise other oxidases and may perform aerobic, 
anaerobic or facultative respiration. While Gram-positive bacteria, such as S. aureus 
are usually oxidase negative, they may be facultative anaerobes. Bacterial respiration 
is not only similar to mitochondrial respiration, but the process is also adaptable since 
a variety of other electron receptors, such as sulphur- and nitrogen-based 
compounds, are used, as described by Richardson (2000). 
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Figure 5-2 Summary of a classic metabolic pathway in aerobic bacteria indicating the electron transport 
system. Structures with underlined labels are common in all bacterial cells. Complex I = NADH 
dehydrogenase; Complex II = SDH; Complex III = cytochrome b-c1; Complex IV = cytochrome c oxidase; 
Complex V = ATP synthase; U = ubiquinone; Cyt c = cytochrome c; SUCC = succinate; FUM = fumarate 
(Alberts et al., 2002c; Portnoy et al., 2010) 
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5.1.6 Examples of the use of the MTT assay in the determination of bacterial cell 
viability and alternative methods used to determine bacterial cell viability 
Mshana et al. (1998) were among the first research groups that attempted to use the 
MTT assay to assess the viability of bacterial cells. Findings of this study indicated 
that rifampin-sensitive Mycobacterium bovis BCG 390955B, Mycobacterium 
tuberculosis H37Ra strain 35836 and clinical isolates of Mycobacterium tuberculosis 
were unable to reduce MTT to formazan after incubation with rifampin. 
Concurrently, rifampin-resistant Mycobacterium tuberculosis H37Rv strain 35838 did 
reduce MTT to formazan after exposure to rifampin (Mshana et al., 1998). The group 
concluded that the rapid and inexpensive method could be used to determine the 
presence of rifampin-resistant Mycobacterium tuberculosis. Consideration could also 
be given to assess the presence of isoniazid-resistant Mycobacterium tuberculosis 
strains using a combined MTT assay for rifampicin and isoniazid since this 
antibacterial drug combination is the primary approach to treat infections against 
Mycobacterium tuberculosis.  
In another study completed by Alenezi et al. (2017) explored the use of the MTT assay 
in measuring cell viability of E. coli GC4468 after incubation with Zinc porphyrin-
based photosensitizers. Results of the study indicated that the bacterial cells were 
unable to completely reduce MTT after photoillumination, which was possibly due to  
bacteriostatic, and not bactericidal, activity (Alenezi et al., 2017). The group reported 
that structural reconfiguration of the compounds could have a greater impact, than 
possession of high cationic charge and lipophilicity, on cell viability resulting in cell 
death. 
Fluorescent dyes have also been proposed as alternative indicators of the viability of 
bacterial cells that adhere to and are phagocytised by mammalian cells. SYTO9 and 
4',6'-diamidino-2-phenylindole, which is also known as DAPI, are membrane 
permeable dyes that have been used in determining the viability of total bacterial 
population of N. gonorrhoea used to infect human neutrophils (Johnson & Criss, 
2013). In the same study, SYTOX Green and propidium iodide have been used to 
assess phagocytised N. gonorrhoea (Johnson & Criss, 2013). 
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5.1.7 Aim of assay 
The aim of this phase of the research work was to measure the viability of bacterial 
cells, which exhibited various known mechanisms of action excluding inhibition of 
bacterial cell respiration, using MTT post-incubation with hexyl to decyl ferrocenyl 
chalcone compounds, which exhibited greater antimicrobial activity as reported in 
Table 3-9 of Chapter 3. 
5.2 Materials and Methods 
5.2.1 Preparation of stock antimicrobial control 
Each stock antimicrobial solution was prepared as described in Section 2.1.4. The 
antimicrobial compounds used were PEN-G and OXY. Stock solution when prepared 
were stored at -20oC. 
5.2.2 Preparation of stock ferrocenyl chalcone 
Fresh stock solution of each ferrocenyl chalcone (hexyl to decyl) was prepared as 
described in Section 2.1.3. The solutions were used immediately after preparation. 
5.2.3 Preparation of MTT solution 
Appropriate volumes of stock MTT solution were prepared at a ratio of 5 mg/ml of 
MTT reagent powder in of PBS as detailed in Section 2.1.5. The stock solution was 
stored at -20oC until required. 
5.2.4 Preparation of inocula 
Each inoculum of S. aureus NCIMB 8244, K. kristinae NCIMB 8884, E. faecalis NCTC 
12697, fully sensitive S. aureus (CRH), PEN-resistant S. aureus (CRH), PEN/ERY/CLI-
resistant S. aureus (CRH) and a MRSA (CRH) was freshly prepared each time as 
detailed in Section 2.2.1. 
5.2.5 Preparation of bacterial standard curves for MTT assay 
Standard curves of S. aureus NCIMB 8244, K. kristinae NCIMB 8884, E. faecalis NCTC 
12697, fully sensitive S. aureus (CRH), PEN-resistant S. aureus (CRH), PEN/ERY/CLI-
resistant S. aureus (CRH) and a MRSA (CRH) were prepared as described in Section 
2.4. The dilutions were converted to percentage of actively respiring cells in terms of 
formazan product and plotted against the absorbance values in Excel producing 
standard curves per organism (Appendix 6, Figure 9-54 to 9-60). 
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5.2.6 Adapted Bacterial MTT assay (Moodley et al., 2014) 
The 96-well microtitre plates were prepared as described in Section 2.6 for S. aureus 
8244, K. kristinae NCIMB 8884, E. faecalis NCTC 12697, fully sensitive S. aureus (CRH), 
PEN-resistant S. aureus (CRH), PEN/ERY/CLI-resistant S. aureus (CRH) and a MRSA 
(CRH) where the organisms were treated with ferrocenyl chalcone solution. After 
incubation of the microplate at 37oC in air for 18-24hrs, 10 µl of MTT solution (5 
mg/ml) was added to all wells. The microplates were then incubated at 37oC in air for 
3 hours. 50 µl of DMSO was added to all wells and mixed by pipetting. The absorbance 
values were measured at 570 nm on a microplate reader, where n= 10. The blank 
wells, where no bacteria were added, were subtracted from the sample wells to give 
the sample absorbance values. The percentage of actively respiring cells (in terms of 
formazan product gained) was calculated using the equation derived from the MTT 
standard curve of each organism. The estimated percentage of each assay was 
plotted in a Box and Whiskers plot showing the mean, median, upper and lower 
values. 
5.2.7 Statistical analysis 
The Kolmogorov-Smirnoff test was used to determine data normality of the MTT 
assay data. Statistical analysis of the MTT assay data in the study was performed 
using a one-way analysis of variance (ANOVA) (Appendix 6, Table 9-4 to Table 9-10) 
to determine whether the mean percentage of actively respiring cells differed 
between the hexyl to decyl ferrocenyl chalcone treatments.  
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5.3 Results 
The results of the MTT assay of non-resistant Gram-positive laboratory organisms 
demonstrated that the percentage of actively respiring cells, in terms of formazan 
product observed (Figure 5-3) decreased after exposure to chalcones at the MIC 
value. No viable cells (mean estimated percentage of 0%) were seen for S. aureus 
NCIMB 8244 when exposed to hexyl, octyl, nonyl and decyl. For K. kristinae NCIMB 
8884, no viable cells (mean estimated percentage of 0%) were seen after exposure 
to heptyl, octyl and nonyl. When exposed to hexyl and heptyl, mean percentage of 
actively respiring E. faecalis NCTC 12697 cells were estimated to be 0%. The highest 
percentage was measured for S. aureus NCIMB 8244 after incubation with heptyl 
(6.681%). Exposure of all cells to PEN produced mean percentages estimated to be 
0%, while the absence of ferrocenyl chalcone or known antimicrobial compound 
produced mean percentages of actively respiring cells from 14.938% to 74.156%. 
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Figure 5-3 Estimated percentage (n=10) of actively respiring non-resistant lab bacterial cells when treated with ferrocenyl 
chalcone at MIC. Box plots represent the lower and upper quartiles with the medians shown as black lines. Whiskers represent 
the minimum and maximum percentages and each X represents the mean values. Dots represent outlying values.
In the MTT assay of resistant and non-resistant Gram-positive clinical isolates the 
percentage of actively respiring cells, in terms of formazan product observed (Figure 
5-4) also decreased after exposure to chalcones at the MIC value. No viable cells 
(mean estimated percentage of 0%) were seen for fully sensitive S. aureus (CRH) 
when exposed to heptyl octyl, nonyl and decyl, for PEN-resistant S. aureus (CRH) 
when exposed to hexyl, heptyl, octyl, and decyl, and for PEN/ERY/CLI-resistant S. 
aureus (CRH) when exposed to hexyl and decyl, and for MRSA when exposed to decyl. 
The highest percentage was determined for PEN-resistant S. aureus (CRH) after 
incubation with nonyl (1.342%). Exposure of all cells to PEN produced mean 
percentages estimated to be 0%, while the absence of ferrocenyl chalcone or known 
antimicrobial produced mean percentages of actively respiring cells from 4.200% to 
14.304%. 
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Figure 5-4 Estimated percentage (n=10) of actively respiring resistant and non-resistant clinically isolated bacterial cells when 
treated with ferrocenyl chalcone at MIC. Box plots represent the lower and upper quartiles with the medians shown as black 
lines. Whiskers represent the minimum and maximum percentages and each X represents the mean values. Dots represent 
outlying values.
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5.4 Discussion 
The MIC values of the ferrocenyl chalcones against the organisms used in this study 
corresponded with the percentage of actively respiring cells in terms of the formazan 
product seen. This suggests that the metabolic process used to convert MTT was not 
active at the concentrations of chalcones present in the cells. Therefore, little or no 
formazan product was detected at 570 nm. In the MTT assay involving Gram-negative 
bacteria, growth inhibition, which was seen at 0.125 mg/ml, may also have resulted 
from exposure of the organisms to DMSO. This implies that the percentage of viable 
cells that were involved in MTT metabolism to formazan were very low at the 
assessed MIC values in combination with DMSO, making it difficult to define the exact 
cause of reduced viability off Gram-negative cells in the current study. 
When compared to MTT screening of ferrocenyl chalcone antimicrobial activity 
against Mycobacterium tuberculosis H37Rv, the MIC values in this study (Chapter 3, 
Table 3-9) sat within the reported range (0.016-0.128 mg/ml) (Moodley et al., 2014), 
except for K. kristinae NCIMB 8884 where a lower MIC (heptyl chalcone) was 
achieved. In the microplate assays, the overall trend showed that the ferrocenyl 
chalcone compounds had a greater inhibitory effect on Gram-positive bacteria than 
on Gram-negative bacteria. Another observation of the ferrocenyl chalcone activity 
in this study was that there were minute variations of complete inhibition of cellular 
respiration across Gram-positive species. This could be due to the diversity of cross-
linkage within peptidoglycan and polymer constituents, such as polysaccharides and 
polypeptides, within the cell wall of different Gram-positive bacterial species 
(Shockman & Barrett, 1983).  
One-way ANOVA tests (Appendix 6, Tables 9-4 to 9-10) were conducted to determine 
whether there were significant differences (p˂0.05) between the longer chain 
chalcones against each Gram-positive organism with respect to their effect on 
bacterial respiration. Results of these analyses indicated that the differences 
between hexyl to decyl chalcones in terms of mean (± SD) percentage (n=10) of 
actively respiring cells present were not significant for S. aureus NCIMB 8244 
(p=0.426), K. kristinae NCIMB 8884 (p=0.442) and E. faecalis NCTC 12697 (p=0.522). 
Thus, the compounds were equally effective at inhibiting respiration in all selected 
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non-resistant Gram-positive bacteria. Similarly, the hexyl to decyl ferrocenyl 
chalcones were equally effective at respiration inhibition in fully sensitive S. aureus 
(CRH) (p=0.426), PEN-resistant S. aureus (CRH) (p=0.408), PEN/ERY/CLI-resistant S. 
aureus (CRH) (p=0.434) and a MRSA (CRH) (p=0.852).  
5.4.1 Possible mode of action 
Ferrocene groups have been theorised to be inhibitors of cellular respiration, in 
which the ferrocene groups act as respiration uncouplers as seen when 
Caenorhabditis elegans  are exposed to organic chalcones  (Gonzalez & Estevez-
Braun, 1997) and ferrocenyl chalcones (Attar et al., 2011). The ferrous (Fe2+) centre 
of ferrocene groups has also been hypothesised to exhibit electrochemical 
properties. Findings of a study by Jaouen et al. (2015) involving ferrocifen 
demonstrated that Fe2+ may be oxidised to Fe3+ by oxygen present in cells. This 
property facilitates anti-cancer activity where ferrocifen binds to oestrogen 
receptors, essential for cancer growth, causing dimer formation of the proteins (Top 
et al., 1996; 2001; 2003). In the current study, the ferrocenyl chalcone compounds 
possibly enter the peptidoglycan layer of Gram-positive organisms and the increased 
chain length may allow the ferrocene groups of the compounds to be trapped in the 
cell membrane adjacent to SDH in the electron transport chain (Figure 5-6). This is 
followed by inhibition of the SDH by the ferrocene moiety where succinate reduction 
to fumarate is blocked and the electron transport machinery is stalled. 
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Since Gram-negative organisms possess outer envelopes, thin peptidoglycan layers 
with increased periplasmic space and cell membranes in their cell envelopes, entry 
into these cells may be more difficult (Figure 5-6). Another possibility is that the cell 
membrane of Gram-positive bacteria is compromised such that the electron 
transport chain cannot function (Haddock & Jones, 1977). Cell viability, as indicated 
by MTT metabolism to formazan, decreased in Gram-positive bacteria when 
compared to Gram-negative bacteria. Therefore, a possible mechanism of action of 
the chalcones with longer alkyl chain lengths may be inhibition of cellular respiration. 
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Figure 5-5 Summary of proposed mode of action of longer alkyl chain ferocenyl chalcone compounds showing 
blockage of succinate reduction in the Krebs Cycle within Gram-positive bacteria (produced by E. Henry, 2017). 
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The physical and external effect of this theorised action of the ferrocenyl chalcone 
chemicals was further investigated using bacterial SEM. 
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Figure 5-6 Summary of proposed mode of action of longer alkyl chain ferocenyl chalcone compounds showing 
no blockage of succinate reduction in the Krebs Cycle within Gram-negative bacteria (produced by E. Henry, 
2017). 
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5.5 Conclusion 
The MTT colorimetric assay, which is used to affirm the presence of actively respiring 
cells, involves the reduction of MTT to formazan by SDH and can be used for both 
eukaryotic and prokaryotic cells. In the present study, percentage of actively 
respiring non-resistant laboratory-adapted, and non-resistant and resistant clinical 
isolates of Gram-positive bacteria were significantly reduced post-incubation with 
ferrocenyl chalcone compounds (hexyl to decyl) comprised of longer alkyl chains. 
Each compound was equally effective at blocking respiration in all tested cells. A 
possible reason for this result was that the compounds were able to penetrate the 
thick peptidoglycan layer of the Gram-positive cells, becoming trapped in the cell 
membrane near SDH and, consequently, block succinate reduction. Thus, cell 
respiration and growth were inhibited. In terms of external damage to the cells, 
micrographic evidence of the effects will be explored in Chapter 6. 
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6 Determination of Changes to Cellular Morphology using 
SEM 
6.1 Introduction 
As described previously, aerobic respiration in bacteria is facilitated by membrane-
bound enzymes, including SDH, that comprise the electron transport chain as 
detailed by several researchers including Hederstedt & Rutberg (1981). Thunberg’s 
(1909) description of SDH as a critical enzyme in electron transfer within the Krebs 
Cycle was confirmed by many successive researchers, including Vogel et al. (2006) 
who demonstrated the ATP-synthesising and respiratory function of the enzyme. 
Hederstedt & Rutberg (1981) also reviewed that SDH catalyses the reduction of 
succinate to fumarate in the Krebs Cycle, an essential function performed in actively 
respiring eukaryotic and prokaryotic cells that constitutes cell viability (Pegg, 1989).  
In Chapter 5, evidence was presented that aerobic bacteria, which were exposed to 
ferrocenyl chalcone compounds with longer alkyl chains (hexyl to decyl), exhibited 
reduced viability. This would infer that there was inhibition of the respiratory 
process, which may indicate damage to the cell membrane structure. SEM provides 
an opportunity of observing this loss of structure. 
6.1.1 SEM 
The principle of the SEM, first proposed by Knoll (1935), involves the transmission of 
a focused electron beam on to a minute area of an object, followed by accumulation 
of the electron currents,  under vacuum, that rebound from the object, and 
compilation and amplification on to a screen of a cathode-ray tube to produce an 
image with high resolution and magnification (Smith et al., 1955). The first SEM 
instrument, constructed by McMullan (1953), obtained micrographs of opaque metal 
specimens. While SEM proved effective in elucidating the topography of metallic 
samples, it was observed by researchers that the imaging method was in effective in 
gaining images of biological samples. This was due to the fact that the conservation 
of biological samples became a major issue, since the maintenance of sample 
integrity under vacuum conditions was of paramount importance as discussed by 
Fischer et al. (2012). Another key factor in the utilisation of SEM for acquiring images 
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of biological samples is that such specimens are comprised of non-conductive 
material from which electrons are not rebounded. These issues resulted in the 
development of modified SEM preparation techniques for organic samples. In 1975, 
Malick & Wilson were among the first research groups to adapt this technology for 
biological samples using air drying preparation. One limitation of this method was 
that it was only effective for hard biological specimens since vacuum conditions, 
which were required to obtain high resolution images, destroyed such samples. To 
overcome this, other preparation techniques such as freeze drying (Boyde & Wood, 
1969), critical point drying (Hayat, 1978), and vapour fixation with osmium tetroxide 
(Quattlebaum & Carner, 1980) have been employed. Another successful sample 
preparation method, developed by Nation (1983), involved pre-fixing in 
glutaraldehyde, dehydrating in a graded series of ethanol and post-fixing in 
hexamethyldisilazane. In a review by Fischer et al. (2012), it was noted that SEM 
methods should be used with caution since chosen techniques should be adapted 
depending on the type of biological sample under assessment. 
6.1.2 Bacterial SEM 
Glauert (1980) designed a method in which solid-based bacterial samples were pre-
fixed in 2-3% w/v glutaraldehyde and post-fixed in osmium tetroxide or Ruthenium 
Red for bacterial samples in fatty or polysaccharide sources. Variations of the Nation 
(1983) method have also been used to prepare bacterial specimens, some of which 
specifically focus on the preparation of bacterial samples from liquid-based media. 
Researchers who have developed such techniques for gaining images of bacterial 
samples in solution discovered that suspension-based bacterial samples require 
filtration using polycarbonate membrane filters diameters of 13 mm and pore sizes 
from 0.2 µm to 1 µm, as discussed by Kaláb, Yang, & Chabot (2008). Previous research 
on antimicrobial agents have used SEM to show changes in the topography of 
bacterial cells when treated with those agents. Successful studies that employed the 
use of bacterial SEM include exposure of bacterial cells to antimicrobial peptides 
(AMP) (Hartmann et al., 2010), treatment of food-related bacteria with sugar fatty 
acid esters (Zhao et al., 2015) and the antimicrobial activity of cinnamon essential oil 
against S. aureus ATCC 25923 and E. coli ATCC 25922 (Zhang et al., 2016). Images 
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derived from these studies indicated that untreated cells retained their smooth 
forms and their normal size, while treated cells exhibited blisters on the surface of 
AMP-treated E. coli cells and craters on the surface of AMP-treated S. aureus cells 
(Hartmann et al., 2010), uneven surfaces post-exposure to sugar fatty acid esters 
(Zhao et al., 2015) and misshapen morphology (Zhang et al., 2016). 
6.1.3 Morphological effects of conventional antimicrobial agents against bacteria 
In a study of the morphological effects of conventional antimicrobial agents on 
clinical isolates of S. aureus, Greenwood  and O’Grady (1972) obtained SEM images 
of affected bacterial cells exhibiting various types of external damage. After 
treatment of clinically isolated S. aureus with cloxacillin, which inhibits the synthesis 
of cell walls, there was evidence of topographical damage where the cell appeared 
shrunken and amorphous (Greenwood & O’Grady, 1972). In the same study, 
Greenwood and O’Grady (1972) also obtained morphological evidence of damage to 
S. aureus clinical isolates after exposure of the cells to lincomycin, erythromycin and 
fusidic acid, which are inhibitors of bacterial protein synthesis. The cells exhibited 
total structural collapse after exposure to the compounds with “discrete” lesions that 
were observed on cells affected by lincomycin, and the appearance of “doughnuts” 
were observed on cells that were treated with erythromycin (Greenwood & O’Grady, 
1972).  
Evidence of external damage to bacterial cells were also obtained in SEM images of 
treatment of S. aureus ATCC 25923 with common antimicrobial agents (Anam et al., 
2010). After treatment with PEN-G, S. aureus ATCC 25923 cells exhibited incomplete 
cell wall synthesis with pores that possessed needle-like structures, which resulted 
from partial transpeptidation (Anam et al., 2010). In the same study, the cells 
exhibited shrinkage and pores after exposure to vancomycin, which is an inhibitor of 
cross-linkage in bacterial cell walls, resulting in weakened peptidoglycan and cell lysis 
(Anam et al., 2010). 
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6.1.4 Aim of the assay 
If the ferrocenyl chalcone compounds are exerting their effect by disrupting the cell 
membrane, then this disruption potentially can cause an effect on the physical 
structure of the organism that can be seen using SEM. The morphological effect(s) of 
these compounds will possibly differ from those observed in previous studies 
described in 6.1.2 and 6.1.3, which could provide further evidence that these 
compounds exhibit a possible alternate mode of action against bacteria. The aim of 
this assay is to reveal external damage to S. aureus NCIMB 8244, K. kristinae NCIMB 
8884 and E. faecalis NCTC 12697 post-incubation with decyl ferrocenyl chalcone 
compound at the respective MIC values. Decyl ferrocenyl chalcone compound, which 
possessed antibacterial activity against all tested bacteria, was randomly selected to 
address this aim. 
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6.2 Materials and Methods 
6.2.1 Preparation of ferrocenyl chalcone solution 
For each bacterial sample, stock solutions of decyl ferrocenyl chalcone were 
prepared as detailed in Section 2.1.3. Each stock solution was further serially diluted 
2-fold in sterile MH broth down to the required MIC values that were measured in 
Chapter 3 (Table 3-9). 
6.2.2 Preparation of inocula 
Fresh inocula of S. aureus NCIMB 8244, K. kristinae NCIMB 8884 and E. faecalis NCTC 
12697 were prepared as described in Section 2.2.1. 
6.2.3 Preparation of bacterial samples for SEM 
Treated and untreated non-resistant bacterial inocula were examined in the SEM. 
The method of preparation of both treated and untreated organisms were detailed 
in Section 2.8. 
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6.3 Results 
Low electron energies between 2 keV and 2.5 keV (Hartmann et al., 2010) and 4keV 
were initially used to capture secondary electron images. However, use of these 
conditions resulted in loss of contrast where cell morphology and possible cell 
damage could not be determined. The next option used to obtain clear images was 
the use of back scattered electron imagery, which proved unsuccessful. After 
productive discussions with other technical staff, it was recommended that the 
electron energy be incrementally increased, and that the working distance be 
incrementally decreased until clear images can be obtained (Figures 6-1, 6-2, 6-3, 6-
4 and 6-5). This approach helped in the SEM method development of the current 
study in relation to the SEM conditions that would produce useful images. 
Additionally, this method development aided in confirming that the preparation 
technique used in the current study was successful. The most successful conditions 
involved the use of 15 keV and WD = 11 mm (Figures 6-6, 6-7, 6-8, 6-9, 6-10 and 6-
11). 
 
Figure 6-1 SEM image of untreated S. aureus NCIMB 8244 using 4kV. Although the use of similar SEM conditions 
as described by Hartmann et al. (2010) produced an image with less contrast, sufficient details were obtained that 
indicated that the untreated cells were undamaged. 
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Figure 6-2 SEM image of treated S. aureus NCIMB using 4kV with increased working distance and decreased 
magnification were considered in an effort to obtain an image with sharper contrast. However, this combination 
of changes in conditions did not yield clear images since cellular damage could not be determined. 
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Figure 6-3 SEM image of treated S. aureus NCIMB 8244 using 5kV with decreased working distance and spot size, 
and increased magnification. Increased electron energy and magnification produced an image with greater 
contrast showing cells with loss of structural integrity. 
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Figure 6-4 SEM image of untreated S. aureus NCMIB obtained after increasing all conditions. Image appears 
clearer than those in in which lower electron energies were used. Greater cell morphology can be seen but any 
cellular damage could not be clearly defined. 
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Figure 6-5 SEM image of untreated S. aureus NCIMB 8244 at 15kV with decreased spot size and increased 
magnification. This combination of changes in SEM conditions resulted in greater contrast where undamaged 
cellular morphology was observed. 
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The SEM images of untreated S. aureus NCIMB 8244 (Figure 6-6), K. kristinae NCIMB 
8884 (Figure 6-8) and E. faecalis NCTC 12697 (Figure 6-10) revealed bacterial cells 
with their normal, spherical or spherical-like appearance. However, after exposure 
to decyl ferrocenyl chalcone compound at respective MIC values, S. aureus NCIMB 
8244 (Figure 6-7), K. kristinae NCIMB 8884 (Figure 6-9) and E. faecalis NCTC 12697 
(Figure 6-11) exhibited severe external damage. The affected cells appeared partially 
or fully lysed. Cell lysis indicates that the integrity of the bacterial cell membrane is 
compromised, which consequently contributes to the inhibition of bacterial 
respiration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 | P a g e  
 
 
Figure 6-6 SEM image of untreated S. aureus NCIMB 8244 where dotted arrows indicate some of the cells with 
normal spherical appearance and undamaged cell membranes where bacterial respiration occurs. 
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Figure 6-7 SEM image of treated S. aureus NCIMB 8244. Dotted arrow indicates an unaffected cell, while solid 
arrows indicate some of the fully lysed cells at MIC 0.031 mg/ml of decyl ferrocenyl chalcone. Cell lysis is similar 
to the damage observed by Li et al. (2014) and Zengin and Baysal (2014), which was caused by the inhibition of 
bacterial cellular respiration. This also shows evidence that the MIC value is equivalent to the MBC value (Chapter 
3). 
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Figure 6-8 SEM image of untreated K. kristinae NCIMB 8884 where dotted arrows indicate some of the cells with 
normal spherical-like appearance and undamaged cell membranes where bacterial respiration occurs. Double-
lined arrow indicates a dividing cell. 
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Figure 6-9 SEM image of treated K. kristinae NCIMB 8884 where solid arrows indicate some of the fully lysed cells 
at MIC 0.016 mg/ml of decyl ferrocenyl chalcone. Cell lysis is similar to the damage observed by Li et al. (2014) 
and Zengin and Baysal (2014) which was caused by the inhibition of bacterial cellular respiration. This also shows 
evidence that the MIC value is equivalent to the MBC value (Chapter 3). 
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Figure 6-10 SEM image of untreated E. faecalis NCTC 12697 where dotted arrows indicate some of the cells with 
normal spherical-like (ovoid) appearance and undamaged cell membranes where bacterial respiration occurs.. 
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Figure 6-11 SEM image of treated E. faecalis NCTC 12697 where solid arrows indicate some of the fully lysed cells 
at MIC 0.063 mg/ml of decyl ferrocenyl chalcone. Cell lysis is similar to the damage observed by Li et al. (2014) 
and Zengin and Baysal (2014) that was caused by the inhibition of bacterial cellular respiration. This also shows 
evidence that the MIC value is equivalent to the MBC value (Chapter 3). 
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6.4 Discussion 
SEM images revealed fully lysed Gram-positive bacterial cells that may have resulted 
from the effects of inhibition of cellular respiration in the bacterial cell membranes 
post-exposure to decyl ferrocenyl chalcone compound at appropriate MIC values 
(Chapter 3, Table 3-9). Although few unaffected bacterial cells were seen, most of 
the treated S. aureus NCIMB 8244 exhibited extensive external damage post-
incubation with decyl ferrocenyl chalcone compound at 0.031 mg/ml MIC value 
(Figure 6-7). This result corroborated the observations seen in the MTT assay of the 
same compound against S. aureus NCIMB 8244 where the mean percentage of 
actively respiring cells was 0.782% (Chapter 5, Figure 5-3). In contrast, untreated S. 
aureus NCIMB 8244 cells displayed undamaged spherical shapes (Figure 6-6). After 
exposure to decyl ferrocenyl chalcone compound at 0.016 mg/ml MIC value, treated 
K. kristinae NCIMB 8884 (Figure 6-9) displayed the same external damage as seen in 
S. aureus NCIMB 8244. Untreated K. kristinae NCIMB 8884 cells showed undamaged 
cells, including some which appear to be dividing, confirming indication of cell 
viability (Figure 6-8). Treatment of E. faecalis NCTC 12697 with decyl ferrocenyl 
chalcone compound at 0.063 mg/ml MIC value also resulted in external damage to 
the cells (Figure 6-11), while untreated E. faecalis NCTC 12697 exhibited their 
undamaged, ovoid shape (Figure 6-10). 
Similar cell lysis caused by respiration inhibitors was seen when S. aureus ATCC 25923 
was exposed to graphene films on three types of conductors (Li et al., 2014). Li et al. 
(2014) demonstrated that upon microbial cell contact with graphene film on 
conductor copper (Cu), electrons were transferred from the respiratory system to 
graphene films and then to conductor Cu, which was the final electron acceptor in 
the bacterial electron transport system. Exposure of bacterial cells to graphene 
resulted in the formation of a Schottky barrier, which involved the transfer of 
electrons from the electron transport system to the semi-metal, and the outcome of 
cell membrane damage. This damage was reported as a “disruption” of membrane 
integrity, which resulted in leakage of critical cellular contents and subsequent cell 
death. Because of the possible removal of electrons from the bacterial respiratory 
chain that is located in the cell membrane, followed by the interruption of the 
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membrane structure and cell lysis, which was seen in SEM images obtained by Li et 
al. (2014), the mode of action of the graphene films as proposed by Li et al (2014) is 
comparable with the mechanism of action of the ferrocenyl chalcone compounds 
used in the current study. 
In another study, evidence of cell lysis resulting from respiratory inhibitors against 
bacterial cells was reported by Zengin & Baysal (2014) when S. aureus RSSK01009 
cells were exposed to essential oil terpenes. Zengin & Baysal (2014) concluded that 
monoterpenes, such as eucalyptol, act as inhibitors of bacterial respiration by 
altering the structural configuration of membrane-bound proteins essential to the 
electron transport chain followed by the inhibition of oxidative phosphorylation. This 
inhibition led to extensive damage to the bacterial cell membrane, including the 
breaking and collapse of the cell membrane, and cell death. The proposed 
mechanism of action and subsequent SEM images of cell lysis obtained by Zengin and 
Baysal (2014) can be considered as evidence of a similar mode of action that was 
displayed after exposure of bacterial cells to ferrocenyl chalcone chemicals in the 
current study. 
As previous research has shown, an association between respiratory inhibition and 
structural damage can be observed in affected bacterial cells. As discussed in Chapter 
5, bacterial cells perform respiration to ensure viability and cell growth. The aerobic 
version of this process is achieved through the electron transport chain, which is 
bound to the cell membrane (Hederstedt & Rutberg, 1981). This ATP-producing 
system includes SDH, an enzyme that reduces succinate to fumarate in the Krebs 
Cycle (Hederstedt & Rutberg, 1981). Ferrocene, which was present in the ferrocenyl 
chalcone compounds in this study, has been proposed to inhibit succinate reduction 
(Gonzalez & Estevez-Braun, 1997; Attar et al., 2011). This results in blockage of the 
Krebs Cycle and eventual cellular respiration and cell damage, which has been 
observed in SEM micrographs. 
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6.5 Conclusion 
The SEM technique has been shown to be a viable tool to illustrate the topography 
of bacterial cells. In the current study, images of selected Gram-positive bacteria, 
post-incubation with decyl ferrocenyl chalcone compound at the appropriate MIC 
values from Chapter 3, were obtained. The images revealed extensive external 
cellular damage, which are comparable with previously published research (Li et al., 
2014; Zengin and Baysal, 2014). The observed cellular damage may have resulted 
from inhibition of bacterial respiration. This inhibition was caused by a possible 
interaction between the ferrocene group of the chalcone compound and SDH in the 
electron transport chain of the Krebs Cycle. Thus, the SEM images provide further 
support for the potential mode of action of ferrocenyl chalcones with longer alkyl 
chains. 
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7 Conclusions 
This study focussed on the characterisation and antimicrobial action of novel 
ferrocenyl chalcone chemicals, which possess increasing alkyl chains, as well as to 
determine their possible mode of action. Chalcones are plant-based compounds, 
which exhibit antibacterial activity and can be easily modified to form ferrocenyl 
compounds, as reported by several researchers (Attar et al., 2011; Pejović et al., 
2012; Kowalski et al., 2013; Medu, 2013; Prasath et al., 2013; Ahmed et al., 2015; 
Mishra et al., 2015; Smith, 2017 pers. comm.). These ferrocene-type antibacterial 
agents are potential inhibitors of bacterial respiration.  
7.1 Determination of MIC 
Key discoveries that were presented in Chapter 3 of this current study are that the 
ferrocenyl chalcone compounds with longer alkyl chains (hexyl to decyl) exhibited 
greater antimicrobial activity than those with shorter alkyl chains (methyl to pentyl). 
Findings also indicated that the compounds, which possessed antimicrobial activity, 
were more effective against Gram-positive bacteria than against Gram-negative 
bacteria. Another key finding of the current study was that the ferrocenyl chalcones 
demonstrated significant antimicrobial activity, with MICs ranging from 0.008 mg/ml 
to 0.063 mg/ml ± 0.000 mg/ml, against non-resistant laboratory-adapted organisms 
and resistant and non-resistant clinical isolates. These values were observed using 
the broth microdilution, as detailed by Andrews (2001), after alternative methods, 
such as agar well diffusion, disc diffusion and broth macrodilution, yielded minimal 
practical results. Further assays demonstrated that the MIC values are also equal to 
the MBC values and that bactericidal activity occurred within 0 to 4 hours as shown 
by the time-kill assays. The results of the time-kill assays indicate that the time taken 
to kill bacteria are comparable with other studies (Barbour et al., 2014; Scheerans et 
al., 2015; del Valle et al., 2016; Rolston et al., 2017). These findings indicate that 
these compounds possess favourable antimicrobial properties. 
135 | P a g e  
 
7.2 Elucidation of the possible causes and consequence of colour change 
and particulate formation in diluted ferrocenyl chalcone solutions  
An issue encountered early in the study was that 2-fold dilution of the solubilised 
compound in MH broth resulted in a colour change from deep red to dark brown and 
the formation of brown particles despite the facile solubilisation of the novel 
ferrocenyl chalcones in DMSO. Initially, disposed iodine was proposed to be the 
possible cause of the presence of the dark brown solution. Based on the reported 
findings of Hildebrand et al. (1950) and Smith et al. (2013), diethy ether was used to 
indicate the presence of iodine, which is soluble in polar solvents (Kaiho, 2015). 
However, in the current study, brown residue was seen at the bottom of the 
borosilicate tubes instead of a brown ring at the top of the suspension, as reported 
by Smith et al. (2013). An alternative explanation was that this reversible colour 
change was possibly caused by the oxidation of Fe2+ ions in ferrocene to Fe3+ ions 
(ferrocenium) as demonstrated in Chapter 4 of this study and reported by Charette 
& Sholkovitz (2002). This phenomenon resulted in an equivalent mix of ferrocene 
(reddish orange) and ferrocenium (bluish green), which formed the dark brown 
colour. The presence of brown particles may have been caused by iron ion chelation 
due to casein hydrolysate in MH broth. Further investigations involving the reaction 
between the ferrocene-type compounds and casein hydrolysate are required to 
verify the cause of this particle formation. 
The colour change of these compounds initiated the study by Bennett (2016) to 
investigate the effect of environmental condition on solubilised compounds and 
whether the antibacterial activity of these affected compounds were altered. 
Bennett concluded that solubilised ferrocenyl chalcones were affected by light and 
heat. However, the study indicated that there was no significant change in 
antibacterial activity. This means that neither colour change, nor the formation of 
brown particles, affects the activity of these compounds after solubilisation in DMSO. 
7.3 Cell Viability 
Cell viability studies implied that the potential mechanism of action of the ferrocenyl 
chalcone compounds involved the inhibition of bacterial respiration, as reported and 
discussed in Chapter 5, where there was approximately 0% of actively respiring 
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bacterial cells present after exposure to the compounds. The absence of actively 
respiring bacterial cells was represented by the absence of reduced MTT compound, 
which is a chemical that is reduced from yellow to the purple coloured formazan by 
membrane-bound respiratory dehydrogenases that are essential for cell viability and 
production. This absence of the reduced compound may have been achieved by 
interaction between the ferrocene group and respiratory dehydrogenases in the 
electron transport chain, which is bound to the bacterial cell membrane as 
demonstrated by Hederstedt & Rutberg (1981). This mechanism may have resulted 
in structural alteration of the cell membrane. If this is the mechanism of action, then 
further work is required to determine the effect of such compounds on mammalian 
cells, which also utilise respiratory dehydrogenases. This would establish whether 
mammalian apoptosis occur should these ferrocenyl chalcones be considered as 
alternative antimicrobial therapeutic agents. 
7.4 SEM 
After the use of several SEM technical conditions, useful images of bacterial cells that 
were treated and untreated were obtained. The SEM images highlighted in Chapter 
6 demonstrated that exposure to decyl ferrocenyl chalcone, a potent ferrocenyl 
chalcone, resulted in substantial external damage to bacterial cells at the MIC. The 
affected cells presented a shrivelled and wrinkled appearance suggesting that the 
integrity of their cell wall structural had been affected after interaction with the 
ferrocenyl chalcone compound. Evidence of the external morphological damage was 
demonstrated in similar studies where bacterial respiration was inhibited (Li et al., 
2014; Zengin & Baysal, 2014). Thus supporting the view that the inhibition was 
occurring, the SEM images obtained in the current study further strengthen the 
findings of the MIC determination using broth microdilution (Chapter 3), time-kill 
assays (Chapter 3) and the MTT assay (Chapter 5). The overall findings contribute to 
significant implications in the development of new antimicrobial drugs. 
7.5 Overall Implications 
The findings from this study indicate that these novel ferrocenyl chalcone 
compounds possess potential antimicrobial activity against clinical bacterial isolates, 
specifically fully sensitive S. aureus, PEN-resistant S. aureus, PEN/ERY/CLI-resistant S. 
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aureus and MRSA. The ferrocenyl chalcone compounds used in the current study may 
exhibit similar potency to that observed with conventional antimicrobial agents since 
the observed MICs of the functional ferrocenyl chalcones from hexyl to decyl (0.008 
mg/ml-0.063mg/ml) fall within the ranges of PEN (0.000015-0.128 mg/ml) and TET 
(0.00025-0.128 mg/ml) as reported by Andrews (2001). Additionally, as discussed in 
Chapter 5, Section 5.3, these ferrocenyl chalcone compounds appear to demonstrate 
inhibition of respiration in actively respiring bacterial cells, which resulted in no 
viable cells. This is significant since there was possible evidence of a mode of 
antimicrobial action that differed from conventional antimicrobial mechanisms but 
possibly similar to the mode of action of zinc porphyrin-based photosensitisers as 
proposed by Alenezi et al. (2017).  
In comparison to reported natural-based antimicrobial compounds, the group of 
ferrocenyl chalcone compounds used in the current study may be considered to be 
more effective than methanolic abstracts from birch (Duric et al., 2013), similarly 
effective as α-mangostin (Koh et al., 2013) but less effective against Gram-negative 
bacteria as observed with the activity of methanol extracts from seaweed (Kavita, 
Kumar, & Jha, 2014). These ferrocenyl compounds, which exhibited antimicrobial 
activity against a MRSA, PEN-resistant, CLI-resistant and ERY-resistant Gram-positive 
bacteria, and non-resistant Gram-positive bacteria, also appeared to exhibit mixed 
efficacy when compared to antimicrobial agents derived from the human body 
(Yamaguchi et al., 2002; Domanski et al., 2005; Yadava et al., 2006) but can be 
sufficiently compared to agents derived from pure colonies (Ovchinnikov et al., 2017) 
and from mixed colonies in soil (Ling et al., 2015). When compared to other 
ferrocenyl chalcones, the compounds used in the current study can be considered to 
be as effective against bacteria. Additionally, an investigation of this family of novel 
ferrocenyl chalcones, which are semi-synthetic analogues of plant-based 
compounds, used in the current study reveal that the common structure of these 
compounds play a vital role in potential antimicrobial therapy. This enhances the 
increasing interest of researchers into the development of similar chemicals as 
possible antimicrobial agents.  
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Some findings of the study failed to support the primary aim of this study, which 
involves the characterisation and determination of antimicrobial activity of novel 
ferrocenyl chalcones, but may be useful tools in other directions of research into the 
development of novel antimicrobial agents. Firstly, despite the fact that the solubility 
issues and the evidence of colour change of the dissolved compounds that occur 
under certain conditions require additional scrutiny, the solutions maintained their 
antimicrobial activity, as explored by Bennett (2016). These characteristics may be 
used to explore other forms of drug delivery such as topical therapy so as to minimise 
any adverse effects. Secondly, although the compounds were ineffective against 
Gram-negative bacteria, evidence of their activity against Gram-positive bacteria 
may lead to the production of an alternative source in the dwindling supply of 
antimicrobial therapeutics to which the latter group of bacteria are not resistant. 
Overall, the antimicrobial characteristics exhibited by the ferrocenyl chalcone 
compounds used in the current study, such as the favourable MICs and killing times, 
reduction of viable bacterial cells that is indicative of bactericidal activity, possibly 
caused by respiration inhibition, and SEM images of severe external damage, 
positively impacts antimicrobial therapy research by contributing to the exploration 
and development of similar compounds as potential therapeutic agents.  
7.6 Further work 
In order to progress the possible use of ferrocenyl chalcones with medium to long 
alkyl iodide chains as promising alternative antimicrobial drugs, future research into 
these current chemicals, which includes their effects against biofilms and mammalian 
cells, as well as chemical modification, should be considered. Further assays involving 
the efficacy of the compounds against biofilms, such as a comparable study reported 
by Kunthalert et al. (2014), and cytotoxicity against mammalian cells, such as a similar 
study reported by Kowalski et al. (2013) are needed to strengthen the profile of the 
ferrocenyl chalcone compounds. Another useful investigation would be to expand 
the current group of ferrocenyl chalcones to include, for example, longer alkyl chains 
greater than 10 carbons, which may provide a complete profile with respect to the 
structural relationships among the family of compounds. These modified 
compounds, along with the ferrocenyl chalcones used the current study, can also be 
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compared to chalcones that possess a similar structure. Additionally, the 
determination of the effect of these compounds on spheroblasts, which are cell wall 
free cells, should be included since this may provide vital information regarding the 
inefficacy of the compounds against Gram-negative organisms. The outcome would 
provide additional evidence that these compounds are potential additions to the 
rapidly decreasing availability of effective antimicrobial agents or that they may be 
useful as scaffolds in broad spectrum antimicrobial chemotherapy. 
7.7 Key Findings of the study 
1. Solubilised ferrocenyl chalcone compounds exhibit colour change from 
deep red to dark brown, which initially was proposed to be caused by the 
presence of displaced iodine. However, after an assay involving the use of 
diethyl ether to indicate the presence of iodine resulted in no occurrence 
of the reported brown ring at the top of the suspension (Hildebrand et al., 
1950; Smith et al., 2013), an alternate cause of the brown colour change 
was explored. This brown colour change may result from oxidation of Fe2+ 
to Fe3+ causing the simultaneous presence of both Fe2+ (reddish orange) 
and Fe3+ (bluish green). While the occurrence of Fe2+ oxidation has been 
reported by Charette & Sholkovitz (2002), further work is needed to 
confirm that this occurred in the current study.  
2. Colour change of ferrocenyl chalcone compounds may be influenced by 
temperature, light and type of reaction vessel. The effect of these 
environmental conditions on these compounds were further explored by 
Bennett (2016) who concluded that the observed colour change did not 
affect the antimicrobial activity of the ferrocenyl chalcone compounds. 
This is the first known report that focussed on the colour change 
ferrocenyl chalcones with respect to environmental conditions. 
Therefore, this theory requires further investigation. 
3. Dilution of solubilised compounds in MHB exhibit the reversible formation 
of particles, which may result from iron ion chelation by casein 
hydrolysate in MHB as reported by Gu et al. (2010) and Luo, Pan & Zhong 
(2014). The current study is also the first to report this occurrence in 
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relation to ferrocenyl chalcone chemicals. After exploring the possible 
effect of the presence of these particles on antimicrobial activity, Bennett 
(2016) reported that no change in antimicrobial efficacy was observed. 
4. Ferrocenyl chalcone compounds with increased alkyl chain lengths 
demonstrated greater antibacterial activity than those with decreased 
alkyl chain lengths. This structural feature of the compounds may be a 
critical factor in the determination of the mode of action. Additionally, the 
antimicrobial activity of similar compounds with chain lengths that 
possess more than 10 carbons may be investigated in order to strengthen 
this theory. 
5. Functional compounds exhibited greater antibacterial activity against 
Gram-positive bacteria than against Gram-negative bacteria. Although 
antibacterial activity against Gram-negative bacteria was not observed, 
this result indicates that the compounds used in the current study can be 
considered as potential additions to the cache of antimicrobial 
compounds against Gram-positive bacteria. Additionally, spheroblasts 
may be used to confirm the ineffectiveness of the same compounds 
against Gram-negative bacteria. 
6. Ferrocenyl chalcones compounds exhibited antibacterial activity against 
non-resistant Gram-positive laboratory-adapted organisms and PEN-
resistant, CLI-resistant and ERY-resistant Gram-positive clinical isolates, a 
MRSA, and non-resistant Gram-positive clinical isolates. The antibacterial 
activity of these plant-based semi-synthetic compounds against Gram-
positive bacteria can be comparable with the antibacterial activity of 
other plant-based chemicals such as methanolic abstracts (Duric et al., 
2013) and α-mangostin (Koh et al., 2013) but incomparable against Gram-
negative bacteria (Kavita et al., 2014). 
7. Antibacterial activity of these compounds, which is consistent with 
bactericidal activity, is initiated from 0 to 4 hours after exposure. The 
results of the time-kill assays, in which MIC values that were obtained 
against each organism (0.008 mg/ml – 0.063 mg/ml) were used, indicate 
that the bactericidal activity of the compounds can be comparable to 
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other reported antimicrobial therapeutic agents such as linezolid 
(Scheerans et al., 2015), telavancin and vancomycin (Barbour et al., 2014; 
Rolston et al., 2017) and kaempferol (del Valle et al., 2016). 
8. Evidence of cellular damage possibly caused by blockage of bacterial 
respiration was observed in SEM micrographs, which were eventually 
obtained after several SEM conditions were used. The mode of action may 
be characterised by chalcone inhibition of membrane-bound respiratory 
enzymes, which results in interference of bacterial respiration. 
Morphological damage of the bacterial cells can be comparable to 
damage observed in cells with inhibited bacterial respiration (Li et al., 
2014; Zengin & Baysal, 2014). 
9. This possible mode of action differs from that of the conventional 
antimicrobial mechanisms. Further investigations involving the 
determination of cell death that result from the inhibition of bacterial 
respiration are required. 
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9 Appendices 
9.1 Appendix 1 – Structures and molecular weights of ferrocenyl chalcone compounds 
Table 9-1 Structures and Molecular Weights (g/mol) of 11 ferrocenyl chalcone compounds. 
Name of ferrocenyl chalcone Structure of ferrocenyl chalcone 
Molecular weight of ferrocenyl 
chalcone (g/mol) 
Nonmethylated 
 
 
 
 
 
 
 
 
 
 
 
 
317.16 
Fe 
O 
N+ 
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Methyl 
 
 
 
 
 
 
 
 
459.10 
 
 
 
 
 
Ethyl 
 
 
 
 
 
 
 
 
473.13 
Fe 
O 
I- 
N+ 
Fe 
O 
I- 
N+ 
176 | P a g e  
 
Propyl 
 
487.15 
Butyl 
 
501.18 
Fe 
O 
I- 
N+ 
Fe 
O 
I- 
N+ 
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Pentyl 
 
515.21 
Fe 
O 
I- 
N+ 
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Hexyl 
 
529.23 
Fe 
O 
I- 
N+ 
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Heptyl 
 
543.26 
Fe 
O 
I- 
N+ 
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Octyl 
 
557.29 
Fe 
O 
I- 
N+ 
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Nonyl 
 
571.31 
Fe 
O 
I- 
N+ 
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Decyl 
 
585.34 
 
  
Fe 
O 
I- 
N+ 
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9.2 Appendix 2 – 1H NMR, MS and IR spectra of ferrocenyl chalcone compounds 
 
Figure 9-1 1H NMR spectrum of nonmethylated ferrocenyl chalcone compound without the iodide component. 
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Figure 9-2 1H NMR spectrum of methyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-3 1H NMR spectrum of ethyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-4 1H NMR spectrum of propyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-5 1H NMR spectrum of butyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-6 1H NMR spectrum of pentyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-7 1H NMR spectrum of hexyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-8 1H NMR spectrum of heptyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-9 1H NMR spectrum of octyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-10 1H NMR spectrum of nonyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-11 1H NMR spectrum of decyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-12 MS spectrum of nonmethylated ferrocenyl chalcone compound without the iodide component.
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Figure 9-13 MS spectrum of methyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-14 MS spectrum of ethyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-15 MS spectrum of propyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-16 MS spectrum of butyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-17 MS spectrum of pentyl ferrocenyl chalcone compound without the iodide component. 
 
  
200 | P a g e  
 
 
Figure 9-18 MS spectrum of hexyl ferrocenyl chalcone compound without the iodide component. 
 
  
201 | P a g e  
 
 
Figure 9-19 MS spectrum of heptyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-20 MS spectrum of octyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-21 MS spectrum of nonyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-22 MS spectrum of decyl ferrocenyl chalcone compound without the iodide component. 
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Figure 9-23 IR spectrum of nonmethylated ferrocenyl chalcone compound with the iodide component. 
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Figure 9-24 IR spectrum of methyl ferrocenyl chalcone compound with the iodide component.  
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Figure 9-25 IR spectrum of ethyl ferrocenyl chalcone compound with the iodide component. 
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Figure 9-26 IR spectrum of propyl ferrocenyl chalcone compound with the iodide component. 
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Figure 9-27 IR spectrum of butyl ferrocenyl chalcone compound with the iodide component. 
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Figure 9-28 IR spectrum of pentyl ferrocenyl chalcone compound with the iodide component. 
211 | P a g e  
 
 
Figure 9-29 IR spectrum of hexyl ferrocenyl chalcone compound with the iodide component. 
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Figure 9-30 IR spectrum of heptyl ferrocenyl chalcone compound with the iodide component. 
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Figure 9-31 IR spectrum of octyl ferrocenyl chalcone compound with the iodide component. 
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Figure 9-32 IR spectrum of nonyl ferrocenyl chalcone compound with the iodide component. 
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Figure 9-33 IR spectrum of decyl ferrocenyl chalcone compound with the iodide component.
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9.3 Appendix 3 – Schematics of 2-fold broth microdilution plates 
Table 9-2 Schematics of 2-fold broth microdilution 96-well plate: Ch (n) = initial chalcone dilution (mg/ml). 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
Blank 
Ch (1.0) 
+ 
MHB 
Ch (0.5) 
+ 
MHB 
Ch (0.25) 
+ 
MHB 
Ch (0.125) 
+ 
MHB 
Ch (0.063) 
+ 
MHB 
Ch (0.031) 
+ 
MHB 
Ch (0.016) 
+ 
MHB 
Ch (0.008) 
+ 
MHB 
Ch (0.004) 
+ 
MHB 
Ch (0.002) 
+ 
MHB 
ABX 
+ 
MHB 
5% DMSO 
+ 
MHB 
B 
Blank 
Ch (1.0) 
+ 
MHB 
Ch (0.5) 
+ 
MHB 
Ch (0.25) 
+ 
MHB 
Ch (0.125) 
+ 
MHB 
Ch (0.063) 
+ 
MHB 
Ch (0.031) 
+ 
MHB 
Ch (0.016) 
+ 
MHB 
Ch (0.008) 
+ 
MHB 
Ch (0.004) 
+ 
MHB 
Ch (0.002) 
+ 
MHB 
ABX 
+ 
MHB 
5% DMSO 
+ 
MHB 
C 
Org 1 
Ch (1.0) 
+ 
Org 1 
Ch (0.5) 
+ 
Org 1 
Ch (0.25) 
+ 
Org 1 
Ch (0.125) 
+ 
Org 1 
Ch (0.063) 
+ 
Org 1 
Ch (0.031) 
+ 
Org 1 
Ch (0.016) 
+ 
Org 1 
Ch (0.008) 
+ 
Org 1 
Ch (0.004) 
+ 
Org 1 
Ch (0.002) 
+ 
Org 1 
ABX 
+ 
Org 1 
5% DMSO 
+ 
Org 1 
D 
Org 1 
Ch (1.0) 
+ 
Org 1 
Ch (0.5) 
+ 
Org 1 
Ch (0.25) 
+ 
Org 1 
Ch (0.125) 
+ 
Org 1 
Ch (0.063) 
+ 
Org 1 
Ch (0.031) 
+ 
Org 1 
Ch (0.016) 
+ 
Org 1 
Ch (0.008) 
+ 
Org 1 
Ch (0.004) 
+ 
Org 1 
Ch (0.002) 
+ 
Org 1 
ABX 
+ 
Org 1 
5% DMSO 
+ 
Org 1 
E 
Org 2 
Ch (1.0) 
+ 
Org 2 
Ch (0.5) 
+ 
Org 2 
Ch (0.25) 
+ 
Org 2 
Ch (0.125) 
+ 
Org 2 
Ch (0.063) 
+ 
Org 2 
Ch (0.031) 
+ 
Org 2 
Ch (0.016) 
+ 
Org 2 
Ch (0.008) 
+ 
Org 2 
Ch (0.004) 
+ 
Org 2 
Ch (0.002) 
+ 
Org 2 
ABX 
+ 
Org 2 
5% DMSO 
+ 
Org 2 
F 
Org 2 
Ch (1.0) 
+ 
Org 2 
Ch (0.5) 
+ 
Org 2 
Ch (0.25) 
+ 
Org 2 
Ch (0.125) 
+ 
Org 2 
Ch (0.063) 
+ 
Org 2 
Ch (0.031) 
+ 
Org 2 
Ch (0.016) 
+ 
Org 2 
Ch (0.008) 
+ 
Org 2 
Ch (0.004) 
+ 
Org 2 
Ch (0.002) 
+ 
Org 2 
ABX 
+ 
Org 2 
5% DMSO 
+ 
Org 2 
G 
Org 3 
Ch (1.0) 
+ 
Org 3 
Ch (0.5) 
+ 
Org 3 
Ch (0.25) 
+ 
Org 3 
Ch (0.125) 
+ 
Org 3 
Ch (0.063) 
+ 
Org 3 
Ch (0.031) 
+ 
Org 3 
Ch (0.016) 
+ 
Org 3 
Ch (0.008) 
+ 
Org 3 
Ch (0.004) 
+ 
Org 3 
Ch (0.002) 
+ 
Org 3 
ABX 
+ 
Org 3 
5% DMSO 
+ 
Org 3 
H 
Org 3 
Ch (1.0) 
+ 
Org 3 
Ch (0.5) 
+ 
Org 3 
Ch (0.25) 
+ 
Org 3 
Ch (0.125) 
+ 
Org 3 
Ch (0.063) 
+ 
Org 3 
Ch (0.031) 
+ 
Org 3 
Ch (0.016) 
+ 
Org 3 
Ch (0.008) 
+ 
Org 3 
Ch (0.004) 
+ 
Org 3 
Ch (0.002) 
+ 
Org 3 
ABX 
+ 
Org 3 
5% DMSO 
+ 
Org 3 
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Table 9-3 Schematics of 2-fold broth microdilution 96-well plate: DMSO (n) = initial DMSO concentration (%). 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
Blank 
DMSO(100) 
+ 
MHB 
DMSO(50) 
+ 
MHB 
DMSO(25) 
+ 
MHB 
DMSO(12.5) 
+ 
MHB 
DMSO(6.3) 
+ 
MHB 
DMSO(3.1) 
+ 
MHB 
DMSO(1.6) 
+ 
MHB 
DMSO(0.8) 
+ 
MHB 
DMSO(0.4) 
+ 
MHB 
DMSO(0.2) 
+ 
MHB 
ABX 
+ 
MHB 
5% DMSO 
+ 
MHB 
B 
Blank 
DMSO(100) 
+ 
MHB 
DMSO(50) 
+ 
MHB 
DMSO(25) 
+ 
MHB 
DMSO(12.5) 
+ 
MHB 
DMSO(6.3) 
+ 
MHB 
DMSO(3.1) 
+ 
MHB 
DMSO(1.6) 
+ 
MHB 
DMSO(0.8) 
+ 
MHB 
DMSO(0.4) 
+ 
MHB 
DMSO(0.2) 
+ 
MHB 
ABX 
+ 
MHB 
5% DMSO 
+ 
MHB 
C 
Org 1 
DMSO(100) 
+ 
Org 1 
DMSO(50) 
+ 
Org 1 
DMSO(25) 
+ 
Org 1 
DMSO(12.5) 
+ 
Org 1 
DMSO(6.3) 
+ 
Org 1 
DMSO(3.1) 
+ 
Org 1 
DMSO(1.6) 
+ 
Org 1 
DMSO(0.8) 
+ 
Org 1 
DMSO(0.4) 
+ 
Org 1 
DMSO(0.2) 
+ 
Org 1 
ABX 
+ 
Org 1 
5% DMSO 
+ 
Org 1 
D 
Org 1 
DMSO(100) 
+ 
Org 1 
DMSO(50) 
+ 
Org 1 
DMSO(25) 
+ 
Org 1 
DMSO(12.5) 
+ 
Org 1 
DMSO(6.3) 
+ 
Org 1 
DMSO(3.1) 
+ 
Org 1 
DMSO(1.6) 
+ 
Org 1 
DMSO(0.8) 
+ 
Org 1 
DMSO(0.4) 
+ 
Org 1 
DMSO(0.2) 
+ 
Org 1 
ABX 
+ 
Org 1 
5% DMSO 
+ 
Org 1 
E 
Org 2 
DMSO(100) 
+ 
Org 2 
DMSO(50) 
+ 
Org 2 
DMSO(25) 
+ 
Org 2 
DMSO(12.5) 
+ 
Org 2 
DMSO(6.3) 
+ 
Org 2 
DMSO(3.1) 
+ 
Org 2 
DMSO(1.6) 
+ 
Org 2 
DMSO(0.8) 
+ 
Org 2 
DMSO(0.4) 
+ 
Org 2 
DMSO(0.2) 
+ 
Org 2 
ABX 
+ 
Org 2 
5% DMSO 
+ 
Org 2 
F 
Org 2 
DMSO(100) 
+ 
Org 2 
DMSO(50) 
+ 
Org 2 
DMSO(25) 
+ 
Org 2 
DMSO(12.5) 
+ 
Org 2 
DMSO(6.3) 
+ 
Org 2 
DMSO(3.1) 
+ 
Org 2 
DMSO(1.6) 
+ 
Org 2 
DMSO(0.8) 
+ 
Org 2 
DMSO(0.4) 
+ 
Org 2 
DMSO(0.2) 
+ 
Org 2 
ABX 
+ 
Org 2 
5% DMSO 
+ 
Org 2 
G 
Org 3 
DMSO(100) 
+ 
Org 3 
DMSO(50) 
+ 
Org 3 
DMSO(25) 
+ 
Org 3 
DMSO(12.5) 
+ 
Org 3 
DMSO(6.3) 
+ 
Org 3 
DMSO(3.1) 
+ 
Org 3 
DMSO(1.6) 
+ 
Org 3 
DMSO(0.8) 
+ 
Org 3 
DMSO(0.4) 
+ 
Org 3 
DMSO(0.2) 
+ 
Org 3 
ABX 
+ 
Org 3 
5% DMSO 
+ 
Org 3 
H 
Org 3 
DMSO(100) 
+ 
Org 3 
DMSO(50) 
+ 
Org 3 
DMSO(25) 
+ 
Org 3 
DMSO(12.5) 
+ 
Org 3 
DMSO(6.3) 
+ 
Org 3 
DMSO(3.1) 
+ 
Org 3 
DMSO(1.6) 
+ 
Org 3 
DMSO(0.8) 
+ 
Org 3 
DMSO(0.4) 
+ 
Org 3 
DMSO(0.2) 
+ 
Org 3 
ABX 
+ 
Org 3 
5% DMSO 
+ 
Org 3 
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9.4 Appendix 4 – Standard curves of test organisms in MIC determination 
 
 
Figure 9-34 Broth microdilution standard curve of S. aureus NCIMB 8244. 
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Figure 9-35 Broth microdilution standard curve of K. kristinae NCMIB 8884. 
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Figure 9-36 Broth microdilution standard curve E. faecalis NCTC 12697. 
 
y = 0.0082x - 0.041
R² = 0.9288
-0.020
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0 2 4 6 8 10 12
A
b
so
rb
an
ce
6
2
0
n
m
Bacterial log cfu/ml
Standard curve of E. faecalis NCTC 12697
221 | P a g e  
 
 
Figure 9-37 Broth microdilution standard curve of fully sensitive S. aureus (CRH). 
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Figure 9-38 Broth microdilution standard curve of PEN-resistant S. aureus (CRH). 
 
y = 0.0197x - 0.1094
R² = 0.9482
-0.020
0.000
0.020
0.040
0.060
0.080
0.100
0.120
0.140
0 2 4 6 8 10 12
A
b
so
rb
an
ce
 6
2
0
n
m
Bacterial log cfu/ml
Standard curve of PEN-resistant S. aureus clinical isolate (CRH)
223 | P a g e  
 
 
Figure 9-39 Broth microdilution standard curve of a MRSA (CRH). 
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Figure 9-40 Broth microdilution standard curve of E. coli NCIMB 9483. 
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Figure 9-41 Broth microdilution standard curve of K. pneumonia (IH). 
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Figure 9-42 Broth microdilution standard curve of Salmonella "Manchester" NCTC 7372. 
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Figure 9-43 Broth microdilution standard curve of E. coli (CRH). 
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9.5 Appendix 5 – Estimations of RA of each ferrocenyl chalcone based on type of vessel and environmental condition 
 
Figure 9-44 – Mean (± SD) absorbance values of hexyl ferrocenyl chalcone in polypropylene tubes exposed to three different environmental conditions (room temperature and light, 37oC, room 
temperature in darkness) over time. RA (ΔU/min) from 0 to 180 minutes (reproduced with permission from Bennett, 2016). 
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Figure 9-45 – Mean (± SD) absorbance values of hexyl ferrocenyl chalcone in borosilicate glass tubes exposed to three different environmental conditions (room temperature and light, 37oC, 
room temperature in darkness) over time. RA (ΔU/min) from 0 to 180 minutes (reproduced with permission from Bennett, 2016). 
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Figure 9-46 – Mean (± SD) absorbance values of heptyl ferrocenyl chalcone in polypropylene tubes exposed to three different environmental conditions (room temperature and light, 37oC, room 
temperature in darkness) over time. RA (ΔU/min) from 0 to 180 minutes (reproduced with permission from Bennett, 2016). 
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Figure 9-47 – Mean (± SD) absorbance values of heptyl ferrocenyl chalcone in borosilicate glass tubes exposed to three different environmental conditions (room temperature and light, 37oC, 
room temperature in darkness) over time. RA (ΔU/min) from 0 to 180 minutes (reproduced with permission from Bennett, 2016). 
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Figure 9-48 – Mean (± SD) absorbance values of octyl ferrocenyl chalcone in polypropylene tubes exposed to three different environmental conditions (room temperature and light, 37oC, room 
temperature in darkness) over time. RA (ΔU/min) from 0 to 180 minutes (reproduced with permission from Bennett, 2016). 
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Figure 9-49 – Mean (± SD) absorbance values of octyl ferrocenyl chalcone in borosilicate glass tubes exposed to three different environmental conditions (room temperature and light, 37oC, room 
temperature in darkness) over time. RA (ΔU/min) from 0 to 180 minutes (reproduced with permission from Bennett, 2016). 
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Figure 9-50 – Mean (± SD) absorbance values of nonyl ferrocenyl chalcone in polypropylene tubes exposed to three different environmental conditions (room temperature and light, 37oC, room 
temperature in darkness) over time. RA (ΔU/min) from 0 to 180 minutes (reproduced with permission from Bennett, 2016). 
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Figure 9-51 Mean (± SD) absorbance values of nonyl ferrocenyl chalcone in borosilicate glass tubes exposed to three different environmental conditions (room temperature and light, 37oC, room 
temperature in darkness) over time. RA (ΔU/min) from 0 to 180 minutes (reproduced with permission from Bennett, 2016). 
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Figure 9-52 – Mean (± SD) absorbance values of decyl ferrocenyl chalcone in polypropylene tubes exposed to three different environmental conditions (room temperature and light, 37oC, room 
temperature in darkness) over time. RA (ΔU/min) from 0 to 180 minutes (reproduced with permission from Bennett, 2016). 
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Figure 9-53 – Mean (± SD) absorbance values of dexyl ferrocenyl chalcone in polypropylene tubes exposed to three different environmental conditions (room temperature and light, 37oC, room 
temperature in darkness) over time. RA (ΔU/min) from 0 to 180 minutes (reproduced with permission from Bennett, 2016)
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9.6 Appendix 6 – Standard curves of test organisms and One-way ANOVA data tables in MTT assay 
 
 
Figure 9-54 MTT standard curve of S. aureus NCIMB 8244. 
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Figure 9-55 MTT standard curve of K. kristinae NCIMB 8884. 
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Figure 9-56 MTT standard curve of E. faecalis NCTC 12697. 
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Figure 9-57 MTT standard curve of fully sensitive S. aureus (CRH). 
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Figure 9-58 MTT Standard curve of PEN-resistant S. aureus (CRH). 
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Figure 9-59 MTT Standard curve of PEN/ERY/CLI-resistant S. aureus (CRH). 
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Figure 9-60 MTT Standard curve of a MRSA (CRH). 
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Table 9-4 Results of the One-way ANOVA of hexyl to decyl ferrocenyl chalcones against S. aureus NCIMB 8244 in 
the MTT assay. 
Source of Variation SS df MS F P-value F crit 
Between Groups 5.951647 4 1.487912 1 0.426093 2.75871 
Within Groups 37.19779 25 1.487912 
   
       
Total 43.14944 29   
 
    
 
 
Table 9-5 Results of the One-way ANOVA of hexyl to decyl ferrocenyl chalcones against K.kristinae NCIMB 8884 
in the MTT assay. 
Source of Variation SS df MS F P-value F crit 
Between Groups 0.008105 4 0.002026 0.968872 0.441968 2.75871 
Within Groups 0.052287 25 0.002091 
   
       
Total 0.060392 29         
 
 
Table 9-6 Results of the One-way ANOVA of hexyl to decyl ferrocenyl chalcones against E. faecalis NCTC 12697 
in the MTT assay. 
Source of Variation SS df MS F P-value F crit 
Between Groups 0.107456 4 0.026864 0.824965 0.521732 2.75871 
Within Groups 0.814094 25 0.032564 
   
       
Total 0.92155 29         
 
 
Table 9-7 Results of the One-way ANOVA of hexyl to decyl ferrocenyl chalcones against fully sensitive S. aureus 
(CRH) in the MTT assay. 
Source of Variation SS df MS F P-value F crit 
Between Groups 0.197154 4 0.049289 1 0.426093 2.75871 
Within Groups 1.232213 25 0.049289 
   
       
Total 1.429367 29   
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Table 9-8 Results of the One-way ANOVA of hexyl to decyl ferrocenyl chalcones against PEN-resistant S. aureus 
(CRH) in the MTT assay. 
Source of Variation SS df MS F P-value F crit 
Between Groups 0.247876 4 0.061969 1.03753 0.407599 2.75871 
Within Groups 1.493188 25 0.059728 
   
       
Total 1.741065 29         
 
 
Table 9-9 Results of the One-way ANOVA of hexyl to decyl ferrocenyl chalcones against PEN/ERY/CLI-resistant S. 
aureus (CRH) in the MTT assay. 
Source of Variation SS df MS F P-value F crit 
Between Groups 0.08013
6 
4 0.02003
4 
0.98448
9 
0.43394
2 
2.75871 
Within Groups 0.50874
4 
25 0.02035 
   
       
Total 0.58888 29         
 
 
 
Table 9-10 Results of the One-way ANOVA of hexyl to decyl ferrocenyl chalcones against a MRSA (CRH) in the 
MTT assay. 
Source of Variation SS df MS F P-value F crit 
Between Groups 0.02665
6 
4 0.00666
4 
0.33512
7 
0.85166
7 
2.75871 
Within Groups 0.49712
1 
25 0.01988
5 
   
       
Total 0.52377
7 
29         
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Appendix 7 – Details and copies of publications 
 Henry, E.J., Smith, R.B., Collins, M., Bird, S.J., Gowland, P. & Cassella, 
J.P., 2017. Novel Ferrocenyl Chalcone Compounds as Possible 
Antimicrobial Agents. In A. Méndez Vilas, ed. Antimicrobial Research: 
Novel Bioknowledge and Educational Programs. Spain: Formatex 
Research Centre, pp. 140–148. 
 Henry, E., Smith, R.B., Collins, M., Bird, S.J., Gowland, P. & Cassella, J.P., 
2017. Infection Control in the UK : An Antimicrobial Resistance 
Perspective. International Journal of Infection Control, 13(i2), pp.1–7. 
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